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The immune response is strongly associated with outcome in CRC (stages I-III). Cytotoxic 
CD8+ T-cells are the most important subset of immune cells positively associated with 
outcome, in most solid malignancies and especially CRC. However, in the advanced stage of 
CRC, this is not always the case. Stage-IV CRC metastasises (mCRC) commonly to the liver, 
which this thesis addresses. The gold standard for treatment of colorectal liver metastasis 
(CRLM) is surgical liver resection. Indeed, improvements in surgical techniques have greatly 
improved the 5-year survival of these patients; however, up to 60% of patients still recur 
following surgical liver resection. Understanding the progression of mCRC in the context of the 
immune response is the main focus of this thesis.  
 
To investigate the immune response at the primary site of CRC, a unique retrospective cohort of 
de novo or synchronous mCRC patients (n=109) was explored. Included in this cohort were 
patients that had microsatellite unstable tumours (MSI) (n=12), which in the metastatic setting 
have a reduced overall survival (OS) and have been found to respond to checkpoint blockade 
inhibition (CBI). I analysed the primary tumours of these patients in the context of tumour 
infiltrating lymphocytes (TILs), immune escape mechanisms and oncogenic potential of these 
primary tumours, where the patients had synchronous metastatic disease. Despite high 
frequencies of cytotoxic CD8+ T-cells in some tumours, there was no association with OS, 
indicating the tumour had surpassed immune control. Expression of PD-L1 >1% on tumour 
cells was independently correlated with OS in multivariate analysis suggesting that tumour cells 
have the ability to progress in part at least by evading the immune response. 
 
To evaluate the immune response at the metastatic site in the liver, a prospective cohort of 
CRLM patients was recruited (n=11) to examine the immune context in these tumours. Patients 
undergoing liver resection were included in the study, and freshly isolated lymphocytes from 
the tumour; normal liver and peripheral blood were analysed by flow cytometry. These tumours 
were found to have a reduced infiltration of cytotoxic CD8+ T-cells and increased infiltration of 
CD4+ T-cells, including T-regulatory cells that are known to suppress immune responses. This 
immune milieu in these tumours alludes to a reduced cytotoxic and increased 
immunosuppressive environment. To investigate the functional capacity of these immune cells, 
a novel immune cytotoxic assay was developed. This assay involved co-culturing patient-
derived tumouroids with expanded autologous TILs to assess dynamic interaction of function of 
these cells. TILs expanded from these tumours were able to kill matched tumouroids, further 
indicating that when removed from the immunosuppressive TME these cells have functional 
ability to kill tumouroids. To assess if these TILs respond to CBI, addition of anti-PD-1 
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antibody was included in the co-culture assays where no improvement in killing was observed. 
Further investigation of other immune cell subsets in CRLM tumours was undertaken to gain an 
insight into other immune cell populations that may contribute to the tumour microenvironment 
(TME). 
 
One population of unconventional T-cells abundant in the liver are mucosal-associated invariant 
T-cells (MAIT cells). These cells play a role in bacterial infections and bridge a gap between 
innate and adaptive immune responses, and their role in tumour immunity is less defined. These 
cells are of interest in the context of the TME as they have cytotoxic capability and rapid 
produce cytokine. When assessing MAIT cell presence in CRLM (n=25) by flow cytometry, 
MAIT cell frequency was reduced in the tumour compared to surrounding normal liver. The 
phenotype of MAIT cells in the tissue was phenotypically distinct compared to the periphery, 
with high expression of PD-1 and CD69, both markers of activation. To assess the potential of 
MAIT cells, peripheral MAIT cells were isolated from healthy donors and co-cultured with 
patient-derived tumouroids in an unstimulated and stimulated state. MAIT cells in both states 
were able to kill patient-derived tumouroids. This is the first documentation of MAIT cell 
killing with patient-derived material. Despite PD-1 expression on these cells, addition of anti-
PD-1 antibody did not enhance this killing. Even though at reduced frequency in the tumour, 
MAIT cells are activated and may contribute to the tumour microenvironment (TME) in CRLM. 
 
Patients with advanced-stage CRC have a reduced survival compared to earlier stage CRC 
patients. In the context of the immune response, it is evident that these tumours have evaded the 
immune response to progress to metastasis. The work of this thesis highlights that at the primary 
tumour site of patients with de novo mCRC, despite high frequencies of cytotoxic CD8+ T-
cells, there is an inability at controlling tumour progression. This has likely arisen through 
immune evasive mechanisms. Therefore there should be a focus on improving the 
immunogenicity of these tumours to again be recognised by the immune cells. Secondly, at the 
metastatic site, the TME is immunosuppressed and reinvigorating the function of cytotoxic 
immune cells present may restore improved immune responses. Importantly, understanding the 
immune biology of these tumours will provide greater guidance to improve potential immune 
therapies for these patients into the future. 
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1. LITERATURE REVIEW 
1.1 Cancer 
Cancer is responsible for approximately 8.2 million cancer-related deaths and approximately 17 
million new cases worldwide arising in 2018 (UK, 2019). The incidence of cancer cases is 
estimated to rise up to 70% over the next two decades (Stewart, 2014b). The broad term 
‘cancer’ is used to describe a variety of diseases that can affect different organs within the body. 
The pathology involves abnormal growth of cells uncontrollably, in most cases forming a 
malignant tumour. These tumours can invade surrounding tissue and spread to distal sites, 
often-another organ in the body, a process referred to as metastasis. Metastasis to the liver is a 
primary cause of death from colorectal cancer (CRC) and is referred to as metastatic CRC 
(mCRC). 
 
1.2  Colorectal Cancer 
CRC is a form of cancer that develops in the colon or rectum. It is the third most common 
tumour worldwide, with 1.4 million cases reported and 694, 000 deaths recorded in 2012 
(Stewart, 2014a). In Australia CRC is projected to account for 13.5% of new cancer cases in 
2015. The number of new CRC cases in 2018 is 17,004 including 9,294 males and 7,709 
females. The number of deaths due to CRC in 2018 is projected to surpass 4,129. However, the 
prospect of five-year relative survival has improved from 51% in the years 1985-89 to 69% in 
the years 2010-2014 (Welfare, 2014). CRC and its metastases are the focus of this thesis. 
 
1.2.1 Risk Factors 
Approximately 85-90% of CRC cases arise sporadically, due to chromosomal instability (CIN) 
(Grady & Carethers, 2008). The risk factors associated with CRC include increasing age and 
previous polyps or previous CRC. A number of environmental factors also influence the risk of 
developing CRC. Diet is one factor where high fat, high intake of red meat and lack of fibre 
may increase the risk of developing CRC (Boyle & Langman, 2000). Other environmental 
factors include smoking, high alcohol consumption and a sedentary lifestyle. Further, diagnosis 
of inflammatory bowel disease (IBD) including Crohn’s disease and ulcerative colitis (UC) 
make up approximately 60% of the risk incidence for CRC, with severity and duration of IBD 
increasing risk (Jess, Rungoe, & Peyrin-Biroulet, 2012; von Roon et al., 2007). After initial 
diagnosis of IBD, the risk of developing CRC may occur within eight to 10 years. Crohn’s 
disease affects the ilium and the colon, whereas UC affects the colon and rectum only (Abraham 
& Cho, 2009). 
 
Hereditary diseases associated with CRC include Lynch syndrome (also collectively called 
Hereditary Non-Polyposis CRC (HNPCC)) and Familial Adenomatous Polyposis (FAP), which 
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account for 10-15% of CRC cases (Kinzler & Vogelstein, 1996). Lynch syndrome is 
characterised by a younger onset of CRC, average age 45, compared to the general population 
average age onset of 63. The tumours are predominantly right-sided, proximal to the splenic 
flexure in the colon. Adenomas can develop rapidly into carcinomas within two to three years, 
compared to eight-10 years in the general population (Vasen, Watson, Mecklin, & Lynch, 
1999). The pathology of these tumours is poorly differentiated, with a higher infiltration of 
lymphocytes, and has a better prognostic outcome compared to patients with non-HNPCC CRC 
(Dolcetti et al., 1999). The diagnosis of Lynch syndrome typically involves the genetic 
screening for defects in DNA mismatch repair (MMR) genes that have a germline mutation in 
the DNA MMR genes including PSM2, MLH1, MSH2 and MSH6 (Dinh et al., 2011). Such 
cases are referred to as microsatellite instability (MSI) cases and may lead to different treatment 
approaches in the clinic, explained subsequently in this review. 
1.2.2 Diagnosis 
CRC is diagnosed by taking a biopsy of the primary tumour during a colonoscopy or 
sigmoidoscopy, which is then confirmed as adenocarcinoma by a pathologist. Subsequent whole 
body examination using imaging techniques including: computated topography (CT), magnetic 
resonance imaging (MRI) and fluorine-18 (F-18) fluorodeoxyglucose (FDG)-positron emission 
tomography (FDG-PET) of the chest, abdomen and pelvis is undertaken to rule out metastatic 
disease (Kekelidze, D'Errico, Pansini, Tyndall, & Hohmann, 2013). Not only do these imaging 
techniques help diagnosis but also guide the approach for appropriate treatment and surgical 
procedures. An effective way of determining diagnosis, prognosis and the appropriate treatment 
plan is a multidisciplinary team approach which includes a consensus between surgeons, 
medical oncologists, radiologists, pathologists and, increasingly, researchers (Morris et al., 
2010).  
1.2.3 Prognosis 
The prognosis of CRC is determined (most commonly) by the American Joint Committee on 
Cancer (AJCC) Tumour Node Metastasis (TNM) staging system, which classifies the primary 
tumour growth (T), the number of lymph nodes affected (N) and the degree of metastatic spread 
(M). The prognosis of the CRC disease classified by the AJCC and compared to Duke’s staging 
is outlined in Table 1. Progression of primary tumour describes invasion of the tumour into 
surrounding structures. Tis: Tumour in situ: intraepithelial or invasion of lamina propria; T1: 
Tumour invades sub-mucosa; T2: Tumour invades muscularis propria; T3: Tumour invades 
through the muscularis propria; T4a: Tumour penetrates to the surface of the visceral 
peritoneum; T4b: Tumour directly invades or is adherent to other structures. 
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When regional lymph nodes become involved the following classification describes the 
presence and number of lymph nodes affected, confirmed by a pathologist. Nx: Node cannot be 
assessed; N0: No regional lymph node metastasis; N1: Metastasis in one to three regional lymph 
nodes that may include; N1a: metastasis in one regional lymph node; N1b: metastasis in two to 
three regional lymph nodes; N1c: Tumour deposit(s) in the sub-serosa, mesentery, or non-
peritonealised peri-colic or perirectal tissues without regional nodal metastasis; N2: Metastasis 
in four or more regional lymph nodes; N2a: Metastasis in four to six regional lymph nodes; 
N2b: Metastasis in seven or more regional lymph nodes. 
 
Grading of metastases involves the following classification, which is based on the location and 
site of metastatic spread. M0: No metastasis; M1: Distant Metastasis; M1a: Metastasis confined 
to one organ or site (for example, liver, lung, ovary, non-regional node); M1b: Metastases in 
more than one organ/site or the peritoneum (Cancer, 2010). 
 
Table 1.1. Anatomic stage/prognostic groups (AJCC, 7th Edition) 
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1.2.4 Primary Colorectal Cancer Treatment 
1.2.4.1 Surgery 
Surgical resection of the primary tumour is required with adequate margins to ensure there is no 
residual disease left behind. For primary colon carcinoma, the margins recommended are at 
least five cm or more. Adherent T4 tumours adjacent to other structures require en-bloc 
resection to obtain a resection margin of R0 (no gross or microscopic tumour remains in the 
primary tumour bed) (Nahas et al., 2017). If the disease has progressed, with lymph node 
involvement, a lymphadenectomy is performed with at least 12 nodes required for appropriate 
nodal staging (Ong & Schofield, 2016). 
1.2.4.2 Chemotherapy 
Local disease at the primary site in the colon or rectum is typically treated by surgical removal 
of the tumour and any regional lymph nodes that are involved (Chang, Rodriguez-Bigas, 
Skibber, & Moyer, 2007). Adjuvant chemotherapy regimens may also be administered 
including: 5-fluorouracil (5-FU) and leucovorin (FU/LV), FU/LV with irinotecan (FOLFIRI) or 
FU/LV with oxaliplatin (FOLFOX) or, more recently, a combined regimen of 5-FU, irinotecan 
and oxaliplatin (FOLFOXFIRI) for metastatic disease. 
1.2.4.3 Radiotherapy 
In the context of locally advanced rectal cancer, neoadjuvant chemoradiotherapy (NACRT) is 
offered prior to planned rectal cancer total mesorectal excision (rcTME). There have been 
previous reports in patients where the residual tumour is undetectable through imaging and 
endoscopy that are monitored for a ‘watch and wait approach (no surgery but with intensive 
follow up). In a study by Habr-Gama et al, patients who demonstrated a complete clinical 
response (cCR) with no follow-up surgery were monitored for a minimum of 60 months. Five-
year overall survival (OS) was 93% and disease-free survival (DFS) was 85% (Habr-Gama et 
al., 2004). In addition to this, approximately 15-20% of patients who underwent NACRT and 
subsequent surgery had a pathological complete response (pCR), where no tumour is detected 
histologically post-resection (Maas et al., 2011). Theoretically, these patients did not require the 
morbid operation of rcTME. Identifying ways to predict which patients will present with a pCR 
is a current challenge in the field, and it is likely that randomised controlled trials (RCTs) will 
be required to predict this. We have developed an assay to assist in the prediction of patient 
response to NACRT, which will be discussed further in this review. 
1.3 Metastatic Colorectal Cancer (mCRC) 
The most common site of mCRC is the liver, followed by lung and peritoneum, and up to 40% 
of patients with CRC will develop systemic recurrence following curative treatment for the 
primary colorectal tumour (Manfredi et al., 2006). The accepted standard of care for liver 
metastases is surgical resection for patients with deemed resectable disease (Koh, 2017). Based 
on current guidelines by the National Health and Medical Research Council (NHMRC), patients 
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presenting with colorectal liver metastasis (CRLM) are stratified into three groups of either: 
definitively resectable disease, ‘borderline’ resectable and unresectable disease (Koh, 2017).  
1.3.1 Surgery for Synchronous Disease 
Patients may present with synchronous disease, where the primary and the metastatic tumours 
are both detected in situ at the time of diagnosis. Traditional strategies for treatment of 
synchronous CRC have been staged resections, where the primary tumour is resected with 
subsequent resection of the hepatic metastases. This traditional approach is mostly because 
synchronous resections are viewed as too challenging for the health of these patients, with a 
perception of higher morbidity and mortality risk. However in more recent years surgical 
strategies for mCRC have developed, due to safety improvements of surgical and anaesthetic 
procedures (Silberhumer et al., 2015).  
 
Synchronous mCRC resections are becoming more common in selected patients. In a systematic 
review by Hillingsø & Wille-Jørgensen assessing 16 studies, it was found that there was no 
difference in terms of five-year survival between synchronous and staged surgical resections. 
Additionally, it was found that synchronous resections had a shorter hospital stay with lower 
perioperative morbidity. However, synchronous resection patients had a higher mortality rate 
than in the staged resections, although this does not appear to affect OS rates (Hillingso & 
Wille-Jorgensen, 2009). The flaws of this systematic review are that there is considerate 
heterogeneity between studies, and there is bias affecting the endpoints of the analysis, therefore 
a RCT would be required to settle this issue. Nevertheless, this systematic review supports the 
notion that a combined approach is safe in selected patients with synchronous disease with 
access to specialist colorectal and hepatobiliary surgeons (Hillingso & Wille-Jorgensen, 2009; 
Vassiliou et al., 2007; Weber, Bachellier, Oussoultzoglou, & Jaeck, 2003). 
1.3.2 Surgery for Metachronous Disease 
Metachronous disease presentation is where the first and second malignant transformation is 
variable. This means that the primary tumour may develop and be resected and a distant 
metastatic tumour develops consequently (Tziris et al., 2008). If the hepatic metastases are 
deemed resectable with curative intent, surgical resection offers improved long-term survival 
(Padman et al., 2013). A retrospective population-based study by Morris et al, demonstrated 
patients who presented with stage IV disease at diagnosis survived one year following primary 
colorectal tumour resection. Subsequent five-year survival was 42.5 per cent and 18.5 per cent 
for those who did and did not have liver resection respectively, as seen in Figure 1.1 (Morris et 




Figure 1.1 Kaplan-Meier curves for study population overall and patients with Stage III 
or IV CRC with and without liver resection (Morris et al, 2010) 
1.3.3 Hepatectomy for CRLM 
The standard of care for resectable hepatic metastases is surgical resection of the liver and this 
is associated with improved survival outcomes. Five-year survival rates post surgical resection 
average 40% (Choti et al., 2002). Studies that span 10-year follow up periods have reported that 
20% of patients who underwent liver resection have shown benefit from the resection and are 
considered to be cured (Luca Vigano, 2012; Tomlinson JS1, 2007). Technical considerations for 
liver resection include the remnant volume of functional liver tissue after resection and whether 
vasculature is involved, to proceed with the surgery.  
 
Surgical resection margins of the liver have an influence on prognosis and are described as the 
border of the tissue removed in cancer surgery (Tranchart et al., 2013). A positive margin 
indicates that tumour cells are found at the edge of the tissue and that the tumour has not been 
entirely resected (R1). Negative margins (>1cm) have an improved DFS (R0), however R1 
margins (<1cm) have decreased DFS. The accepted gold standard is 1cm, yet more recent 
studies have claimed that negative margins of <1mm are associated with significantly improved 
five-year survival (Cady et al., 1998; Vandeweyer et al., 2009). Additional prognostic 
considerations include the number of liver metastases present, the response to treatment at the 
primary site and the degree (if any) of extra-hepatic disease (Bilchik, Poston, Adam, & Choti, 
2008; Folprecht et al., 2010). 
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Observational studies reported by Morris et al have suggested that surgical resection of hepatic 
tumours either with, or without, adjuvant therapy have improved survival, compared to non-
interventional therapy options (Morris et al., 2010; Padman et al., 2013; Zeman, Maciejewski, 
Poltorak, & Kryj, 2013).  However patients that are deemed ‘borderline resectable’ require 
perioperative chemotherapy treatment to obtain any survival benefit to be eligible for liver 
resection (Padman et al., 2013). 
1.3.4 Chemotherapy for mCRC 
Unfortunately, not all patients with metastasis will have the option of a liver resection, with 
curative intent. The majority of patients will have disease that is either borderline resectable or 
unresectable (Manfredi et al., 2006). For patients with borderline resectable disease, 
perioperative chemotherapy is offered in both the neoadjuvant and adjuvant setting. Patients 
with potentially resectable disease should be discussed at a multidisciplinary meeting, with the 
treatment plan taking into consideration co-morbidities and suitability for aggressive treatment 
(Nott, 2017). Furthermore, in all cases, patients must be considered to be able to tolerate 
intensive chemotherapy (Benson et al., 2018; Nott, 2017; Padman et al., 2013; Van Cutsem et 
al., 2016). 
1.3.5 Chemotherapy in the Neoadjuvant and Perioperative Setting 
Combination of surgical resection and chemotherapy reduces the risk of relapse in mCRC 
patients. Down staging chemotherapy in the neoadjuvant setting provides the opportunity to 
reduce the size of ‘borderline’ resectable disease to be resectable, by debulking tumours. It can 
also guide adjuvant treatment, following assessment of tumour responsiveness to the 
chemotherapy (Nordlinger et al., 2008). Oxaliplatin is a third-generation platinum derivative, 
and the doublet combination as FOLFOX makes it the current most effective chemotherapeutic 
reagent for mCRC (Andre et al., 1999; Andre et al., 2004). In a RCT comparing FU/LV and 
FOLFOX, the latter provided a beneficial response rate of 50% with a prolonged progression-
free survival (PFS) in patients with advanced CRC (de Gramont et al., 2000). 
 
In line with the aforementioned study, Nordlinger et al adopted the FOLFOX4 regimen (Day 1: 
oxaliplatin, Day 2: Leucovorin) in a RCT known as the European Organisation for Research 
and Treatment of Cancer (EORTC) 40983 study to assess perioperative FOLFOX compared to 
surgery alone. Patients were randomly assigned to FOLFOX4 six weeks pre and six weeks post-
surgery or surgery alone. Compared to surgery alone, perioperative FOLFOX reduced 
progression-free survival (PFS) by 25% in patients with mCRC. It also demonstrated that 
perioperative chemotherapy treatment is complementary with surgery, and this formed the basis 
of FOLFOX4 perioperatively as current standard practice (Nordlinger et al., 2008). A 
population-based study assessed three-year survival rates comparing chemotherapy alone 
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(19.5%), surgery alone (73.8%), and surgery with perioperative chemotherapy (73.7%). A very 
important finding of this study was that the combination therapy significantly improved 
resection margins compared to surgery alone, 86.2% versus 95.9% in the group treated with 
resection alone (p=0.038) (Padman et al., 2013). Collectively these studies all demonstrate the 
survival benefit of chemotherapy in the perioperative and adjuvant setting. 
1.3.6 Chemotherapy in the Adjuvant Setting 
Following surgical liver resection, relapse occurs in 75% of patients, with five-year relapse-free 
survival between 15-35% (Fong, Fortner, Sun, Brennan, & Blumgart, 1999; Nordlinger et al., 
1996). Recurrences tend to occur within the first two years following resection, which are often 
confined to the liver (Fong et al., 1997). Therefore, using chemotherapy in the adjuvant setting 
may reduce the risk of hepatic recurrence and improve survival. Current NHMRC guidelines 
indicate that patients with a higher risk of recurrence following liver resection should receive 
adjuvant chemotherapy (Koh, 2017). In a pooled analysis of two multicentre randomised control 
phase III trials, the efficacy of systemic adjuvant chemotherapy with bolus FU/LV following 
liver resection was investigated. Patients were randomly assigned surgery alone or surgery 
followed by adjuvant chemotherapy. By combining the studies as a pooled analysis, Mitrey et al 
reasoned that this would improve statistical power. Adjuvant chemotherapy improved both PFS 
and overall survival (OS) in multivariate analysis, with five-year survival rates of 52.8% in the 
chemotherapy group and 39.6% in the surgery alone group (Mitry et al., 2008). These studies 
again confirm that adjuvant chemotherapy improves survival, with oxaliplatin-based doublet 
chemotherapy used as the most common regimen (Padman et al., 2013). 
1.4 Biological Agents 
Biological agents are used in first-line therapy for patients with mCRC. The first is 
bevacizumab (Avastin®) a humanised monoclonal antibody that targets the Vascular 
Endothelial Growth Factor-A (VEGF-A) inhibiting binding to its receptors. The second includes 
cetuximab (Erbitux®) and panitumumab (Vectibix®) humanised monoclonal antibodies that 
target the Epidermal Growth Factor Receptor (EGFR). 
 
VEGF-A is a glycoprotein produced by neoplastic and normal cells. It is an important regulator 
of pathogenic and physiological angiogenesis (Ferrara, Gerber, & LeCouter, 2003; Hurwitz et 
al., 2004). Pre-clinical studies in human xenograft models demonstrated that a monoclonal 
antibody against VEGF-A has the ability to inhibit tumour growth in vivo (K. J. Kim et al., 
1993). Initial Phase II trials investigated the efficacy of bevacizumab with FU/LV at high and 
low doses compared to FU/LV alone in patients with mCRC. It was reported that the addition of 
bevacizumab at both high and low doses increased median survival (control arm, 13.8 months; 
95% confidence interval (CI), 9.1 to 23.0 months; low-dose arm, 21.5 months, 95% CI, 17.3 to 
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undetermined; high-dose arm, 16.1 months; 95% CI, 11.0 to 20.7 months) (Kabbinavar et al., 
2003). Subsequently, a phase III RCT was established for patients with mCRC, to determine if 
combination chemotherapy folinic acid, fluorouracil and irinotecan (FOLFIRI) with addition of 
bevacizumab improves survival. Herwitz et al found that the median OS was 20.6 months with 
the addition of bevacizumab compared to 15.6 months with placebo alone. There was a modest 
increase in side effects, including thrombosis, bleeding, proteinuria, and hypertension, which 
were usually managed easily (Hurwitz et al., 2004).  
 
Epidermal growth factor receptor (EGFR) is commonly unregulated in mCRC through receptor 
dimerisation by Epidermal growth factor (EGF)-like ligands (of which six have been 
characterised). Downstream signaling pathways are then activated, the most common being the 
MAP/ERK and PI3K-PTEN-AKT pathways, involved in cell survival and proliferation (Alroy 
& Yarden, 1997; Mendelsohn & Baselga, 2000). Therefore, it is important that tumours treated 
with anti-EGFR therapies are RAS-wild type (WT) so determining the RAS mutational status of 
the tumour is a requirement for treatment with anti-EGFR therapies. Targeted therapies of this 
pathway in mCRC include cetuximab and panitumumab. Cetuximab synergies with FOLFIRI 
and FOLFOX, improving response rate, median PFS and OS (Maughan et al., 2011; Van 
Cutsem et al., 2015). Cetuximab induces pro-apoptotic mechanisms and inhibits the 
proliferative capacity of tumour cells. Interestingly, there have been pre-clinical in vitro studies 
demonstrating an immunogenic response via the Fc receptor on immune cells, particularly 
natural killer (NK) cells through antibody dependent cell-mediated cytotoxicity (ADCC) (Roda 
et al., 2007; Veluchamy et al., 2016). This highlights multi-faceted targeting of tumour-intrinsic 
molecular pathways and extrinsic immune cell responses by this therapy. These targeted 
therapies demonstrate the importance of understanding molecular pathways involved in tumour 
progression, so that they can be targeted therapeutically to improve patient outcome. 
1.5 Colorectal Carcinogenesis 
The molecular carcinogenic steps for CRC mostly arise through the adenoma-carcinoma 
sequence in the normal colon mucosa, which occurs over decades. This is a sporadic pathway 
that accounts for 85-90% of CRC cases and is due to mutational inactivation of tumour 
suppressor genes and mutational activation of oncogenes within the genome (Vogelstein et al., 
1988). The model of colorectal carcinogenesis was first proposed by Vogelstein & Fearon, and 
described the genetic ‘hits’ required for an adenoma to progress to carcinoma (E. R. Fearon & 
Vogelstein, 1990). 
 
In the normal colonic mucosa, adenoma formation is the benign beginning of this sequence. 
Adenoma formation arises from a small pocket of epithelial stem cells following inactivation of 
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the adenomatous polyposis coli (APC) gene. Subsequently mutations in the KRAS gene are 
important somatic alterations, which leads to a conversion of a small adenoma to a larger 
dysplastic one. Approximately 30-50% of CRC patients harbour a KRAS mutation, and such 
mutations can be the initiating event in a subset of colorectal tumours (Vogelstein et al., 1988). 
Other oncogene mutations may be activated through amplification or rearrangement including 
MYC and MYB (Alitalo et al., 1984; Finley et al., 1989). Additionally, loss-of-function 
mutations including tumour suppressor genes such as TP53 occur frequently in CRC. 
Accordingly by the common region of loss of chromosome 17p in CRC was found to harbour 
the TP53 tumour suppressor gene (Baker et al., 1989). This Vogelgram model has been useful 
to understand carcinogenesis, but it is important to note that only a few of CRCs strictly develop 
by this sequence (Wood et al., 2007). 
 
Shortly after the proposition of the adenoma-carcinoma sequence, researchers began 
investigating the genome for novel tumour suppressor genes. During this time Perucho et al 
observed that in approximately 130 colorectal tumours, deleted DNA bands were found. In 12% 
of cases these DNA bands were not deleted but were shortened in length. When analysing these 
sequences they contained simple repetitive sequences (microsatellites), with an estimate of 
approximately 105 somatic mutations per tumour (Boland & Goel, 2010). These tumours were 
also noted to be pathologically and clinically distinct. Typically these tumours arose in the 
proximal colon, were less invasive, unlikely to have mutations in KRAS and TP53, were poorly 
differentiated and more common in younger patients (Ionov, Peinado, Malkhosyan, Shibata, & 
Perucho, 1993). The authors concluded that these deletions represented a unique pathway of 
tumour development that was likely to be hereditary, although this was not proven.  
 
At the same time Thibodeau et al were investigating another type of microsatellite known as 
dinucleotide repeat sequences. They observed deletion mutations in sequences in these regions 
and coined the term microsatellite instability (MSI). A type I MSI mutation had large deletions 
or insertions into the sequences, whereas a type II MSI mutation involved a two-base-pair repeat 
change. Similarly to Perucho et al, 90% of these tumours were found in the proximal colon, and 
it was also concluded that these tumours represented a unique tumour progression pathway that 
‘does not involve loss of heterozygosity’ (Thibodeau, Bren, & Schaid, 1993). 
 
It has since been determined that the 12-17% of CRC cases have a unique mechanism of 
pathogenesis and these tumours are collectively described as microsatellite unstable. MSI is 
associated with defective DNA MMR genes. These MMR genes in mammals are: MLH1, 
MLH3, PMS1 and PMS2. Loss of MLH1 results in total loss of MMR activity, while loss of 
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PMS2 can be partially compensated by retention of MLH3 (Boland & Goel, 2010). Therefore, 
determining which MMR genes are lost is important in diagnostic confirmation of MSI. 
 
The most common hereditary condition is HNPCC or Lynch syndrome, an autosomal dominant 
genetic condition, with a high risk of multiple tumours. Conversely, most CRCs with MSI are 
sporadic and methods to detect this defect include immunohistochemistry (IHC) or by 
polymerase chain reactions (PCR) that amplify microsatellite regions using the Bethesda panel 
(Murphy et al., 2006). Most of these tumours have loss of MLH1 and PMS2 proteins. 
Alternatively, Kane et al showed that MSH2 was silenced by methylation in most of these 
tumours (Kane et al., 1997). The features of sporadic MSI colorectal tumours include the 
absence of significant familial clustering, biallelic methylation of the MLH1 promoter, loss of 
MLH1 and PMS2 protein expression and frequent mutations in BRAF (V600E) (Valine 
substituted by glutamic acid driver mutation) (Sinicrope et al., 2006). The tumours are often 
diploid (74%) and patients with sporadic MSI colorectal tumours have a better prognosis than 
tumours that are microsatellite stable in earlier stages of disease, but this is not the case in 
advanced mCRC.  
 
It is well known that HPNCC-associated and sporadic colorectal tumours (stage I-III) with high 
MSI have an improved five-year survival of up to 10-20% compared to MSS, which is 
independent of other prognostic factors (Gryfe et al., 2000; Wright et al., 2000). The presence 
of tumour infiltrating lymphocytes (TILs) within primary colorectal tumours has been 
associated with this improved DFS (Galon et al., 2006). It has also been observed in MSI-high 
(MSI-H) colorectal tumours with a higher infiltration of cytotoxic CD8+ T-cells are associated 
with a more favourable prognostic outcome (Dolcetti et al., 1999; House & Watt, 1979). Recent 
studies demonstrate patients with MSI-H tumours respond to checkpoint blockade inhibition 
(CBI) including anti-Programmed cell death protein 1 (PD-1) therapy compared to 
microsatellite stable (MSS) tumours (Le et al., 2015).  
1.6 Tumour Immunity 
Due to the nature of tumour progression, the mutational status of a tumour is dynamic with both 
genetic and epigenetic mutations acquired over time. A process known as “immunoediting” can 
lead to altered antigenic peptide profiles on tumour cells that are selectively recognised by 
immune cells. MacFarlane Burnett & Paul Ehrlich initially coined the term 
‘immunosurveillance’ stating that the immune system could suppress carcinoma (Dunn, Bruce, 
Ikeda, Old, & Schreiber, 2002). This arose from the idea that mutations acquired in tumours are 
mostly somatic, due to errors in DNA replication and repair. The immune cells can detect 
peptides encoded by these mutations as foreign, which results in an immune response. 
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Therefore aberrant expression of mutated proteins as peptides presented on major 
histocompatibility complex (MHC)-I molecules is confined to tumour cells only and not normal 
tissue (Segal et al., 2008). The dynamic nature of acquiring such mutations therefore 
continually exposes the immune system to neoantigens (Gilboa, 1999; Wortzel, Philipps, & 
Schreiber, 1983). Two forms of mutations can occur: the first is a passenger mutation, where 
there is no positive or negative advantage to the tumour cells, but are retained through cell 
division and clonal expansion. Conversely, a driver mutation is one that provides the cell with a 
selective advantage that is necessary in promoting survival and tumourogensis. (Greenman et 
al., 2007). As the tumour evolves in parallel with the immune response, the tumour can reduce 
its immunogenicity through immune-resistance mechanisms. Over time the tumour can 
therefore evade the immune response and continue progression, which will be expanded upon 
below. 
1.6.1 Innate Immunity 
The immune system is composed of an innate and adaptive arm, which traditionally has been 
viewed separately. However, it is becoming more apparent that these two arms of the immune 
system work in concert. The innate immune system is an archaic response of host defence 
against infection. It occurs rapidly and involves innate leukocytes including NK, NK T-cells 
(NKT), γδ T-cells and mucosal associated invariant T-cells (MAIT) as well as phagocytic cells 
such as macrophages, dendritic cells (DCs) and neutrophils (D. T. Fearon & Locksley, 1996). 
These cells become activated during an inflammatory response often due to the presence of a 
pathogen causing an infection (Janeway & Medzhitov, 2002). However we also know that most 
innate immune cells are involved in tumour control, as tumourogenesis can also create an 
inflammatory environment.  
 
Natural killer (NK) cells were first identified for their ability to kill tumour cells independent of 
deliberate activation (Wu & Lanier, 2003). This mechanism was later realised to be due to a 
lack of MHC-I recognition on tumour cells, resulting in NK-cell mediated cytotoxicity. Unlike 
adaptive immune cells that require specific recognition of antigen, NK cells express a variety of 
unspecific activating (CD94-NKG2 receptors) and inhibitory (KIR receptors) receptors 
(Pegram, Andrews, Smyth, Darcy, & Kershaw, 2011). Upon activation NK cells have the ability 
to rapidly secrete cytokines including IFNγ, TNFα, MIP-1α, GM-CSF and RANTES (Biron, 
Nguyen, Pien, Cousens, & Salazar-Mather, 1999; Dorner et al., 2004). NK cells can also 
produce cytolytic molecules including granzyme B and perforin, without the requirement for 
transcription and proliferation (Gismondi, Stabile, Nisti, & Santoni, 2015; Pegram et al., 2011). 
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Natural Killer T-cells (NKT) share some common phenotypic and effector properties with NK 
cells and are CD1d-restricted. There are two subsets of NKT cells: invariant NKT cells (iNKT), 
which play a significant role in tumour immunosurveillance and ‘non-invariant’ NKT cells 
(Coquet et al., 2008; Gumperz, Miyake, Yamamura, & Brenner, 2002). iNKT cells recognise 
lipid antigens presented by the monomorphic MHC-like molecule CD1d, which is expressed on 
antigen presenting cells (APC), predominantly DCs. These cells recognise microbial and 
endogenous antigens such as glycolipids and play an important role in infection control. Upon 
T-cell receptor (TCR) stimulation and CD1d activation, iNKT cells can secrete regulatory 
cytokines including IL-4, IL-10 and IL-13 and inflammatory cytokines including IL-2, IFNγ 
and IL-17 (Stolk, van der Vliet, de Gruijl, van Kooyk, & Exley, 2018). Through production of 
IFNγ and cross-presentation to DCs, iNKT cells have the ability to boost and activate CD8+ T-
cells in the tumour microenvironment (TME) (Brennan, Brigl, & Brenner, 2013; S. Fujii, 
Shimizu, Smith, Bonifaz, & Steinman, 2003). They have cytotoxic function through mediation 
of granules including perforin, granzymes and Fas/FasL dependant killing. In the context of 
tumour immunity iNKT cells have been found to control IL-6 producing CD1d+ CD68+ tumour 
associated macrophages (TAMs) and control regulatory myeloid derived suppressor cells 
(MDSCs) (Altman, Benavides, Das, & Bassiri, 2015; Song et al., 2009). In these indirect ways, 
iNKT cells have the ability to influence the TME. 
1.6.2 Mucosal-Associated Invariant T-cells (MAIT cells) 
MAIT cells are a recently defined subset of innate-like T-cells. MAIT cells are characterised by 
an invariant TCR that recognises bacterial vitamin B metabolites presented via MHC-related 
molecule, MR1 (Gherardin, McCluskey, Rossjohn, & Godfrey, 2018; Kjer-Nielsen et al., 2018; 
Kjer-Nielsen et al., 2012). MAIT cells express Vα7.2-Jα33 chain with an almost near invariant 
α chain that is paired with a limited diversity β chain (Vβ2 and Vβ13) (Tilloy et al., 1999). This 
TCR is restricted by the highly conserved molecule MR1 that captures a novel class of antigens 
that are released into the extracellular environment or can be found in the lumen of phagosomal 
compartments following microbe engulfment (McWilliam et al., 2016). This unique class of 
ligands belong to vitamin B antigens, and MAIT cell activation depends on recognition of the 
ligands bound to MR1. Therefore MAIT cells are recruited to the site of infection of microbial 
organisms that synthesise components of the riboflavin pathway. The specific ligand discovered 
to activate MAIT cells was recently found to be 5-(2-oxo-propylideneamino)-6-D-
ribitylaminouracil (5-OP-RU) that is a derivative of the riboflavin biosynthesis pathway (Kjer-
Nielsen et al., 2012). Synthesis of 5-OP-RU is strictly limited to certain strains of bacteria 
including E. coli as well as by some yeast (Gherardin, McCluskey, et al., 2018). Mammals 
cannot synthesise this metabolite, obtaining vitamin B2 (riboflavin) from dietary sources. 
Vitamin B2 (folate) derivatives including 6-formyl pterin (6-FP) can also be captured by MR1 
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however when presented it inhibits binding and does not activate the MAIT TCR (McWilliam et 
al., 2016). Bacteria and yeasts therefore specifically activate MAIT cells. 
 
Recent studies have documented indirect MAIT cell activation through the cytokines IL-12 and 
IL-18, due to MAIT cells expressing these receptors (Shaler, Choi, et al., 2017). In a 
pathological state, it is evident that viruses are able to induce activation through this mechanism 
in a bystander cytokine-dependent fashion (Loh et al., 2016; van Wilgenburg et al., 2016). 
Upon microbial and mitogeneic stimulation, MAIT cells have the ability to secrete IFNγ and 
TNFα (Gold et al., 2010; Le Bourhis et al., 2013). MAIT cells also have the ability to produce 
IL-17 however this is independent of TCR ligation. IL-17 secretion has largely been 
demonstrated when stimulated via phorbol 12-myristate (PMA) and ionomycin and other 
mechanisms via IL-7 in hepatic MAIT cells (Dusseaux et al., 2011; X. Z. Tang et al., 2013). 
Direct and optimal stimulation of MAIT cells induces their cytotoxic potential with production 
of a granzyme B and perforin to induce cell death against MR1+ cells, typically those that have 
been infected by pathogens (Gold et al., 2010; Kurioka et al., 2015). Consistent across most 
studies, MAIT cells are reported to be predominantly CD8αα+, double negative (DN) (CD8-
CD4-) with some CD4+ or double positive (DP) (CD8+CD4+) populations (Gherardin, Loh, et 
al., 2018; Gherardin, Souter, et al., 2018). As their name suggests, MAIT cells are often 
confined to mucosal-barrier surfaces including the gut, peripheral blood (5-10% of T-cells) and 
in the liver (up to 45% of T-cells) (E. Martin et al., 2009).  
 
The role of MAIT cells in various pathogenic diseases is still unclear and understanding if they 
are involved in tumour immunosurveillance, specifically CRC has been explored over the last 
five years. This interest is mainly due to their presence in sites where inflammatory processes 
can drive carcinogenesis such as the colon and the liver. More recent studies demonstrate that 
MAIT cells are also present within primary human CRC tumours. Sundström et al were the first 
to document the presence of MAIT cells within these CRC tumours and their functionality. A 
higher percentage of MAIT cells accumulated in the tumour compared to surrounding 
unaffected mucosa, however CD8+ MAIT cells in the tumour were reduced. MAIT cells from 
the tumour produced significantly less IFNγ compared to those from the normal tissue, but 
produced similar amounts of Granzyme B. Analysis of MR1 mRNA expression by real-time 
PCR revealed MR1 was present within both the tumour and unaffected tissues, suggesting that 
both tumour cells and epithelial cells have the ability to present and activate MAIT cells via 




Validating these above studies, Zabijack et al found a higher frequency of MAIT cells in CRC 
tumours compared to the healthy mucosa (Zabijak et al., 2015). When stratifying patients based 
on their MAIT infiltrate and TNM score (II-IV), there were no statistical differences observed. 
However there were statistical differences observed when comparing DFS and OS. Using a cut-
off MAIT score whereby the number of MAIT cells within the tumour were three times higher 
than in the healthy tissue, it was concluded that a higher infiltration of MAIT cells within the 
tumour was associated with a poor prognosis. This was the first study to document MAIT cell 
correlation and prognosis. 
 
Ling et al found that MAIT cells were significantly reduced in the peripheral blood of CRC 
patients compared to healthy donors (Ling et al., 2016). MAIT cells within the total tumour 
infiltrating lymphocyte (TIL) population were significantly increased compared to MAIT cells 
in the surrounding healthy tissue, validating both findings from Sundström and Zabijack. 
Interestingly, the Ling et al study had a prospective cohort of patients that had been treated with 
FOLFOX4. When tracking MAIT cell frequency in peripheral blood, there was an increase of 
2% after six-cycles of FOLFOX4, indicating MAIT cells might be chemoresistant.  
 
It is well known that MAIT cells are highly abundant within the human liver. A recent paper by 
Shaler et al investigated the role of MAIT cells in colorectal liver metastasis (CRLM) and found 
a reduced infiltration of MAIT cells within the tumour compared to surrounding normal liver 
(Shaler, Choi, et al., 2017). To investigate their functional capacity cells were stimulated using 
TCR/MR1-dependent and -independent stimuli. They found that upon stimulation, MAIT cells 
isolated from the tumour produced low amounts of IFNγ compared to distant liver. Following 
stimulation, granzyme B in hepatic MAIT cells was substantially higher than tumour and 
tumour margin MAIT cells. This highlights a potential tumour suppressive TME similar to that 
in the primary tumour. Shaler et al also investigated MAIT cell susceptibility to chemotherapy, 
in the context of FOLFOX and Avastin. There was no difference in MAIT frequency in the 
chemotherapy versus treatment naïve group. In addition, MAIT cell function was investigated 
by their ability to produce IFNγ, which was also not affected by chemotherapy. Whether this is 
a good or bad phenomenon in terms of CRC therapy is unknown. 
 
The most recent study by Duan et al, investigated MAIT cells in in 50 patients with 
hepatocellular carcinoma (HCC). It was found that MAIT cells were reduced in the tumour 
compared to the normal surrounding liver. MAIT cells from the tumour had significantly 
upregulated inhibitory molecules including cytotoxic T-lymphocyte associated protein-4 
(CTLA-4), PD-1 and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). MAIT 
cells had a reduced capacity to produce IFNγ and minimal granzyme B and perforin. In this 
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study MAIT cells significantly correlated with an unfavourable clinical outcome, and it was 
therefore concluded that MAIT cells had tumour-promoting capacity (Duan et al., 2019). 
 
MAIT cells bridge the continuum area of innate versus adaptive immunity, similar to iNKT 
cells. The intriguing observation across all studies is that most MAIT cells are CD8+, which has 
prognostic implications in a range of solid tumours, including CRC. Therefore, it is likely that 
MAIT cells are pooled with conventional CD8+ T-cells and may account for up to 40% of TILs 
even though they are clearly not conventional cytotoxic T lymphocytes (CTLs). This matter 
warrants further investigation, which will be addressed in this thesis. 
1.6.3 Adaptive Immunity 
Unlike the innate immune response, the adaptive immune response is highly specific. Helper T-
cells (Th) are classified as CD3+CD4+ effector cells and upon stimulation have the ability to 
produce IFNγ and IL-2 that favour cellular immunity. This influences the microenvironment 
and affects cytotoxic CD8+ T-cells, macrophages and NK cells. Th1 cells favour humoral 
immunity by producing IL-4, IL-5 and IL-15, acting on B-cells. Th17 cells produce IL-17A, IL-
17F, IL-21 and IL-22, which has direct antimicrobial effects on tissue inflammation including 
epithelial, fibroblasts and immune cells (Fridman, Pages, Sautes-Fridman, & Galon, 2012). 
 
T-regulatory cells (T-regs) are classified as CD3+CD4+Foxp3+ T-cells and have regulatory 
effector functions. T-regs have the ability to secrete immunosuppressive cytokines including 
Transforming growth factor beta (TGF-β) and IL-10. These cells are important in maintaining 
immune cell homeostasis and reducing autoimmunity (Fridman et al., 2012). However, in the 
TME these cells have the ability to influence tumour progression by suppressing the effector 
cells including Th1 and cytotoxic T-cells. CRC has the ability to secrete TGF-β, which can see 
conversion of infiltrating CD4+ T-cells to T-regs (Zdanov et al., 2016). This shows how 
potential mechanisms of the tumour cells may have extrinsic effects in the TME. 
 
Cytotoxic CD3+CD8+ T-cells are effector T-cells that contain cytotoxic granules including 
granzymes and perforin. When a CD8+ T-cell interacts with a target cell through cognate 
antigenic MHC-I/TCR complex along with the immune synapse, cytotoxic granules are 
released. This causes subsequent death of the target cell through apoptosis. This is the 
mechanism by which CD8+ T-cells recognise and eliminate pathogen-infected cells as well as 
tumour cells. The infiltration of CD8+ T-cells in solid tumours, particularly CRC tumours, has 
now been strongly correlated with prognosis (Galon et al., 2006; Pages et al., 2005; Pages et al., 
2009; Pages et al., 2018).  
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1.7 Immune Escape 
We now know the host immune system can play both a tumour-protective and tumour-
enhancing role. Therefore, as the original concept of immunosurveillance focused only on the 
protective role of the host immune system, this idea is no longer accurate. Instead, the broader 
term ‘cancer-immunoediting’ is more widely accepted to address these dual concepts (Dunn et 
al., 2002).  
 
There are three main steps to the proposed framework of cancer-immunoediting that involve 
elimination, equilibrium and escape, also known as the “3 E’s” of cancer immunoediting”. The 
initial elimination step does encompass the original concept of immunosurveillance, whereby 
immune cells are successful in destroying the developing tumour. Tumour growth results in 
inflammation, with an influx of innate immune cells including NK, NKT and γδ T-cells to the 
site of the tumour resulting in IFNγ production (Girardi et al., 2018; Matzinger, 1994; Smyth & 
Trapani, 2001) and leading to IFNγ induced tumour cell death and release of chemokines, with 
an influx of APCs. In the draining lymph node DCs prime tumour specific CD4+ T-cells, which 
causes activation and accumulation of CD8+ and CD4+ T-cell infiltrate into the tumour site 
(Ferlazzo et al., 2002; Gerosa et al., 2002). Tumour destruction occurs via cytolytic T-cells, as 
the tumour bears antigens that have been immunogeneically enhanced (MHC-I) by exposure to 
local IFNγ production (Shankaran et al., 2001). 
 
In the equilibrium state, remaining tumour and immune cells that have survived the elimination 
phase now experience a dynamic equilibrium. Lymphocytes continue to control the tumour and 
IFNγ production is exerted towards tumour cells, but the TILs do not eradicate the tumour. This 
scenario results in “Darwinian-like” selection of tumour cells, that become resistant to immune-
mediated destruction. This process may span years, and could be the longest process of 
immunoediting (Dunn et al., 2002). The final phase is escape by the tumour cells to this 
immune cell-mediated killing. These tumour cells are insensitive to detection and elimination 
by immune cells and have undergone genetic or epigenetic mechanisms, to progress in an 
uncontrolled growth manner. Thus resulting in a clinically detectable tumour. The next section 
of this review will highlight the immune response in the context of CRC. 
1.8 The Immune Response in Colorectal Cancer  
In the past decade it has become strikingly apparent that the immune response in CRC tumours 
plays a major role. Most importantly measure of immune activity have been found to have 
greater prognostic significance than current AJCC and UICC TNM tumour staging (Pages et al., 
2018). Conversely, the TNM staging system, explained earlier in this review, fails to take into 
account additional factors including the immune cell infiltrate that is known to affect prognosis. 
Other new technologies such as molecular pathway analysis, mutational status and tumour 
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gene-expression based stratification are important contributors to disease stage and treatment 
response but have moderate prediction accuracy and limited clinical utility (Guinney et al., 
2015; Pages et al., 2018). 
The concept of the host immunological reaction in CRC is not a new one. Studies conducted by 
House & Watt in 1979 first documented functional immune cell inhibition by tumour antigen. 
In functional migration studies of TILs, patients with sera that inhibited cancer cell migration in 
vitro had a high risk (50%) of developing recurrence or death, indicating systemic immune 
suppressive factors that can influence tumour progression (House & Watt, 1979).  
In the mid 1980s, Jass investigated the prognostic significance of TILs in a large retrospective 
cohort of 447 rectal cancer formalin-fixed paraffin embedded (FFPE) sections with follow-up 
data of 15 years, using H&E staining to define lymphocytes (Jass, 1986). Fifteen-year survival 
was 90%, 60% and 40% when graded as pronounced, moderate and little to none, respectively. 
This study was one of the first to observe TILs at the margin of the tumour in rectal cancer 
specimens a feature that has now become prominent in current assessment of TIL. 
 
In the 1990s, Ropponen et al and Naito et al investigated TILs in primary CRC to determine if 
this correlates with prognosis. Ropponen et al found a linear association between TIL infiltrate 
and Duke’s stage A-B, however TILs were absent or weak in the stroma of large invasive 
Duke’s stage C and D tumours. Reduced TILs were observed in later stages of disease 
demonstrating immune escape by the tumour and resulting in shorter survival. Naito et al 
defined the T-cell subsets and found that high cytotoxic CD8+ T-cell scores were associated 
with earlier Duke’s A and B stages of disease (Naito et al., 1998). Collectively both of these 
studies show quantification of TILs as a prognostic measure and more importantly stratification 
of patients according to disease stage. 
 
To address this question of ongoing immunoediting, Pages et al investigated the role of the 
immune system in early metastatic phases of tumour progression including vascular emboli, 
lymphatic invasion, and perineural invasion (collectively referred to as “VELIPI”) (Pages et al., 
2005). This was done in a large cohort of 959 CRC patients. Tumours that had features of 
VELIPI had a reduced five-year survival than those with no VELIPI. When assessing TIL 
subsets for prognosis and VELIPI, the presence of a strong immune infiltrate correlated with 
VELIPI-negative tumours. This was an interesting finding, as it may be assumed that with a 
more vascularised tumour, there would be a higher immune infiltrate, but this is not the case. 
Some tumours “hijack” the inflammatory response to promote invasiveness, proliferation and 
survival (Liotta & Kohn, 2001). However, in this study it was found that VELIPI-negative 
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tumours had a higher lymphocyte infiltrate, which indicates the host immune response is 
providing a protective role, perhaps by inhibiting VELIPI progression. 
 
The seminal study by Galon et al defined the different immune subsets as well as the spatial 
location of immune cells within primary colorectal tumours. It was found that typing these 
tumours with immunological markers was a better predictor of patient survival compared to 
current TNM staging used for CRC (Galon et al., 2006). Assessing of CD3+ infiltrate at both 
the central tumour (CT) and invasive margin (IM), increased prediction of DFS and OS. Adding 
the immune memory marker CD45RO strengthened DFS, stratifying patients into long and 
short-term survivors, regardless of traditional TNM stage. Thus, although immunoediting 
occurs over time, the favourable adaptive immune response likely persists throughout tumour 
progression. 
 
Since these studies, many investigations of TIL in primary CRC have been published (Fridman 
et al., 2012; Galon, Angell, Bedognetti, & Marincola, 2013; Mlecnik et al., 2010; Pages et al., 
2009). For instance, we reported on the importance of an immune cell infiltrate in early stage 
node-negative microsatellite stable (MSS) CRC. We found that patients who had a high 
infiltration of cytotoxic CD8+ T-cells had a better relapse-free survival, as shown in Figure 1.2. 
We did not find statistical significance when assessing CD45RO+ infiltrate and this could 
indicate that the memory response is not as crucial in the early development of tumours as the 
cytotoxic response of the CD8+ T-cells (Millen et al., 2016). This study highlighted the 
importance of the immune response in the early stages of disease progression, and how this can 




Figure 1.2 Abundance of tumor infiltrating lymphocytes (TILs) in early stage MSS 
colorectal cancers track with relapse-free survival. (A) CD8+ cells were evaluated in 
patients that had tumor relapse (n =10) and those who did not relapse (n = 10). Infiltrating 
CD8+ T-cells were found to be significantly higher in relapse-free patients (two-way T-test) (B) 
Data from (A) were used to calculate the statistical median, which was used to partition with an 
area above 9.5% and those 9.5% and below. Relapse-free patients were found to have 
significantly higher CD8C cells that tracked with relapse-free survival (Log-rank, Mantel–Cox 
test).  
The latest reiteration of TILs in CRC has been an international validation of the Immunoscore, 
developed by Galon & Pages et al (Pages et al., 2018). The “Immunoscore” was found to 
predict the clinical outcome of patients with early and advanced stage CRC (Mlecnik et al., 
2018; Pages et al., 2009). In a three-category “Immunoscore” analysis, a 0–25% density was 
scored as low, 25-70% intermediate and 70-100% was scored as high as shown in Figure 1.3 
(Pages et al., 2018). There was a significant positive correlation between survival and the 
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densities of CD3+ and CD8+ immune cells in each tumour region, in the training set. The 
lowest risk of recurrence and longest survival was seen in patients with a high Immunoscore. 
This was validated in the internal and external validation sets: overall patients with high 
Immunoscore had the lowest risk of recurrence and also a significantly longer risk to recurrence, 
OS and DFS. 
 
This study also assessed immune infiltrates in MSI and MSS tumours and found when stratified 
using the three-category (low, intermediate and high) analysis, 45% of MSI tumours were 
associated with a high Immunoscore compared to 21% in the MSS cohort. However, when 
comparing the groups using the two-category (low and high [intermediate plus high]) analysis, 
patients with a high Immunoscore had prolonged DFS, time to recurrence and OS, regardless of 
microsatellite status. In addition to this, patients with MSI tumours with weak lymphocyte 
infiltrate did not have a survival advantage compared to MSS tumours against the overall trend 




Figure 1.3 Kaplan-Meier estimates of disease-free survival . (A) Kaplan-Meier curves for 
disease-free survival according to the Immunoscore in all cohorts of patients with AJCC/UICC 
TNM stage I–III colon cancers. (B) Disease-free survival according to the Immunoscore and 
MSI status in 1579 patients with known MMR status. The Immunoscore is based on two 
categories (low Immunoscore vs. intermediate plus high Immunoscore). Five-year survival: 
56% (95% CI 43−73) for patients with low Immunoscore and MSI (green), 75% (69−80) for 
patients with high Immunoscore and MSI (red), 53% (48−59) for patients with low 
Immunoscore and MSS (black), and 72% (69−74) for patients with high Immunoscore and MSS 
(blue). MSI=microsatellite instability. MMR=mismatch repair. MSS=microsatellite stable 
(Pagés et al, 2019) 
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1.9 The Immune Response in Metastatic Colorectal Cancer 
TIL presence is well established in primary CRC tumours, but is the immune response the same 
at the metastatic site? Most studies that have focused on TILs in CRLM have defined TILs 
using either Haematoxylin & Eosin (H&E) or immunohistochemistry (IHC). Okano et al found 
an association between weak TIL infiltrate and reduced survival (one, three, five-year: 73, 26 
and 19% respectively). They also reported an association between weak TILs and portal vein 
invasion, thus indicating the immune response is unable to control the tumour growth and 
spread in the liver (Okano et al., 2003). 
 
Most studies describe CRLM tumours with a high number of TILs namely CD3+ and CD8+ 
cells, typically along the margin between the tumour and liver parenchyma, as being associated 
with a better OS (Halama et al., 2011; Kwak et al., 2016; Maker et al., 2015). There have been 
studies that also look into the difference of immune infiltrate between the primary colorectal 
tumour and the metastatic site. Shibutani et al report the density of the CD8+ and CD4+ T-cells 
in the primary tumour as being similar to the metastatic site. They found that Foxp3+ T-cells 
were higher in the primary than the metastasis. Due to this immunosuppressive TME, it may be 
advantageous for tumour growth and progression leading to subsequent metastasis through 
escape mechanisms (Shibutani et al., 2018). 
 
Although metastatic tumours are thought to be poorly immunogenic and more 
immunosuppressed following escape from the primary site, these data collectively highlight the 
importance of accurately determining the immune response at the metastatic site. Therefore, 
such an assessment of the axis between the immune cells and the tumour cells is likely ongoing. 
Still, we can observe the strong importance of cytotoxic CD8+ T-cells in CRLM, and that this 
cytotoxic function is clearly important in tumour control. Despite these correlations of good 
immune response in the metastatic lesion and survival, immunotherapy responses in these 
tumours are still low. Therefore, establishing models to better understand this functional 
relationship is the next step to assess the quality of these immune cells. 
 
Yoong & Adams questioned if TILs from CRLM were functionally impaired and if this could 
be reversed in vitro or in vivo by manipulating the defects (Yoong & Adams, 1998). 
Collectively they found that T-cells freshly isolated from CRLM have incomplete cellular 
activation, reduced proliferative capacity and impaired cytotoxic effector function likely due to 
a reduced CD3γ expression. This could be restored in vitro with rIL-2 however tumour-specific 
activity was not detected in any of the freshly isolated TILs. This phenotype is likely due to the 
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poor immunogenicity of the tumour cells, with lack of expression of MHC antigens and co-
stimulatory molecules and reflects immunosuppressive factors in the TME (Bubenik, 2003). 
 
A deeper functional study of TILs in CRLM was undertaken by Wagner et al who investigated 
tumour reactive T-cells and their subsequent function. Although the sample size of this study 
was small (n=16) it was the first study to document in situ tumour reactive T-cells. It assessed 
using freshly isolated TILs and Elispot to determine production of IFNγ specific to tumour 
antigen function MUC1. Interestingly there was no difference in frequency of CD3+ T-cells in 
the tumour and the liver. Higher frequencies of activated CD4+ T-cells and reduced cytotoxic 
CD8+ T-cells were also found. These activated CD8+ T-cells correlated with high CD4+ 
infiltrate, indicating T-helper cell effects in the TME (Wagner et al., 2008). 
 
Therefore the assessment of immune cells using the Immunoscore is likely to have a profound 
impact on the clinic in the context of prognosis, however how might this information be 
employed? This is important in the era of immunotherapies, where the immune response needs 
to be considered. Collectively scoring TILs provides a quantitative measure of the immune 
response and how this affects clinical outcome. Nevertheless, what this system lacks is a 
measure of qualitative function. Although we know these TILs are present, and in cases at high 
frequencies, we don’t know the quality of the TILs and how tumour specific these TILs are. The 
aforementioned functional assays are from over a decade ago and are surrogate measures. 
Currently, there is a real need for the development of assays that assess functionality of TILs in 
terms of active tumour control. 
 
1.10 Modelling Responses to Immunotherapy In Vitro and In vivo 
It is known that CRC is a heterogeneous disease, defined by significant inter-patient differences 
in response to therapy, perhaps due to the molecular diversity of the tumour (Linnekamp et al., 
2018). Traditional in vitro models depended upon patient-derived cell lines that are 
commercially available. Almost all of these cell lines have been established decades prior with 
continial use in research laboratories and have therefore been cultured for years since they were 
initially derived from patients (Medico et al., 2015). There is an ongoing debate as to whether 
or not cell lines maintain tumour heterogeneity in vitro. Medico et al interrogated 152 CRC cell 
lines, using gene expression-based hierarchical clustering and short tandem repeat (STR) 
analysis. It was reported that cell lines with identical genetic background consistently clustered 
together, indicating that the genotype maintained strong control over the transcriptome, 
although all of these cells are essentially homogeneous (Medico et al., 2015). 
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To account for heterogeneity, patient-derived xenograft (PDX) models have been established to 
investigate the biology of the tumour in an in vivo system. They are developed by surgically 
implanting a section of patient-derived tumour into an immunodeficient mouse, to ensure the 
tumour is not rejected (Hidalgo et al., 2014). Such a model provides a platform to test 
therapeutics for drug safety and efficacy as well as investigating the biology of the tumour (S. 
A. Williams, Anderson, Santaguida, & Dylla, 2013). PDX models can be arduous, slow to 
establish and require further validation to ensure the graft is the true tumour type that was 
implanted. This may therefore not be the best model to use in clinical decision-making, as the 
replicative pace of these tumours in mice is not necessarily reflective of the tumour in humans 
and can take several months (Aparicio, Hidalgo, & Kung, 2015). Along with these factors, a 
critical component that PDX models lack is an immune system. Therefore, there is a need to 
develop less expensive and rapid models to accurately model the patient’s functional immune 
response, which may potentially provide platforms for screening response to immunotherapies. 
Perhaps more comparatively such a platform needs to be effective in a clinically relevant time 
frame. 
1.11 Organoid Culture  
One such system that may have the capacity to model functional immune responses includes 
organoid cultures. Almost a decade ago, organoid culture was developed by Sato et al to study 
the stem-cell compartment of intestinal crypts (Sato et al., 2011). Crypts and villi are located in 
the small intestine, and allow the self-renewal capacity of the epithelium to be replaced every 
five days in the mouse. The stem-cell niche exists at the bottom of the crypt, where Lgr5+ cells 
reside and give rise to the rapidly proliferating transient amplifying (TA) cells. The number of 
estimated stem cells per crypt is four to six, where enterocytes, goblet cells and enteroendocrine 
cells develop from the TA cells, and continuously move in coherent bands along the crypt-villus 
axis. Paneth cells are the fourth most differentiated cell type in the crypt structure, and reside at 
the base of the small intestine crypts (Sato et al., 2009). In 2009, Sato et al, developed a 
technology where one Lgr5+ cell could be enriched in growth factor medium and produce an 
entire crypt-like structure in vitro, as seen in Figure 1.4. This study demonstrated that Lgr5+ 
cells are indeed the stem cells within the intestinal epithelium that give rise to progenitor cells. 
This study also pioneered the in vitro culture of organoids, optimising the ideal growth factors 
used in tissue culture media to establish long-term culture of normal intestinal epithelia.  
 
To grow normal intestinal organoids the following growth factor combination was developed by 
Sato & Clevers et al to sustain long-term passaging in vitro. It was long known that 
Wingless/integrated (Wnt) signalling is important for proliferation of crypts, and therefore the 
Wnt agonist R-spondin 1 was used to induce crypt hyperplasia (K. A. Kim et al., 2005). To 
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enhance intestinal proliferation Epidermal Growth Factor (EGF) was used and Noggin was used 
to induce crypt proliferation by blocking TGF-β. Finally, crypts undergo anoikis outside the 
normal tissue context and a rho kinase (ROCK) inhibitor was used to inhibit anoikis. Laminin 
(α1 and α2)-enriched matrigel was used in the culture systems to support intestinal epithelial 
growth. Matrigel is a commercially available product, which forms the collagen-like matrix for 
the intestinal crypts to grow in three-dimensional structures, recapitulating native tissue 
architecture (Sato et al., 2009; Stingl, Eaves, Zandieh, & Emerman, 2001). However, due to the 
nature of colorectal tumours, some of these GFs were not required for growth of tumouroids. 
1.11.1 Co-Culture of Tumouroid and Immune Cells 
To address the lack of organoid-immune cell co-culture systems, we hypothesised that immune 
cells could be co-cultured with organoids to assess cell-to-cell interactions. We focused only on 
the growth of cancer cells as organoids, rather than normal intestinal structure, and therefore 
called tumour-derived organoids tumouroids. At the time (2015), no other studies to our 
knowledge had been undertaken to address this concept. However since 2015 there have been 
several contributions to the field, including our own. 
 
 
Figure 1.4 Colony-forming efficiency of single cells sorted in individual wells. An example 
of a successfully growing single GFPhi cell. Numbers above the images are the days of growth: 
days zero to four, five to seven, eight to eleven, 12 and 13 (Sato et al, 2009). 
To this end, Nozaki et al investigated intestinal intraepithelial lymphocytes (IELs) and their 
interaction with intestinal epithelial cells (IECs), however models to study such interactions 
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were limited. This is partly due to IELs undergoing apoptosis following isolation, but this has 
been overcome with the recognition that growth factors required were to maintain growth in 
vitro. Intestinal mouse organoids were established and IELs were subsequently isolated from 
mice and added as a co-culture. These were cultured for seven days using whole-mount analysis 
and time-lapse live imaging was used to study the interactions. They showed that IELs are 
motile in this system, changing their contact status with epithelial organoids. This was the first 
study demonstrating lymphocyte interaction with epithelial cells in an ex vivo system. It proved 
that such a system could be used to study dynamic interactions using organoids (Nozaki et al., 
2016). 
To understand response to immunotherapy, namely checkpoint blockade inhibition (CBI), 
Jenkins et al used murine- and patient-derived organotypic tumour spheroids 
(MDOTS/PDOTS). Their system utilized a 3D-microfluidic-culture device, in which single-cell 
suspension of tumour were first fractionated to different sizes and then embedded in a collagen-
based matrix, added to the device and cultured for a further six days. This device was viewed on 
a microscope to assess live/dead analysis of cells and supernatant was also assessed for cytokine 
production. Murine-derived tumours from the colon adenocarcinoma line MC38 and the 
melanoma line B16F10 were grown as MDOTS ex vivo. MDOTS were able to retain autologous 
immune contexture and short-term culture. To test CBI, MDOTS were treated with anti-PD-1 
antibody in the device and sensitivity to treatment was assessed with live/dead microscopy 
imaging. The MC38 MDOTS were sensitive to anti-PD-1 in a dose-dependent manner. To 
validate the murine studies, PDOTS from cancers responsive to anti-PD-1 tumours including 
melanoma and merkel cell carcinoma (MCC) were assessed using flow cytometry. When 
compared to the original tumour tissue, immune cell populations were retained validating the 
use of PDOTS to assess function of immune cells from patient-derived material. Together these 
data describe the functional utility of MDOTS/PDOTS to model ex vivo responses to CBI (R. 
W. Jenkins et al., 2018). 
Another recent study employed more traditional organoid culture without using a 3D-
microfluidic-culture device. Dijkstra et al designed a platform to study tumour-reactive T-cells 
from patients with CRC and non-small cell lung cancer (NSCLC). To do this, patient-derived 
tumouroids were established and autologous peripheral blood mononuclear cells (PBMCs) were 
isolated and co-cultured with the tumouroids to select for tumour-specific T-cells. In the 
colorectal cohort, only deficient MMR (dMMR) patients were recruited, as these patients are 
known to respond to CBI. As 60% of dMMR colorectal tumours lose MHC-I, tumouroids were 
screened for MHC-I loss, by stimulating with IFNγ, with 62% of the tumouroid samples being 
proficient for MHC expression. Importantly it was found that tumouroids classified as MHC-I 
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deficient were also MHC-I deficient in the native tumour, confirming that MHC-I loss is not a 
result of organoid culture. To select for tumour-reactive T-cells, MHC-I and programmed death 
liand-1 (PD-L1) expression was induced on tumouroids using IFNγ stimulation and autologous 
PBMCs co-cultured for two weeks. An anti-PD-1 antibody was included in the co-culture to 
avoid immune inhibition by the tumouroids. In four out of eight samples, IFNγ and CD107a 
expression was detected in and on CD8+ cells. In one particular patient there were tumour 
reactive T-cells detected pre-stimulation and following co-culture with tumouroids the CD8+ 
tumour-reactive T-cells increased 10-fold, implying that a tumour-specific T-cell pool was 
already present. To ensure these responses were tumour-specific, autologous T-cells were co-
cultured with matched normal organoids from dMMR, proficient-MMR (pMMR) CRC tumours 
and NSCLC, with no reactive T-cells detected.  
Occasionally, CD4+ reactive T-cells were observed against normal organoids, and it was 
hypothesised that this may be directed against foreign antigens from the extracellular matrix, as 
this is a murine-basement membrane matrix. It was noted that this matrix (Geltrex) does have 
the ability to induce a CD4+ T-cell response, which is not tumour reactive and this could be 
bypassed by using other alternative synthetic products. Finally to test the cytotoxicity of these 
cells, after three days of co-culture with tumour-reactive T-cells, the number of live cells was 
quantified by flow cytometry. Substantial reduction of live cells was observed across all 
samples. This was further validated with live imaging microscopy. It was found that after the 
addition of tumour-reactive T-cells, tumouroid size was reduced and widespread apoptosis was 
observed. To confirm specificity, tumouroids were cultured without T-cells or in the presence of 
blocking MHC-I and –II antibodies, where the tumouroids continued to proliferate indicating 
MHC-mediated mechanism. Together these data validate and demonstrate the use of this 
platform to understand immune cell reactivity to autologous tumour cells, ex vivo. It opens up 
the possibility of the utility of this platform to test drugs, especially in the field of immune-
oncology, as current patient-derived model systems are lacking (Dijkstra et al., 2018).  
Contemporaneously with this study, our group investigating the co-culture of autologous TILs 
and tumouroids was accepted for publication (Kong, 2018). Our platform will be subsequently 
explained in this thesis, and was used to investigate TIL function against autologous 
tumouroids. I was involved in the establishment of the assay and the assay was subsequently 
employed in a controlled prospective trial where patients with rectal cancer were assessed using 
the assay. Subsequently, these patients underwent definitive NACRT prior to surgical resection. 
As explained earlier in this review, there is a need for a robust individualised pre-treatment test 
that predicts pCR with high concordance with outcome (Ryan, Warrier, Lynch, & Heriot, 2015; 
Smith, Wiland, Mace, Pai, & Kalady, 2014). We found functionality of patient specific 
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cytotoxic TILs to be highly predictive of pCR to NACRT. It is instructive that this assay is 
performed before the effects of the tumor cell damage are induced by NACRT. Because this 
implies that the quality of the endogenous TILs impact upon the multiple actions of NA. Like 
the previous studies described, we were also able to highlight the utility of assessing TIL 
function and response to CBI using patient-derived material that will hopefully lead to better 
treatment stratification of patients. 
1.12 Checkpoint Blockade Inhibition (CBI)  
The concept of CBI as a therapy has only been employed clinically for the past decade, however 
the mechanism underpinning these pathways has been investigated since the 1970s. The initial 
work reporting on T-cell anergy by Mueller, Jenkins & Schwartz, where they discovered that 
some T-cells entered a state of reduced responsiveness when encountering processed antigen 
presented by MHC-Ia molecules in the absence of functional accessory cells (Mueller, Jenkins, 
& Schwartz, 1989). In these studies, murine Type I CD4 T-cells were investigated in the 
presence of antigen and purified Ia molecules in a planar membrane of fixed APCs. The cells 
failed to stimulate proliferation and instead induced a state of “proliferative non-
responsiveness”: where there was neither proliferation nor production of IL-2. This was TCR-
dependent as it happened in the context of both antigen and APCs. (Quill & Schwartz, 1987). 
This state was likened to T-cell tolerance in vivo; a phenomenon that has been explored in the 
context of viral and tumour immunity. 
 
It was later discovered that these stimulatory pathways were independent of TCR-CD3 
signalling but occurred dependant upon CD28 expressed on T-cells. The ligands for CD28 were 
discovered as B7-1 (CD80) and B7-2 (CD86), both can be expressed on professional APCs 
including macrophages, DCs and activated B-cells, which provided the second co-stimulation 
signal for T-cell activation (Linsley et al., 1991; Linsley, Clark, & Ledbetter, 1990). Indeed this 
is the dominant co-stimulatory signal required for T-cells to elicit a strong immune response 
(June, Bluestone, Nadler, & Thompson, 1994). 
 
Allison & Townsend postulated that tumours have the ability to activate T-cells through 
antigen-specific signals, but the lack co-stimulatory mechanisms necessary to render T-cell 
medicated immunity effective. When B7 was expressed on melanoma cells, it was demonstrated 
that tumour rejection could occur in vivo; this was CD8+ T-cell mediated (Townsend & Allison, 
1993). A homolog of CD28 is CTLA-4, which has a stronger affinity for B7-1 and B7-2 than 
CD28. This interaction has the ability to down regulate T-cell responses in vivo. It was 
subsequently found that blocking these inhibitory T-cell receptors can potentially enhance co-
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stimulatory receptors whereby anti-tumour immunity is improved (Leach, Krummel, & Allison, 
1996).  
 
Ipilimumab is a humanised monoclonal antibody that targets CTLA-4 that was developed 
following the successful use in controlling solid tumours in murine models. The mechanism of 
action of Ipilimumab is thought to occur through binding to the CTLA-4 receptor, expressed on 
activated CD4+ and CD8+ T-cells. This ensures that CTLA-4 cannot bind to its inhibitory 
receptor, B7 that can be expressed by APCs or tumour cells, to inhibit effector functions of 
activated T-cells and thus results in enhanced endogenous immune responses (Peggs, Quezada, 
Korman, & Allison, 2006). Initial phase I clinical trials investigated safety and response rates of 
Ipilimumab as a monotherapy in melanoma and renal cell carcinoma (RCC) reporting objective 
response rates of 7-15% (Blansfield et al., 2005; Ribas et al., 2005). Multiple subsequent trials 
in patients with advanced melanoma; advanced NSCLC and RCC have shown Ipilimumab to 
work in some patients as a monotherapy as measured according to the World Health 
Organization (WHO) criteria imaging assessment. More recent studies have reported that a 
combination of Ipilimumab plus Nivolumab, a humanised monoclonal antibody targeting PD-1, 
results in better response rates than monotherapy alone (Hellmann et al., 2018; Motzer et al., 
2018). 
 
The second group of antibodies used in CBI targets the PD-1 receptor (CD274) and PD-L1 
(CD27) ligand axis are transmembrane proteins that are transcriptionally activated and 
expressed on activated immune cells including Myeloid cells, NK, T- and B-cells (Terme et al., 
2011). This regulatory checkpoint pathway is employed by the immune system to dampen the 
immune response in peripheral tissues to maintain immune homeostasis. Following T-cell 
activation, immune dampening occurs at the time of an inflammatory response thus reducing the 
risk of autoimmunity whilst maintaining immune tolerance (Pardoll, 2012). 
 
Ishida et al first discovered the PCDC1 gene in the early 1990s; when investigating lymphoma 
cells lines undergoing cell death and that in these cells PD-1 transcription was activated (Ishida, 
Agata, Shibahara, & Honjo, 1992). The ligands for the PD-1 receptor are PD-L1 or PD-L2, 
which can be expressed on placental cells, activated APCs and parenchymal cells that are 
involved in inflammation (Freeman et al., 2000). Freeman et al proved that binding of PD-1 by 
PD-L1 inhibits TCR mediated proliferation of T-cells, resulting in a strong inhibitory signal 
(Freeman et al., 2000). 
 
Tumour cells have adapted mechanisms to exploit this pathway and evade the immune response 
with the ability to express PD-L1 or –L2. In murine model studies, Blank et al found that PD-
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L1 expression could be induced by IFNγ treatment in the poorly immunogenic B16-F10 
melanoma line. When testing the function of the B16-F10 cells, engaging transgenic CD8+ T-
cells expressing a high-affinity TCR, had reduced effector function with minimal cytokine 
production and cytolysis. By eliminating PD-1 engagement, effector function could be restored. 
This was one of the first studies to demonstrate the potential effects of targeting anti-PD-1/PD-
L1 interactions in a tumour system (Blank et al., 2004). Blocking the interaction of PD-1 and 
PDL1 therefore results in restoration of T-cell activation signals and subsequent effector 
functions of T-cells including cytokine production (Barber et al., 2006). However, it is still 
unknown how to predict which patients will respond to this therapy. PD-L1 expression on 
tumour cells is heterogeneous and is variable, so understanding PD-L1 inhibitors needs to be 
understood in greater detail (Alsaab et al., 2017). Patient characteristics including the tumour 
type, gender, mutational status of genes (EGFR and KRAS) and metastases of tumours have 
varying affects in response to PD-1 and PD-L1 inhibitors (D'Incecco et al., 2015). 
 
Topalian et al was the first to report on safety and activity of anti-PD-1 therapy (Nivolumab) 
tested in advanced melanoma, NSCLC, castration-resistant prostate cancer, RCC and CRC. 
They found that treatment with anti-PD-1 antibody produced objective response rates in 20-25% 
of patients with advanced melanoma, RCC and NSCLC. Cumulative response rates were 18%, 
28% and 27% in NSCLC, melanoma and RCC respectively. In patients that had positive PD-L1 
expression on the tumour, 36% had an objective response (Topalian et al., 2012). More recently 
studies have been conducted investigating Nivolumab in the neoadjuvant setting in NSCLC. In 
this study, few immediate adverse events were reported, and a major pathological response was 
observed in 45% of tumours that could be evaluated (Forde et al., 2018). These studies 
demonstrate that targeting immune checkpoints provides survival benefits, particularly when 
used in combination. It is an exciting time in the field with the emergence of using CBI in the 
neoadjuvant setting.  
1.12.1 Checkpoint Blockade in Colorectal Cancer 
Although CBI therapies have proven efficacious in multiple solid malignancies, they have only 
been effective in select CRC patients. In initial reports of CBI, only one of 33 CRC patients 
treated with anti-PD-1 antibody responded, and this patient was found to have a microsatellite 
unstable tumour (Topalian et al., 2012). 
 
Le et al conducted a subsequent phase 2 clinical trial to evaluate the clinical activity of anti-PD-
1 (Pembrolizumab) in patients with progressive metastatic carcinoma, including CRC, with or 
without mismatch repair deficiency. The study found that colorectal tumours with dMMR had 
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objective response rates of 40% and PFS of 78%. Conversely CRC tumours that were pMMR 
had 0% objective response rate and 11% PFS rates, as seen in Figure 1.5. 
 
This was the first study to definitively demonstrate that tumours with dMMR are more 
responsive to anti-PD-1 therapy than pMMR tumours. The hypothesis that dMMR tumours 
have an enhanced immune response is not a new concept, with many previous reports observing 




Figure 1.5 Clinical benefit of anti-PD-1 therapy demonstrates response in patients with 
mismatch-repair deficiency. (A) Kaplan–Meier curves are shown for PFS and (B) OS in the 
cohorts with colorectal cancer (Le et al, 2015). This was one of the first studies to show 
response to anti-PD-1 therapy in CRC. 
 
Patients with MSI tumours have an improved prognosis stage-for-stage except those who have 
advanced Stage IV disease (Goldstein et al., 2014). This subset of patients typically does not 
respond to conventional chemotherapy and have a shorter OS compared to advanced stage IV 
microsatellite stable tumours. A recent multicentre phase 2 trial investigated the safety of 
Nivolumab as a monotherapy in this subset of MSI-H mCRC patients (Overman et al., 2017). In 
this study Nivolumab provided durable responses and disease control in previously treated 
mCRC patients that were microsatellite unstable. Understanding the disease progression in the 
context of the immune response in advanced stage IV mCRC will be addressed in this thesis. It 
will be important to understand in these responsive patients if they have high TIL densities 
compared to the non-responders mCRC-MSI high cases. 
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1.13 Overview, Hypothesis and Aims 
Patients with advanced stage IV mCRC have a reduced survival compared to patients with 
earlier stages of CRC. In those patients who have CRLM, if left untreated, patients succumb to 
the disease within 12-24 months. Surgical intervention has certainly improved five-year survival 
in these patients, but recurrence is still common. We know that the immune response plays a 
role in CRC patients, and this is highlighted by the myriad studies that report tumours with high 
TIL presence have an improved OS and PFS at the primary site. This immune response in 
CRLM continues to be affective with improved survival correlated with increased cytotoxic 
CD8+ T-cells presence in these tumours. However in almost all studies, these TILs are only 
present on the invasive margin (IM) of the tumour indicating that there may be 
immunosuppressive factors at play. 
 
The “Immunoscore” provides strong prognostic significance of patient outcome, however it 
only documents immune cell presence and not function. Developing novel strategies to 
additionally assess function of TILs is an area that requires further development in the field of 
tumour immunity. This thesis seeks to investigate the innate and adaptive immune responses 
involved in the progression of advanced stage IV CRC. 
 
To investigate the immune responses in tumour progression at the primary site of advanced 
stage IV CRC, primary tumours of de novo mCRC stage IV patients were evaluated in Chapter 
3. This was done in a retrospective cohort of these patients, a proportion of which have 
dMMR/MSI-H tumours. Understanding the biology of the immune infiltrate, tumour escape 
mechanisms together with clinical outcome in patients with advanced mCRC of both 
microsatellite stable and unstable tumours will be important contribution for potential treatment 
strategies of these patients.  
 
Understanding the progression of metastasis to the liver in the context of the immune response 
may also provide insight into the mechanisms of tumour progression, in this setting. 
Additionally, determining not only immune cell presence but also immune function is an 
important property that warrants attention when assessing TILs. Therefore, Chapter 4 describes 
the process of development of a novel cytotoxic immune assay that can be utilised to assess TIL 
function from patient-derived material ex vivo. The frequency, location and function of immune 
cells within CRLM tumours were evaluated. Additional investigation into the responsiveness of 
these CRLM TILs to CBI is assessed to determine if the cells are in a functional state and 
respond to CBI. 
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Finally, novel subsets of CD8+ T-cells, namely MAIT cells that are abundant in the liver were 
evaluated in the context of CRLM in Chapter 5. These cells may be of therapeutic interest in 
cancer immunotherapy as they have rapid effector functions and act independently of MHC-I, 
meaning they can be allogeneic. Their role in disease pathogenesis and cancer is starting to be 
understood and further investigation is required for their role in CRLM.  
 
Therefore the following aims and hypotheses are in this thesis: 
 
Aim 1: Determine immune escape mechanisms at the primary site that leads to metastatic 
progression in primary tumours of patients with advanced stage IV de novo mCRC. 
Hypothesis: Patients with microsatellite unstable tumours will have a poor prognosis despite an 
increased infiltration of TILs. 
 
Aim 2: Develop a novel method to determine the effector function of TILs from CRLMs in 
patients with mCRC. 
Hypothesis: The presence and frequency of immune cells in situ alone does not always reflect 
their effector function. 
 
Aim 3: Investigate a novel subset of cytotoxic CD8+ T-cells to determine their purpose in 
tumour immunity in the context of CRLM. 
Hypothesis: MAIT cells are present within CRLM tumours due to their abundance in the liver.
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2. METHODS  
2.1 Human Participants 
Patients undergoing surgical liver resection for their CRLM or synchronous resection for their 
primary colorectal and hepatic metastases were prospectively enrolled to the study following 
informed consent between October 2015-October 2018. This took place across three hospitals 
including St. Vincent’s Hospital Melbourne, Peter MacCallum Cancer Centre and Royal 
Melbourne Hospital, all located in Melbourne, Australia. In total n=23 patients with CRLM were 
recruited, n=7 were treatment naïve and n=16 had neoadjuvant chemotherapy prior to liver 
resection. Inclusion criteria were radiological Magnetic Resonance Imaging (MRI) and 18Fluoro 
Deoxy-Glucose Positron Emission Tomography/Computerised Tomography (18FDG PET/CT), 
confirmed diagnosis of CRLM and surgical resection with curative intent. Patients <18 years old 
were excluded from the study. Patients were discussed at the colorectal and hepatobiliary 
multidisciplinary team meeting whereby treatment decisions are made between the oncology, 
radiation oncology and surgical teams. 
 
All work involving human participants was conducted according to ethical guidelines; using a 
protocol approved by the St. Vincent’s Hospital Melbourne Human Research Ethics Committee 
(HREC) across all three hospitals (reference HREC/15/SVHM/54). Subsequent governance 
approval was obtained at each site. 
Table 2.1. Clinical and demographic characteristics of patients recruited to this study 
Demographic Attributes  
Total patients, n 23 
Female gender, n (%) 
 
9 (39) 
Male gender, n (%) 14 (61) 
Mean age, years (±SD) 58±10 
Median age (Range) 60 (40-77) 
Oncologic Attributes  
Liver Segment Involvement  
≤3, n (%) 18 (82) 
>3, n (%) 4 (18) 
Extrahepatic Disease, n (%) 6 (26) 
Chemotherapy, n (%)  
Neoadjuvant Chemotherapy 16 (70) 
Chemotherapy Naïve 7 (30) 
Progression free survival (PFS)  
Recurrence, n (%) 8 (40) 
No recurrence, n (%) 14 (60) 
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2.2 Human Sample Processing 
 
Blood Collection: SepMateTM tubes 
Following general anesthesia, 40-50 mL of peripheral blood was drawn through an arterial line 
into ethylenediaminetetraacetic acid (EDTA)-blood collection tubes (Sarstedt AG & Co, 
Nümbrecht Germany). Tubes were centrifuged at 300 x g, 5 minutes to collect plasma, which was 
subsequently stored at -80°C. 
 
PBMCs were obtained by density gradient centrifugation using SepMateTM-50 tubes (Stemcell 
Technologies, Vancouver, Canada) containing 15 mL low-endotoxin (<0.12 EU/mL) Ficoll-Paque 
PLUS (GE health care life sciences, Massachusetts, USA). Blood was diluted 1:2 with Phosphate 
Buffered Saline (PBS) and 25 mL were layered onto SepMateTM tubes. Tubes were centrifuged 
at 1200 x g, 10 minutes with the break on at room temperature (RT). Mononuclear cell layer was 
poured off and cells were washed with PBS at 300 x g, 8 minutes. Red blood cells were treated 
with ammonium chloride lysis (ACK) solution for 3 minutes and subsequently washed with PBS 
at 300 x g, 8 minutes. Cells were suspended in RPMI 1640 (Gibco, Thermo fisher Scientific, 
Massachusetts, USA) supplemented with 10% (v/v final) human AB-serum (Valley Biomedical, 
Inc., Virginia, USA), 100 U/mL penicillin and 100 μg/mL streptomycin (Sigma-Aldrich, 
Missouri, USA), glutamax (=2mM L-glutamine) (Gibco, Thermo fisher Scientific, Massachusetts, 
USA), 25mM HEPES, 10 μg/mL gentamycin and 0.25 μg/mL fungizone (Gibco, Thermo fisher 
Scientific, Massachusetts, USA) herein referred to as Complete Medium (CM). Cells were 
counted in 0.4% trypan blue (Gibco, Thermo fisher Scientific, Massachusetts, USA) using a 
haemocytometer and were either used immediately or were cryopreserved. 
 
Blood Collection: BD Vacutainer® CPT™ Cell Preparation Tube with Sodium Citrate 
Blood was collected by venepuncture in BD Vacutainer® CPT™ Cell Preparation Tubes (BD 
Biosciences, New Jersey, USA), stored upright and processed within 2 hours of collection. Tubes 
were centrifuged for 20 minutes, 1700 x g, at RT in a horizontal rotor (swing-out head). After 
centrifugation, whole plasma was removed by transfer pipette and stored at -80°C if required or 
discarded. Mononuclear cell and platelet layer was gently transferred into falcon tube (maximum 2 
CPT tubes per falcon) using a transfer pipette. Cell suspension was washed with 30 mL of PBS, 
inverted 5-10 times and centrifuged for 10 minutes, 300 x g, RT. Supernatant was gently removed 
without disturbing the pellet. To remove red blood cells, 1-2 mL of ACK buffer was added at RT 
for 2-3 minutes and the reaction was stopped by adding 30 mL PBS and consequent centrifugation 
for 10 minutes, 120 x g, RT. Supernatant was discarded, and one final wash step completed, by 
adding PBS and centrifuging again for 10 minutes, 300 x g, RT. Cells were counted in 0.4% 
trypan blue (Gibco, Thermo fisher Scientific, Massachusetts, USA) using a haemocytometer and 
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were used immediately or cryopreserved for future experiments. 
 
Storage of Clinical Samples 
For snap frozen material, tissue was dissected and placed in a cryotube (Thermo fisher Scientific, 
Massachusetts, USA) and placed immediately on dry ice and subsequently transferred to -80°C. 
For cryopreservation, cells were resuspended in 10% Dimethyl sulfoxide (DMSO) (Sigma 
Aldrich, Missouri, USA) in fetal bovine serum (FBS) (Gibco, Thermo fisher Scientific, 
Massachusetts, USA) and immediately transferred to -80°C in Mr Frosty containers (Thermo 
fisher Scientific, Massachusetts, USA). After 24 hours vials were removed from the Mr Frosty 
containers and stored long term at -80°C. 
 
Fresh Tissue Preparation 
Following surgical resection of primary and/or hepatic metastases, fresh tumour and liver 
specimens were collected in RPMI 1640 (Gibco, Thermo fisher Scientific, Massachusetts, USA) 
supplemented with 5% (v/v) fetal bovine serum (FBS) (Gibco, Thermo fisher Scientific, 
Massachusetts, USA), 100 U/mL penicillin and 100 μg/mL streptomycin (Sigma Aldrich, 
Missouri, USA), and placed on ice. Tissue was initially dissected to remove necrotic regions and 
adjacent liver to expose a viable tumour margin and divided into four pieces: 1) snap-freezing 
tissue was immediately frozen on dry ice, 2) to cryo-preserve tissue, tissue pieces were added to 
10% DMSO (Sigma Aldrich, Missouri, USA) in FBS (Gibco, Thermo fisher Scientific, 
Massachusetts, USA) and immediately transferred to -80°C in Mr Frosty containers, 3) formalin-
fixing tissue was placed in 10% Neutral-Buffered Formalin (NBF) (Australian Biostain, 
Traralgon, Australia). Formalin-fixed tissues were transferred to 70% Ethanol (EtOH) after 24 
hours and subsequently embedded in paraffin. FFPE blocks were stored at RT and slides were cut 
fresh prior to use for heamatoxylin and eosin (H&E) staining, Immunohistochemistry (IHC) and 
multiplex immunohistochemistry (mIHC), as detailed in Immunohistochemistry section. The 
fourth tissue piece was further divided and this margin was used to establish tumouroids and 
expansion of TILs. 
2.3 Expansion of Lymphocytes 
 
Tumour Infiltrating Lymphocyte (TIL) Expansion 
To establish TIL expansion, small pieces of viable tumour (1 mm3) were divided and each placed 
in 48-well plate containing CM supplemented with 6000 IU/mL recombinant human interleukin-2 
(IL-2) (NCI, Charles River Laboratories, Massachusetts, USA). Media was changed twice weekly; 
by removing half of the CM and replacing with fresh CM supplemented with 12,000 IU/mL IL-2. 
Once cells reached 100% confluency, wells were transferred to a T25 flask and maintained at 
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1.5x106 cells/mL of CM supplemented with IL-2 (6000 IU/mL). When in culture, expanded TILs 
were used for downstream assays or cryopreserved for long-term storage at  -80°C. 
 
MAIT Cell Expansion Protocol 
To expand MAIT cells from peripheral blood, PBMCs were isolated by Ficoll-Plaque density 
gradient using the SepMate protocol and sorted by FACS as described in Cell Separation: 
Fluorescent Activated Cell Sorting (FACS). Primary human MAIT cells were stimulated for 48 
hours on 96 well plates with 10 µg/mL plate-bound anti-human CD3 (OKT3; BD Biosciences, 
New Jersey, USA) and 1:40 dilution of Immunocult™ (Stemcell Technologies, Vancouver, 
Canada) in CM supplemented with 100 U/mL recombinant human IL-2 (NCI, Charles River 
Laboratories, Massachusetts, USA), 10 ng/mL rhuIL-7 (NCI, Charles River Laboratories, 
Massachusetts, USA), 50 ng/mL rhuIL-12 (Lonza, Basel, Switzerland), 50 ng/mL rhuIL-15 (NCI, 
Charles River Laboratories, Massachusetts, USA) and 50 ng/mL rhuIL-18 (R&D Technologies, 
Rhode Island, USA). After 48 hours, cells were removed from anti-CD3, anti-CD28 and PHA 
stimulation and maintained in human T cell media and supplemented cytokines. 
2.4 Tumouroids 
 
Establishment of Patient-Derived Tumouroid Cultures 
To establish tumouroids, viable tumour was minced and enzymatically digested using Advanced 
DMEM F-12 (Gibco, Thermo fisher Scientific, Massachusetts, USA) supplemented with 100 
U/mL penicillin and 100 μg/mL streptomycin (Sigma Aldrich, Missouri, USA), glutamax (=2mM 
L-glutamine) (Gibco, Thermo fisher Scientific, Massachusetts, USA), 25mM HEPES, 10 μg/mL 
gentamycin (Pfizer, New York, USA) and 0.25 μg/mL amphotericin B (Gibco, Thermo fisher 
Scientific, Massachusetts, USA), 1mg/mL collagenase type IV (Worthington, Biochemical 
Corporation, New Jersey, USA), 125 μg/mL dispase (Gibco, Thermo fisher Scientific, 
Massachusetts, USA), 25 μg/mL hyaluronidase (Sigma Aldrich, Missouri, USA) and 0.1 μg/mL 
DNAse (Sigma Aldrich, Missouri, USA), in a water bath, 37°C for 30-60 minutes. Tumour pieces 
were then titurated using a p-1000 pipette, media was added and homogenate was passed through 
a 70 uM filter. Cells were centrifuged at 400 x g, supernatant discarded and cell pellet resuspended 
in matrigel. 50 uL of the matrigel-cell suspension was seeded in corning 24-well plate, and 
maintained in 500 uL OB Media supplemented with: 5mM A8301 (Torcis Bioscience, Bristol, 
UK), 1 X B27™ (Gibco, Thermo fisher Scientific, Massachusetts, USA), 500 μg/mL Epidermal 
Growth Factor (Sigma Aldrich, Missouri, USA), 1 mg/mL Gastrin (Sigma Aldrich, Missouri, 
USA), 612.78 mM N-acetylcysteine (Sigma Aldrich, Missouri, USA), 10 mM SB202190 (Sigma 
Aldrich, Missouri, USA), 10 mM Y27632 (Sigma Aldrich, Missouri, USA), herein referred to as 
CRC media. Tumouroids were passaged every 7-10 days, or as required depending on growth rate. 
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Tumouroids that did not grow within 14-21 days were deemed stunted and were subsequently 
discarded. 
 
Passaging of Patient-Derived Tumouroid Cultures 
When tumouroids had reached 100-200 μm in diameter, tumouroids were considered suitable for 
passaging. A minimum of 2 wells would be cryopreserved for future use, by aspirating the media 
in the well and adding 1 mL of cold 10% DMSO in FCS, which was storage at -80°C.  
The remaining wells to be passaged would be aspirated and cold Advanced DMEM-F/12 (Gibco, 
Thermo fisher Scientific, Massachusetts, USA) supplemented with 100 U/mL penicillin and 100 
μg/mL streptomycin (Sigma Aldrich, Missouri, USA), glutamax (2mM L-glutamine) (Gibco, 
Thermo fisher Scientific, Massachusetts, USA), 25 mM HEPES, 10 μg/mL gentamycin and 0.25 
μg/mL amphotericin B (Gibco, Thermo fisher Scientific, Massachusetts, USA) herein referred to 
as organoid basal (OB) media, would be added and used to scratch off the matrigel. The resulting 
mixture was transferred to a falcon tube, which was incubated on ice to convert the matrigel into a 
liquid state before starting centrifugation at 300 x g, 5 minutes. Media was aspirated, 1 mL of 
Tryple (Gibco, Thermo fisher Scientific, Massachusetts, USA) was added and tumouroids were 
incubated in a waterbath, 37°C for 10 minutes. Tumouroids were then triturated using a p1000 
pipette, 9 mL of OBM was added and tumouroids were centrifuged 300 x g, 5 minutes. Media was 
aspirated and ice-cold matrigel was added to cell pellet. Amount of matrigel added to pellet was 
determined by cell pellet size, as a general rule each well was split 1:2. 50 μL of 
tumouroid/matrigel suspension was seeded per well of a 24-well plate. Plates were incubated for 
30-45 minutes at 37°C for matrigel to set, before 500 μL of tumouroid growth media was added to 
each well. Tumouroids were grown in hypoxic conditions (37°C, 5% O2, 5% CO2) and growth 
media was changed twice weekly, and growth was monitored until subsequent passaging was 
required. 
2.5 Cytotoxic Assay Protocols 
 
Cytotoxic Assay: Preparation of Tumouroids 
Tumouroids were deemed suitable for cytotoxic assay co-culture by passage 2-3 (10-14 days post 
initial biopsy) and were plated at least 5-7 days prior to performing the assay. For optimal assay 
conditions, organoids were grown to >50 μm and checked morphological for viability using a light 
microscope on the day of assay, before proceeding. Retractile tumouroids were chosen for the 
assay. 
 
Cytotoxic Assay: Passaging of Tumouroids 
At passage 2-3, when tumouroids cultivated in 24-well plate were between 100-200 μm in size, 
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media was aspirated from each well. Wells were washed twice with ice-cold organoid basal (OB) 
media, using the tip of p1000 pipette to scratch Corning Matrigel® Matrix (Sigma Aldrich, 
Missouri, USA) from the well, and transferred to a falcon tube.  
Aspirate was incubated on ice, for 5 minutes and centrifuged 5 minutes, 500 x g, 4°C. OB media 
was aspirated and cell/matrigel pellet was resuspended in 1-5 mL pre-warmed (37°C) TrypLE 
Express (Gibco, Thermo fisher Scientific, Massachusetts, USA), tubes incubated in 37°C water 
bath, 10 minutes. Following incubation, organoids were forcefully triturated by mechanical 
dissociation using a p1000 pipette. To ensure organoids were at the single cell level, suspension 
was checked under the light microscope and further incubation with fresh TrypLE Express was 
commenced, if necessary. Cells were washed with 15 mL of OB media and centrifuged 5 minutes, 
500 x g, 4°C. Supernatant was aspirated and the cell pellet was resuspended in 100 μL of ice-cold 
liquid matrigel. To check cell density, a small aliquot of cell suspension was visualised under a 
light microscope and additional matrigel was added if required. 
Organoids were plated on pre-warmed µ-Plate 96 Well (ibidi, GmbH Germany), by seeding 20 μL 
of matrigel/cell suspension into each well, and placed to set in 37°C incubator for 30-60 minutes. 
Following incubation, 350 μL of pre-warmed CRC media, was added to each well, and 
tumouroids were grown in hypoxic conditions (37°C, 5% O2, 5% CO2) for 7-10 days prior to 
running the cytotoxic assay. 
 
Cytotoxic Assay: Preparation of TILs 
Expanded TILs were harvested from either 24-well plate or T25 flask and filtered through 70uM 
filter. Cells were counted using a haemocytometer, and subsequent TIL concentrations were 
determined. To calculate Effector: Target (E: T) ratio of TILs: tumouroid, tumouroids per well 
were counted. TIL concentration was determined for 5000 TILs: one organoid, and did not exceed 
300,000 TILs/well. TILs were then centrifuged, washed with CM, centrifuged again and 
resuspended in the required volume of pre-warmed CRC media and kept at 37°C until ready for 
addition to the cytotoxic assay. 
 
Preparing the Cytotoxic Assay Media 
The number of wells required for the cytotoxic assay was determined and multiplied by 344 uL of 
CRC media. Propidium Iodide (PI) (Sigma Aldrich, Missouri, USA) was added, for a final 
concentration of 17.1 μg/mL, TILs were then resuspended in this media. 
Media from the cultivated organoids in µ-Plate 96 was aspirated. Wells were set up in duplicate 
per condition with the following conditions: organoids alone (negative control), organoids+TILs, 
organoids+TILs+anti-PD-1 antibody (Keytruda, Merck, New Jersey, USA).  
For the negative control wells 350 μL of CRC media + PI was added. TIL suspension was then 
added to remaining wells and supplemented with 6,000 IU/mL of rh-IL-2. Anti-PD-1 antibody 
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(Keytruda, Merck, New Jersey, USA) was added to respective wells at final concentration of 




The µ-Plate (96 wells) was mounted on a heated stage in a temperature controlled chamber, which 
was maintained at 37°C, 5% CO2 (“The Brick”; ibidi). Using the cellSens software (Olympus), 
imaging of the plate was obtained on a 10x (NA 0.5) air objective, selecting 10 tumouroids at the 
periphery of the matrigel. Optical sections were acquired through sequential scans of brightfield 
and PI (excitation 493nm) every 2 hours for 48 hours. 
Imaging series were analysed using ImageJ software (NIH, Maryland, USA) to obtain the mean 
fluorescence intensity (MFI) of PI uptake in tumouroids over time. The mean of 10 tumouroids 
per well was taken to analyse kinetics of TIL-induced killing over time. The maximum MFI per 
time point was also assessed to obtain the overall maximum killing threshold of each condition. 
 
Caspase 3/7 E:T Titration 
To assess TIL-mediated tumouroid death, generation of activated-caspase 3/7 was used to show 
induced apoptosis using CellEvent™ Caspase-3/7 Green ReadyProbes™ Reagent (Thermo fisher 
Scientific, Massachusetts, USA). One drop of CellEvent™ Caspase-3/7 Green ReadyProbes™ 
Reagent and 17.1 μg/mL PI (Sigma Aldrich, Missouri, USA) was added to 1mL of CRC media 
and subsequently aliquoted to wells containing tumouroids for the assay. As this results 
anticipated, as TIL number increased, rapid tumouroid death was observed. Caspase 3/7 was 
detected using the Olympus IX3 GFP filter. 
 
MAIT Cell Cytotoxic Assay Co-culture 
Patient-derived tumouroids were established and maintained as previously described. 
Approximately 7 days before running the co-culture experiment, tumouroids were passaged and 
20 uL seeded into a 96-well ibidi plate, with 350 uL of CRC media added. Healthy donor whole 
blood was collected following the Blood Collection: BD Vacutainer® CPT™ Cell Preparation 
Tube with Sodium Citrate. Following isolation, cells were counted and stained following the 
Cell Separation: Fluorescent Activated Cell Sorting (FACS) protocol, using antibodies against: 
CD3 PE-CF594, Vα7-2 BV711, CD161 PE and DAPI as a cell viability marker. Once cells were 
collected, they were maintained in SM at RT and centrifuged 300 x g, 10 minutes. Supernatant 
was aspirated and cell pellet was resuspended in 0.5-1 mL CM, and subsequently counted in 0.4% 
trypan blue (Gibco, Thermo fisher Scientific, Massachusetts, USA) using a haemocytometer, to 
confirm cell count from flow cytometry sorter. 
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For stimulated MAIT cells on Day 0 (D0): MAIT cells were stimulated for 48 hours using the 
MAIT Cell Expansion Protocol, before being used in co-culture with tumouroids.  
For unstimulated MAIT cells on Day 2 (D2): Freshly isolated MAIT cells were used immediately 
in co-culture with tumouroids. 
 
For co-culture with tumouroids approximately 2-4x105 MAIT cells were added to each well. This 
would depend on the cell harvest of each individual donor; however, the same number of cells 
would uniformly be added to each condition. The co-culture followed the same protocol: 
Preparing the Cytotoxic Assay Media, with some amendments. In the MAIT co-culture 100 
U/mL of IL-2 was used in all wells. 5-OP-RU was generously donated by Dale Godfrey and Paul 
Beavis and used at 10 nM final concentration. Anti-PD-1 antibody (Keytruda, Merck, New Jersey, 
USA) was used at final concentration of 50 ug/mL Anti-MR1 (Biolegend, California, USA) 
antibody was used at final concentration of 10 μg/mL. 
2.6 Flow Cytometry 
 
Tissue Processing for Flow Cytometry Phenotyping 
Following surgical resection, tumour and normal liver tissue (>3 cm from tumour) were collected 
immediately in RPMI 1640 (Gibco, Gibco, Thermo fisher Scientific, Massachusetts, USA) 
supplemented with 5% FBS (Gibco, Thermo fisher Scientific, Massachusetts, USA), 100 U/mL 
penicillin and 100 μg/mL streptomycin (Sigma Aldrich, Missouri, USA) herein referred to as 
wash medium and kept on ice until processed. Tissue was initially divided for storage, tumouroid 
establishment and TIL expansion, as described above. Remaining tissue was then weighed and 
finely minced using a scalpel blade. Minced tissue was divided into 1g (maximum) and 
enzymatically digested with 5 mL of DMEM supplemented with 75 U/mL collagenase type IV 
(Worthington) and 0.1 μg/mL DNase (Sigma Aldrich, Missouri, USA) in gentleMACS c-tubes 
(Miltenyi Biotech, Bergisch Gladbach, Germany). GentleMACS c-tubes harbouring tissue was 
placed on a gentleMACS dissociator to achieve single cell suspension, by using the human tumour 
program 1, 2 and 3. Following this, tubes were incubated on at shaker at 37°C for 30-60 mins. The 
gentleMACS c-tubes were placed on the gentleMACS dissociator and tumour programs were 
repeated as before. To inhibit the enzymatic reactions, tissue homogenate was passed through a 
100 μm filter into a 50 mL falcon tube, and the plunger of a 3 mL syringe was used to grind 
remaining whole tissue. The filter was rinsed with wash medium and the single cell suspension 
was then poured through 70 μm filter followed by a 40 μm filter, with subsequent washing in-
between. Cells were centrifuged at 330 x g, 10 minutes, 4°C. Supernatant was aspirated and red 
blood cells were lysed by resuspending the cells in ACK buffer for 3 minutes, room temperature 
with constant agitation. Tubes were filled to 50 mL with PBS, centrifuged for 300 x g, 10 minutes, 
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4°C. Supernatant was aspirated and cells resuspended in 2-3 mL wash medium for counting. Cells 
were diluted 1:10 with 0.4% trypan blue (Gibco, Thermo fisher Scientific, Massachusetts, USA) 
and counted using a haemocytometer. Cells were kept at 4°C until ready for downstream 
applications including flow cytometry, fluorescent activated cell sorting (FACS) or in vitro assay. 
Surface Cell Staining for Flow Cytometry 
Following tissue digestion for tumour and liver tissue or isolation of PBMCs, cells were divided 
into 4 wells of a 96-well v-bottom plate (Nunc, Thermo scientific, Massachusetts, USA). For 
unstained (U/S) and Fixable Viability Stain (FVS) only controls, 0.5-1 x105 cells were added to 
respective wells. For stained and isotype control samples 0.5-1.0x106 cells were added to 
respective wells. Cells were washed twice with PBS and centrifuged 400 x g, 4 minutes, 4°C. 
Fixable Viability Stain 575 (BD Biosciences, New Jersey, USA) was thawed on ice and diluted 
1:1000 with PBS, 200 μL diluted FVS575 was added to FVS-only and isotype controls and 
stained sample, U/S control was resuspended in PBS. Cells were incubated at room temperature, 
10 minutes in the dark. Following incubation, plate was centrifuged 400 x g, 4 minutes, 4°C to 
pellet cells, supernatant was discarded and cells were washed in PBS. Human Fc Block (BD 
Biosciences, New Jersey, USA) was diluted 1:10 in Brilliant Stain Buffer (BD Biosciences, New 
Jersey, USA) and stain and isotype-control samples were resuspended in this medium. U/S and 
FVS-only controls were resuspended in RPMI, 4% FCS, 100 U/mL penicillin and 100 μg/mL 
streptomycin (Sigma Aldrich, Missouri, USA) herein referred to as Staining Media (SM), samples 
were incubated 10 minutes, 4°C in the dark. Following incubation, 100 μL of antibody cocktail 
was added to stain and isotype-control wells, SM was added to U/S and FVS-only controls and 
samples were incubated 30 minutes, 4°C in the dark. Samples were washed twice with SM and 
fixed with 100 μL 1% Paraformaldehyde (PFA) in SM and acquired on the BD LSRFortessa™ X-
20 within 48 hours. Alternatively, cells used for intracellular cytokine staining (ICS) or 
transcription factor (TF) staining, were fixed with 100 μL 1x Cytofix/Cytoperm (BD Biosciences, 
New Jersey, USA) or 1x Transcription Factor Buffer (BD Biosciences, New Jersey, USA) 
working solution and incubated 20 minutes or 45 minutes, 4°C in the dark, respectively. 
 
Intracellular Cytokine Staining (ICS) for Flow Cytometry 
Following cytofixation/permeabilisation cells were washed twice with 1x Perm/Wash™ (BD 
Biosciences, New Jersey, USA) working solution and centrifuged 350 x g, 4 minutes, 4°C. Cell 
pellets were resuspended in 50 μL of intracellular cytokine antibody/isotype cocktail and 
incubated 30 minutes, 4°C in the dark. Cells were washed twice with 1x Perm/Wash and 
resuspended in 200 μL of SM. Cells were acquired on the BD LSRFortessa™ X-20 within 8 hours 




Transcription Factor Staining for Flow Cytometry 
Following cytofixation/nuclear permeabilisation, cells were washed twice with 1x TF 
Perm/Wash™ (BD Biosciences, New Jersey, USA) working solution and centrifuged 350 x g, 4 
minutes, 4°C. Cell pellets were resuspended in 100 μL of transcription factor monoclonal 
antibody/isotype cocktail and incubated 30 minutes, 4°C in the dark. Cells were washed twice 
with 1x TF Perm/Wash and resuspended in 200 uL of SM. Cells were acquired on the BD 
LSRFortessa™ X-20 within 48 hours of transcription factor staining. 
Cell Separation: Fluorescent Activated Cell Sorting (FACS) 
Cells were counted using a haemocytometer and resuspended at 2 x108/mL in SM. Surface 
antibodies were added to the cell suspension and incubated for 20 minutes in the dark at RT. Cells 
were washed with 5-10 mL of SM, centrifuged 300 x g, 5 minutes. Cell pellet was resuspended in 
SM at 1-2 x108/mL and acquired on a BD FACSAria™ Fusion 3 or 5. Sorted T-cells were defined 
initially by double exclusion, DAPI negative, lymphocyte morphology (as gated by SSC-A versus 
FSC-H) that were subsequently CD3+. 
 
Expanded TIL FACS Sort 
On the day of the cytotoxic assay, expanded TILs were stained following Cell Separation: 
Fluorescent Activated Cell Sorting (FACS) protocol. Following doublet exclusion, lymphocyte 
morphology (as gated by SSC-A versus FSC-H) that were subsequently CD3+, the following cells 
were defined for the TIL subset cytotoxic assay: NK Cells: CD56+CD8-, NKT Cells: 
CD3+CD56+, CD8: CD3+CD8+, CD4: CD3+CD4+ 
 
MAIT Cell FACS Sort 
MAIT cells were defined as CD161 high, Vα7.2 and 5-OP-RU tetramer positive. Conventional 
cytotoxic T-cells were gated as CD8+. 
 
Cell Separation: Magnetic Activated Cell Sorting (MACS) 
To obtain an enriched population of MAIT cells, PBMCs or freshly isolated tissue-lymphocytes 
were counted using a haemocytometer and resuspended to 1 x 107/mL in PBS, pH 7.2, 0.5% BSA 
and 2 mM EDTA, herein referred to as MACS buffer. Cells were centrifuged 300 x g, 5 minutes 
and resuspended in 90 μL MACS buffer with 10 μL of anti-human Vα7.2-PE (clone REA179, 
Miltenyi Biotech, Bergisch Gladbach, Germany), cells were incubated 20 minutes in the dark, 
4°C. Cells were washed and resuspended in 80 μL of MACS buffer and labelled with 20 μL of 
Anti-PE Microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany) and incubated 15 minutes 
in the dark, 4°C. Cells were washed and resuspended in 500 μL of MACS buffer, which was then 
passed through a magnetic field using a MACS MS column (Miltenyi Biotech, Bergisch 
Gladbach, Germany). The column was washed 3 times, and removed from the magnetic field. One 
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millilitre of MACS buffer was then applied to the column and positively labelled cells were 
collected when pushed through, using a plunger. Cells were counted with a haemocytometer and 




Flow Cytometry Antibodies 
All antibodies were mouse anti-human monoclonal antibodies, unless otherwise stated. Viability 
dyes included the use of Fixable Viability Stain 575 and 620 (BD Biosciences, New Jersey, USA) 
and DAPI (Thermo Fisher Scientific).	
Table 2.2 Flow Cytometry List of Antibodies 
Specificity Clone Fluorochrome Company Dilution 
CD3 PE-Cy7 SK7 BD Biosciences 1:50 
CD3 PE-CF594 UCHT1 BD Biosciences 1:40 
CD45 FITC HI30 BD Biosciences 1:25 
CD45 BV510 HI30 BD Biosciences 1:40 
CD4 APC-H7 RPA-T4 BD Biosciences 1:50 
CD4 BV650 SK3 BD Biosciences 1:40 
CD8α RPA-T8 V500 BD Biosciences 1:50 
CD8α SK1 APC-H7 BD Biosciences 1:20 
CD161 DX12 PE BD Biosciences 1:20 
Vα7.2 3C10 BV711 Biolegend 1:40 
Vα7.2 3C10 BV421 Biolegend 1:20 
Vα7.2 REA179 PE Miltenyi Biotech 1:100 
HLA-DR G46-6 BB515 BD Biosciences 1:20 
CD279/PD-1 EH12.2H7 
 
BV785 Biolegend 1:20 
CD69 FN50 PE-Cy7 BD Biosciences 1:100 
CD45RO UCHL1 PerCP-Cy5.5 BD Biosciences 1:20 
Foxp3 259D/C7 PE BD Biosciences 1:5 
CD25 M-A251 PE-Cy7 BD Biosciences 1:20 
CD107a H4A3 APC BD Biosciences 1:20 
CD56 NCAM16.2 FITC BD Biosciences 1:50 
CD56 NCAM16.2 
 
PE-CF594 BD Biosciences 1:20 
HLA-DR G46-6 BB515 BD Biosciences 1:66 
CD11b ICRF44 BV786 BD Biosciences 1:20 
CD33 WM53 PE-Cy5 BD Biosciences 1:10 
CD279/PD1 MIH4 BV421 BD Biosciences 1:20 
CD274/PD-L1 MIH1 APC-R700 BD Biosciences 1:20 
IFNγ 4S.B3 BV786 BD Biosciences 1:20 
TNFα MAb11 PerCP-Cy5.5 BD Biosciences 1:100 





BV421 NIH  1:20 
 
The MR1 tetramer technology was developed jointly by: Professors James McCluskey, Jamie 
Rossjohn, and David Fairlie; and the material was produced by the NIH Tetramer Core Facility as 
permitted to be distributed by the University of Melbourne. 
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Flow Cytometry Analysis 
For analysis of clinical samples, analysis was performed using FlowJo, LLC, vX0.7 (BD 
Biosciences, New Jersey, USA). T-cells were defined initially by double exclusion, FVS575-, 
lymphocyte morphology (as gated by SSC-A versus FSC-H), CD45+ and were subsequently 
CD3+. 
2.7 Multiplex Cytokine Analysis 
 
Twelve- and Eight-plex Cytokine 
Twelve-plex cytokine array was performed using the Cytometric Bead Array (CBA) Flex Sets: IL-
1α, IL-1β, IL-2, IL-4, IL-10, IL-12p70/IL-23, IL-17F, IFNγ, TNFα, GM-CSF, MCP-1 and VEGF 
(BD Biosciences, New Jersey, USA) according to manufacturers instructions. 
 
Eight-plex cytokine array was performed using the CBA Flex Sets: IL-2, IL-6, IL-10, TNFa, 
FasL/CD178, Granzyme-B, IL-12p70, IFNγ according to manufacturers instructions. 
 
Top standards were prepared at 2500 pg/mL and were serially diluted 1:2 to 10 pg/mL, with a 
blank control at 0 pg/mL. Briefly, capture beads were plexed and mixed 1:2 with standard/sample 
duplicates in 96-well plate. Plate was incubated at room temperature, light protected, 1 hour. PE-
detection reagent was added to standard/sample wells, incubated room temperature, light-
protected, 1 hour. Wells were washed with wash buffer, centrifuged 200 x g, 5 minutes. Wells 
were resuspended in wash buffer and acquired on BD FACSVerse™. Acquisition of each analyte 
included 300 events. Results were analysed using FCAP Array™ unknown concentrations were 
determined from the standard curve of each analyte. 
2.8 Microscopy, Histology & Immunohistochemistry 
 
Scanning Electron Microscopy (SEM) 
Morphological killing was also examined by scanning electron microscopy (SEM) (JCM-6000, 
Jeol, operated at 15 kV under high vacuum). Organoids were plated onto an Aclar film in a 12 
well plate overnight and co-cultured with TILS for 2 hours the following 156 day. Organoid-TILS 
co-cultures were fixed with 2.5% glutaraldehyde, 2% PFA in 0.1M sodium cacodylate buffer for 1 
hour at 37°C, followed by washes in 0.1M sodium cacodylate buffer. For SEM, the fixed 
organoid-TILS co- cultures were dehydrated through a series of increasing concentrations of 
ethanol, underwent critical point drying in Leica EM CPD300, sputter-coated with gold and 






FFPE blocks were cut at 4 μm thickness and transferred onto Superfrost Plus slides (Thermo 
fisher Scientific, Massachusetts, USA) and melted in 60°C oven for 1 hour. Slides were dewaxed 
in histolene and subsequently rehydrated in graded EtOH. Antigen retrieval was achieved by 
incubating slides in antigen retrieval buffer (Table 2.2) in pressure cooker at 125°C, 3 minutes 
followed by 90°C, 10 seconds. Slides were subsequently cooled at RT for 30 minutes, and then 
blocked with 10% hydrogen peroxide (H2O2) (Merck-Millipore, Massachusetts, USA) for 10 
minutes. Slides were washed with 1% Tri-Phosphate Buffer (TBS) Tween (Sigma Aldrich, 
Missouri, USA) and primary antibody was added to each slide covering tissue, and incubated 
either overnight at 4°C or 1 hour at room temperature in humidified chamber. Following 
incubation, slides were washed three times in TBS-Tween and ImmPRESS® (Vector laboratories, 
California, USA) secondary antibody was added to tissue sections and incubated 30 minutes, room 
temperature in a humidified chamber. Slides were washed and staining was developed using DAB 
solution (DAKO, Agilent Pathology, California, USA) visualised using a light microscope. Slides 
were counterstained using Meyer’s haematoxylin, rehydrated in graded EtOH and cover-slipped 
using automated coverslip machine (DAKO, Agilent Pathology, California, USA). Slides were 
scanned using the Virtual Slide microscope VS120 (Olympus Life Sciences, Tokyo, Japan) and 
digital images were analysed on Olyvia (Olympus Life Science, Tokyo, Japan). 
Table 2.3. Immunohistochemistry Antibody List: Manual Staining 
 
Table 2.4. Immunohistochemistry Antibody List: Automated Staining using the Ventana 
Benchmark Ultra platform 
Specificity Clone Dilution Company 
CD8 4B11 1:100 Leica Biosystems 
PD-L1 SP263 Pre-dilute Ventana 
PMS2 EPR3947 Pre-dilute Cell Marque 





Specificity Antigen Retrieval  Clone Dilution Secondary  
Antibody MYB EDTA (10 mM) pH: 8 EP769Y 1:500 Anti-Rabbit  
(Immpress) GRP78 EDTA (1 mM) pH: 8 N-20 1:800 Anti-Goat  
(Immpress) RAD21 Tris (10 mM) pH Ab42522 1:200 Anti-Rabbit 
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Immunohistochemistry: Automated 
These 3 m serial sections of were stained on a Ventana Benchmark Ultra platform (Ventana 
Medical Systems Inc, Arizona, USA) for using anti-CD8+ clone 4B11 (NCL-CD8-4B11, Leica 
Biosystems, Wetzlar, Germany) at a working dilution of 1:100, anti-PDL1 SP263 (790-4905, 
Ventana Medical Systems Inc, Arizona, USA) pre-dilute, anti-PMS2 EPR3947 (288R-18-ADR, 
Cell Marque, California, USA) pre-dilute and anti-MSH6 44 (08-1374, Invitrogen, California, 
USA) at 1:800. FFPE human placental, tonsil, lymph node, normal colon and colorectal tumour 
and were used as controls. 
 
CD8+ and PD-L1 scoring 
A trained pathologist selected two ‘hot spot’ regions, defined as 740x540 pixels, at 1.181mm/pixel 
= 0.56mm2. For our quantitation 2 x 0.5mm2 hotspots were selected per region. The invasive 
margin (IM) was defined as 1mm wide region centered on the border separating the host tissue 
from malignant glands, the central tumour (CT) was defined as everything else. 
Positive tumour cells (TC) were defined as percentage of tumour cells with any discernible 
membrane staining and immune cells (IC) defined as percentage of tumour area covered by PD-L1 
positive immune cells. Areas excluded: surface necrosis, macrophages and neutrophils associated 
with necrotic areas, normal lamina propria in non-invasive component. Cutoff values of 1%, 5% 
and 50% were set for TC or IC expression. 
 
Histoscore for Nuclear and Cytoplasmic Staining 
Each tissue section selected a CT and IM as defined by a registered pathologist. A region of 1mm2 
was assessed for each area (CT or IM). IHC assessment for other antigens involved inspection of 
VS120 generated images and scoring on the basis of a 0-12 Histoscore, which was the product of 
staining intensity (0=none, 1=weak, 2=moderate, 3=strong) and extent (0=none, 1=5% or less, 
2=6-15%, 3=51-75%, 4=>76%). Two investigators in a blinded fashion scored de-identified 
slides. 
 
Multiplex Immunohistochemistry (mIHC)  
Multiplex immunohistochemistry was performed on FFPE sections using the PerkinElmer Opal 6-
colour kit (Massachusetts, USA) as per manufacturer’s instructions using the automated Leica 
bond RX opal multiplex protocol (Leica Biosystems, Wetzlar, Germany) as per manufacturer’s 






Table 2.5 Antibody list for multiplex immunohistochemistry 
Marker  Primary Antibody  Diln Secondary Antibody  TSA Plus 
(Dilution) 
Colour 
-applied PD-1 Cell Marque (NAT105) 1:100 Mouse  (pre-dilute) 690 Red 
PD-L1 Ventana (SP263) Pre-dilute Rabbit (pre-dilute) 620 Yellow 
CD8 Thermo Fisher (4B11) 1:100 Mouse IgG (1:500) 540 Green 
CD4 Spring Bioscience (SP35) 1:100 Rabbit IgG (1:1000) 570 White 
FOXP3 BioSB (polyclonal) 1:100 Rabbit IgG (1:1000) 650 Orange 






Multispectral Imaging and Spectral Unmixing and Phenotyping 
Multiplex stained slides were imaged using the Vectra Multispectral Imaging System version 2 
(PerkinElmer, Massachusetts, USA). Areas of interest included tumour and high power 
multispectral images (20X) were acquired. A spectral library containing the emitting spectral 
peaks of all fluorophores was created with the Nuance Image Analysis software (PerkinElmer, 
Massachusetts, USA), using multispectral images obtained from single stained slides for each 
marker and associated fluorophore. This spectral library was then used to separate each 
multispectral image into its individual components (spectral unmixing) allowing for the colour-
based identification of all six markers of interest in a single image using HALO image analysis 
software (PerkinElmer, Massachusetts, USA). Cells were phenotyped into one of six different 
classes according to our markers of interest as follows: tumour cells (AE1AE3+), cytotoxic  T-
cells (CD8+), helper T cells (CD4+), regulatory T-cells (CD4+FOXP3+), double negative T cells 
(CD3+CD4-CD8-) and other cells (DAPI+). All phenotyping and subsequent quantifications were 
performed blinded to the sample identity and clinical outcomes. 
2.9 Molecular Techniques 
 
Extraction of RNA from Tumour Tissue 
Preserved tissue either snap-frozen or cryopreserved as described in storage of clinical samples 
were thawed on ice. Cryopreserved tissue was washed in media to remove DMSO. The AllPrep 
DNA/RNA Mini (Qiagen, Hilden, Germany) kit was used to extract DNA and RNA 
simultaneously as per manufacturer’s instructions. Briefly, tissue was homogenised and placed in 
RLT buffer, and added to an AllPrep DNA spin column. Flow-through is collected for RNA 
purification and added on a RNeasy column, washed in EtOH, subsequent buffers and eluted off 
the column as purified RNA. Quantification of RNA was analysed on a spectrophotometer. DNA 







The FASTQ files of the whole transcriptomics data were analysed using bcbio-nextgen pipeline 
to obtain the count level data. The bcbioRNASeq and DESeq2 packages in R were used for 
quality control and down-stream analyses. Transcript-per-million (TPM) were calculated for 
visualising the expression of genes. The heatmap was generated using the ComplexHeatmap 
package in R. Data was visualised using heatmaps, as the data had some extent of variability 
and there was a low sample size, which partially masked some of the true differences seen 
between the primary and colorectal tumours.   
 
2.10 Statistical Analysis  
All statistical analyses in this study were performed using GraphPad Prism (version 6 and 7; 
California, USA). Data analyses were conducted using unpaired Student’s t test to compare two 
data sets, or using one-way/two-way ANOVA when analyzing multiple sets of data (more than 
two sets). Data are presented in this thesis as mean ± standard error of the mean (SEM). 
 
Clinical Statistical Analysis 
Data was analysed with IBM SPSS version 22 and Microsoft Excel. Overall survival was 
calculated from date of surgery to date of last follow up or death. Kaplan- Meier analysis with log 
rank test were conducted to estimate the overall (OS). Cox univariate analysis was utilised to 
identify factors affecting overall survival. Cox multivariate Hazards ratio model was developed to 
identify factors independently associated with overall survival. A p value < 0.05 was considered 
statistically significant.  
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3. THE IMMUNE RESPONSE IN mCRC AT THE PRIMARY SITE 
 
3.1 Introduction 
Rudolf Virchow first observed the link between the immune system and cancer in 1863, where 
he noted that neoplastic tissue was infiltrated with leukocytes, essentially connecting 
inflammation with cancer (Balkwill & Mantovani, 2001). Almost two decades later, Virchow 
also proposed the ‘seed and soil’ theory of metastasis, where he believed that metastasis 
occurred due to arrest of tumour-cell emboli in the vasculature (Talmadge & Fidler, 2010). 
These two observations by Virchow set the stage for this chapter, where assessment of the 
immune response and its impact on metastasis was explored. 
 
MacFarlane Burnett and Paul Ehrlich postulated that the immune system could suppress 
carcinoma, in the early 1900s (Dunn et al., 2002). Burnett & Thomas subsequently coined 
“cancer immunosurveillance” as a probable mechanism of an effective immune response by 
which accumulations of tumour cells might be controlled (M. Burnet, 1957). Burnett implied 
that somatic mutations would occur naturally in dividing cells and because of this; an 
evolutionary mechanism must exist for eliminating malignant cells. From this theory, Burnett & 
Thomas speculated it was lymphocytes that actively surveyed and eliminated transformed cells 
(F. M. Burnet, 1970). At the time, such a new concept was highly controversial. 
 
With the progression over the last 50 years these original concepts that have become integral to 
the development of tumour immunity, have been scientifically addressed. We now know the 
host immune system can play both a tumour-protective and tumour-enhancing role. Therefore, 
as the original concept of “immunosurveillance” focused on the protective role of the host 
immune system, this concept is no longer entirely encompassing. Instead, the broader term 
‘cancer-immunoediting’ is more widely accepted to address these concepts (Dunn et al., 2002). 
Cancer immunoediting occurs when the immune cells and tumour cells interact, which can be 
either protective or indeed assist the development of the tumour. In the second instance the 
tumour becomes less immunogenic, and is able to evade the immune response. Such 
mechanisms of immune escape include downregulation of MHC-I, so the tumour cannot be 
readily detectable by the adaptive arm of the immune system (Garcia-Lora, Algarra, & Garrido, 
2003). 
 
Tumours also have the ability to exploit immune checkpoints by up-regulating PD-L1 (CD274) 
that inhibits T-cell function upon binding to the inhibitory checkpoint receptor PD-1 expressed 
on immune cells (Tumeh et al., 2014). PD-L1 can be induced on tumour cells extrinsically in 
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the TME often by IFNγ secretion (Blank et al., 2004). Additionally, PD-L1 can be intrinsically 
upregulated by tumour cells through amplification of the PD-L1 locus (Green et al., 2010) and 
structural variation of the 3’ region of the CD274 gene leading to elevated expression (Kataoka 
et al., 2016). These immune inhibitory mechanisms also lead to immune escape and subsequent 
tumour progression.  
 
Most cancer deaths occur as a result of metastatic disease, which may be present at initial 
diagnosis (de novo stage IV) or when the primary tumour has been treated with curative intent 
and subsequently recurs (Hassett et al., 2017). De novo or synchronous presentation of stage IV 
CRC, with metastasis confined to the liver, represents 13 to 25% of newly diagnosed CRC 
patients (R. Martin et al., 2003). Understanding the immune response in the primary CRC site 
was addressed in this chapter, in a unique cohort of de novo mCRC patients, including some 
that had MSI-H tumours.  
 
Metastatic CRC patients with microsatellite unstable tumours are a subset of patients that 
warrant further investigation. Traditionally, patients with mCRC (stage IV) that are MSI-H have 
a worse outcome than patients with mCRC MSS tumours (Goldstein et al., 2014; Koopman et 
al., 2009). Microsatellite unstable tumours (stages I-III) generally have a better prognosis than 
MSS CRC, stage for stage, except in the metastatic setting (Goldstein et al., 2014). The 
CheckMate142 study recently showed durable responses to Nivolumab, an anti-PD-1 antibody, 
in a group of mCRC patients that had MSI-H tumours. This cohort accounts for 5% of all CRC 
patients, and is a biomarker-defined subset of patients who benefit less from conventional 
chemotherapy and have a worse OS than patients with MSS mCRC (Overman et al., 2017). In 
this open-label phase 2 trial, 69% of patients had disease control for 12 weeks or longer. The 
results of this study suggest that patients with MSI-H mCRC should be considered for 
Nivolumab therapy. Further investigations of Nivolumab with other combinations such as 
Ipilumumab (anti-CTLA-4) should be further pursued in this subgroup of patients. 
 
The basis for microsatellite instability involves DNA mismatch repair (MMR) system defects, 
resulting from epigenetic silencing of MLH1, PSM2 and MLH6 or mutations to these genes. 
Furthermore, Lynch syndrome is a result of germline mutations of a DNA repair gene, followed 
by somatic inactivation of the second allele. This defect results in accumulation of insertions or 
deletions in DNA repeat sequences also called microsatellites (Mlecnik et al., 2016). Frameshift 
mutations can occur in genes containing coding repeats and this can be a potential source of 
immunogenic neoantigen generation (D. S. Williams et al., 2010). Typically, patients who have 
microsatellite unstable tumours have a favourable prognosis and improved outcome, we believe, 
due to a high frequency of TILs (Alexander et al., 2001; Dolcetti et al., 1999; Gryfe et al., 2000; 
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Timmermann et al., 2010). However, as mentioned previously, a favourable prognosis is not 
observed in those patients with metastatic disease. 
 
It is now accepted that there is an association between clinical outcome and immune cell 
presence documented in CRC (Balch et al., 1990; Galon et al., 2013; Galon et al., 2006; Jass, 
1986; Naito et al., 1998; Ropponen, Eskelinen, Lipponen, Alhava, & Kosma, 1997). Pagés & 
Galon et al showed strong correlations between patient outcome and immune cell presence in 
CRC. This has led to the development of the “Immunoscore”, which prognosticates patient 
outcome based on the presence of TILs, the most significant population being cytotoxic CD8+ 
T-cells (Galon et al., 2006; Pages et al., 2005; Pages et al., 2009). A comprehensive study by 
Mlecnik et al found that the Immunoscore was a stronger predictor of patient survival than 
microsatellite status alone (Mlecnik et al., 2016). In this study, it was found that MSI-H 
tumours had a prominent immune gene expression profile, which was also noticed in a 
subgroup of MSS tumours. MSI-H tumours displayed genetic evidence of immunoediting and 
had a high degree of frameshift mutations. These tumours had PD-L1 expression and had a high 
infiltration of Th1 effector cells that also expressed PD-1. Interestingly, those MSS patients that 
had a high “Immunoscore” had a prolonged disease specific survival (DSS) and a higher 
expression of the PD-1 gene PDCD1 than those tumours that were MSS with a low 
Immunoscore (Mlecnik et al., 2016). This demonstrates that microsatellite status alone should 
not be the sole factor when considering patients for immunotherapy, and that the Immunoscore 
should be as part of the treatment decision-making process. 
 
Understanding the immune response within the TME can provide more insight into why some 
patients respond to CBI and others do not. Indeed tumours that are MSI have many more 
somatic mutations and likely result in immunoediting. However, there may be other factors 
involved that regulate the immune response. In 2016, we investigated the immune response in a 
cohort of patients that were MSS with stage B (T2-4N0M0) disease. In addition to determining 
the immune infiltrate by classifying cytotoxic CD8+ T-cells, the transcription factor (TF) MYB 
and its pro-oncogenic target gene GRP78 were evaluated. Patients that had relapsed had a lower 
infiltrate of CD8+ T-cells than those patients who were relapse-free (Millen et al., 2016). MYB 
expression was associated with those patients who relapsed. This correlated with an inverse 
relationship of CD8+ T-cell infiltrate, this and other experiments, and indicated that MYB may 
modulate the immune response. GRP78 is a target gene of MYB and is known to modulate both 
immune response and therapy responses in cancer (Sugawara, Takeda, Lee, & Dennert, 1993; 
Wang et al., 2007). The expression of GRP78 tracked with MYB expression, with high 
expression of GRP78 only found in those patients who had relapsed, and a reduction of TILs in 
these areas. Together these data are the first to implicate MYB and its target gene GRP78 as 
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modulators of the immune response in CRC potentially, providing insight into prognostic 
markers and therapeutic targets. 
 
This	 current	 chapter	 investigated	 the	 immune	 response	 in	 a	 retrospective	 cohort	 of	 de	












and	 tumour	 progression	 mechanisms	 at	 play	 when	 the	 primary	 tumour	 is	 in	 situ	 with	
synchronous	metastatic	disease. 
Hypothesis:  
Patients with microsatellite unstable tumours will have a poor prognosis despite an increased 
infiltration of TILs. 
 
Aims: 
1. Assess the immune environment in primary tumours of de novo mCRC patients. 
2. Determine survival factors in de novo mCRC patients associated with tumour 
progression. 
 
3.2 Immune Status in Primary Tumours of Patients With mCRC  
One hundred and nine patients with de novo mCRC who underwent primary tumour resection 
and had available archival tumour specimens were included in this study. The median OS in the 
entire cohort was 19 months. Microsatellite status was defined as either: deficient MMR 
(dMMR)/MSI-H (n = 12, 11%) or proficient MMR (pMMR)/MSS (n = 97, 89%), as outlined in 
Table 3.1. In univariate hazard ratio analysis we found that patients who were 65 years and 
older had a significantly reduced OS as seen in Table 3.3. No significant difference in OS was 
seen between patients with MSI-H/dMMR and MSS/pMMR tumours, as shown Figure 3.1 
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(median 12 months; 95% CI: 6.13-17.87) MSI/dMMR vs. 19 months (95% CI 13.34-24.66) 
MSS/pMMR, log rank p=0.304). Defects in mismatch repair genes were defined by diagnostic 
pathology using a PCR panel to detect specific microsatellite repeats (MSI-H versus MSS). 
Those samples with unknown MSI status from diagnostic pathology were subsequently tested 
using IHC to determine loss of protein expression and therefore defective mismatch repair 
(dMMR) of PMS2 and MSH6 by a gastric pathologist. Retention of PMS2 and MSH6 was 
therefore defined as proficient MMR (pMMR). Subsequent confirmation and validation of high 
frequency microsatellite instability (MSI-H) and microsatellite stable definition (MSS) was 
determined by the Bethesda PCR panel that interrogated five microsatellite loci (Murphy et al., 
2006). 	
Table 3.1. Microsatellite status demographic 
 
 
Patients were first stratified into MSI-H/dMMR and MSS/pMMR there was no significant 
difference in OS as seen in Figure 3.1 (median 12 months MSI/dMMR vs. 19 months 
MSS/pMMR). However, there was perhaps a trend for MSI-H/dMMR to have a reduced OS, in 
keeping with the current literature. 
Clinical Characteristics Overall  dMMR/MSI-H pMMR/MSS 
Total, n 109 12 97 
Age (years), median 28-89, 89 48-87, 74 28-89, 69 
Female, n (%) 50 (46) 8 (67) 42 (43) 
Male, n (%) 59 (54) 4 (33) 55 (57) 
Pathology Tumor Stage    
T2, n (%) 2 (2) 1 (8) 1 (1) 
T3, n (%) 48 (44) 5 (42) 43 (44) 
T4, n (%) 59 (54) 6 (50) 53 (55) 
Colon, n (%) 99 (91) 12 (100) 87 (90) 
Rectum, n (%) 11 (10) 0 (0) 10 (10) 
Right-sided 45 (41) 10 (83) 46 (47) 
Left-sided 59 (54) 1 (8) 57 (59) 




Figure 3.1 Mismatch repair deficiency is not associated with a survival advantage in de 
novo mCRC tumours. Kaplan-Meier survival curve showing OS stratified on microsatellite 
status of patients with de novo mCRC. Patients were stratified as MSI-H/dMMR (blue line) vs. 
MSS/pMMR (green line) against months. Median survival was 12 months (MSI-H/dMMR) and 
19 months (MSS/pMMR), n=109 patients in total, MSI-H/dMMR n=12, MSS/pMMR n=97 
Survival based on MSI status. Median survival for dMMR 12 months compared to 19 months 
for pMMR (log rank p=0.304). 
 
To understand if survival was affected in some manner, by the immune response, TIL infiltrate 
was assessed. Cytotoxic CD8+ T-cells were quantified using IHC on whole tumour sections. In 
the earlier publications by Galon & Pagès et al, immune ‘hot spots’ were selected and 
quantified within the two tumour regions: CT and IM (Galon et al., 2006). We followed this 
approach in our cohort and a trained pathologist selected two ‘hot spot’ regions, defined as 
740x540 pixels, at 1.181mm/pixel = 0.56mm2. For our quantitation 2 x 0.5mm2 hotspots were 
selected per region. The IM was defined as 1mm wide region centered on the border separating 
the host tissue from malignant glands, the CT was defined as other tumour region. 
 


















Figure 3.2 Tumours that are dMMR/MSI-H have a higher immune infiltrate at both the 
CT and IM. CD8+ T-cells were quantified as positive cells/mm2 in each region of the tumour 
(A) shows CD8+ count/mm2 in tumours that are pMMR/MSS (red) and dMMR/MSI-H (blue) in 
the CT and (B) IM using a linear scale (C) shows CD8+ count/mm2 in the CT and (D) IM using 
a log scale to highlight the broad range of TIL. Green symbols represent patient outliers selected 
for additional microsatellite confirmation. Error bars represent SEM, n=96 (pMMR/MSS), n=12 
(dMMR/MSS), two-tailed unpaired Mann-Whitney t-test, ****p<0.001. 
When quantifying the CD8+ T-cell infiltrate as seen in Figure 3.2, it can be seen that 
microsatellite unstable tumours (dMMR/MSI-H) had a higher CD8+ T-cell infiltrate compared 
to microsatellite stable tumours (pMMR/MSS). This was observed at the CT (median 349.5 
[95% CI 170.5, 421] MSI-H vs. 99 MSS, [95% CI 108.1,151.1]) as well as IM (median 451 
MSI-H [95% CI 242.5, 543.5] vs. MSS 144 [95% CI 138.5, 191.7]. 
 
I also observed from this analysis that there was indeed an outlier group in the MSS/pMMR that 
had high CD8+ T-cell count/mm2 (green symbols) in Figure 3.2. Those patients who were 
outliers in the MSS cohort were selected to have further confirmation of microsatellite status by 
PCR. These slides were retrieved and micro-dissected to extract DNA. The Bethesda gene panel 
was used to probe these samples to further define microsatellite status. All of the samples were 
found to be stable by the Bethesda panel as seen in Table 3.2, confirming that these patients had 
















































































authentic MSS tumours. High TIL infiltrate in tumours of MSS patient was an interesting 
observation because only CRC patients that have microsatellite unstable tumours are 
increasingly considered for checkpoint blockade therapy (CBI). This implies that despite TILs 
being present at high frequencies in tumours that are MSS, CBI does not rescue these TILs and 
these TILs may be dysfunctional. It may also imply that a small proportion of MSS patients 
may benefit from CBI, and quantifying TILs could be used as a measure to determine those who 
may benefit. These patients would not usually be considered based on their microsatellite stable 
status.  
Table 3.2. Microsatellite testing by PCR confirms stable microsatellite status in outlier 
MSS patients 
Case Number Tumour % MSI 
1-21 60-90% STABLE 
 
Quantitation of CD8+ T-cells in microsatellite stable and unstable tumours was assessed as 
depicted in Figure 3.3 and this was used to determine the median cutoff as 124.5 CD8+ T-
cells/mm2 to assess OS. The combined region CT+IM (overall) CD8+ count/mm2 was used to 
determine if CD8+ T-cell infiltrate affects OS. These data demonstrate that there was not a 




Figure 3.3 Median cut-off of 124.5 CD8/mm2 set for high and low TIL infiltrate in 
combined. (A) Bar-plots showing overall CD8+ count/mm2 in tumours that are pMMR/MSS 
(red) and dMMR/MSI-H (blue) in log-scale. Green symbols in microsatellite stable group were 
selected as outliers for further microsatellite testing; median cutoff for CD8+ infiltrate was 
124.5 CD8+ T-cells/mm2. (B) Representative images of CD8+ infiltrate in 2 patients that are 
MSS tumours (left panel) or microsatellite unstable tumours (right panel), scale bar=50 μm. 



























Figure 3.4 No OS advantage when total CD8+ infiltrate was assessed in tumours of de novo 
mCRC patients. Kaplan-Meier survival curve show OS stratified on median cutoff of CD8+ 
cells/mm2 infiltrate to set CD8+ high (green line) and CD8+ low (blue line) infiltration within 
total count/mm2 in patients with de novo mCRC. Cross symbols indicate date of last follow-up, 
n=103 patients in total. Median survival for low CD8+: 20 months and high CD8+: 13 months 
(log rank p = 0.426). 
From these data it appeared that there was no survival advantage based on CD8+ infiltrate 
alone. Despite not influencing survival, the number of CD8+ T-cells infiltrating the tumour in 
MSI-H and some MSS patients was still high. This suggested that these TILs were present in 
numbers but may be in a state of dysfunction or are not tumour specific. Alternatively there 
might be immune-checkpoint mechanisms being exploited by the tumour resulting in 
immunosuppression. To investigate this in more depth, PD-L1 expression on tumour cells and 
infiltrating immune cells was assessed.  
 


















Figure 3.5 PD-L1 expression on tumour cells is more prominent in dMMR/MSI-H than 
pMMR/MSS patients. (A) Bar-plots representing percentage of tumour cells expressing PD-L1 
in dMMR/MSS tumours (red symbols) and dMMR/MSI-H tumours (blue symbols). (B) 
Representative images of PD-L1 expression on tumour cells from MSS tumour (left panel) and 
dMMR (right panel), scale bar= 50 μM. Error bars represent SEM, n=9 (pMMR/MSS), n=6 
(dMMR/MSS), Man-Whitney unpaired t-test, p<0.05. 
As shown in Figure 3.5 PD-L1 expression did not differ between microsatellite unstable and 
stable tumours. There was also no difference observed when PD-L1 expression was assessed on 























Figure 3.6 PD-L1 expression on immune cells is more prominent in dMMR/MSI-H than 
pMMR/MSS patients. (A) Bar-plots representing percentage of immune cells expressing PD-
L1 in dMMR/MSS tumours (red symbols) and dMMR/MSI-H tumours (blue symbols). (B) 
Representative images of PD-L1 expression on stromal immune cells from dMMR tumour (left 
panel) and intra-epithelial immune cells in pMMR tumour (right panel), scale bar= 50 μm. Error 
bars represent SEM, n=22 (pMMR/MSS), n=9 (dMMR/MSS), Man-Whitney unpaired t-test, 
p<0.05. 
Correlation analysis between positive PD-L1 expression, on tumour cells and immune cells, and 
CD8+ infiltrate was analysed, as seen in Figure 3.7A-B. There was a significant correlation 
found between PD-L1 expression on immune cells and CD8+ infiltrate, indicating that 
infiltrating immune cells could also be suppressing TIL effector function. This would need to be 
investigated further to determine what infiltrating immune cells were expressing PD-L1, such as 


























Figure 3.7 Correlation between CD8+ infiltrate and PD-L1 expression on infiltrating 
immune cells, but not tumour cells. XY-plots showing CD8+ count/mm2 in combined regions 
and PD-L1 expression on (A) tumour cells for those patients with positive PD-L1 expression, 
n=15, correlation analysis, r=0.4035, ns and (B) immune cells for those patients with positive 
PD-L1 expression, n=31, correlation analysis, r=0.5177, **p=0.004. 
The trained pathologist who scored these specimens observed direct lymph node involvement of 
invading tumour expressing PD-L1 as highlighted by the arrows in Figure 3.8A-B. 
Lymphovascular invasion (LVI) was also observed, as highlighted by arrows in Figure 3.8C-D, 
indicating escape mechanisms through micrometastases of tumour cells expressing PD-L1. 
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Figure 3.8 Lymph node invasion occurs with tumour cell PD-L1 expression. Representative 
images of tumour PD-L1 expression with (A-B) direct lymph node involvement (C) 
lymphovascular invasion and (D) lymph node metastasis by invading tumour cells expressing 
PD-L1 as indicated by the arrows. Scale bars represent 100, 50 and 25 μm. 
The current pathological assessment of PD-L1 expression in clinical trials uses percentage “cut-
offs” to stratify relatively high or low PD-L1 expression (Herbst et al., 2014; Patel & Kurzrock, 
2015). To assess survival and PD-L1 expression, 1%, 5% and 50% cut-offs were adopted as 
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Figure 3.9 PD-L1 expression on tumour cells. (A) Pathologist scoring of: 0-1 (n=97), 5-50 
(n=4) and 50-100% (n=3) and (B) <1% (n=90) and 1% or higher (n=14) PD-L1 expression on 
tumour cells from the primary tumour of patients with de novo mCRC, n=104. 
When analysing OS based on surface expression of PD-L1 >1% on tumour cells, reduced OS 
was observed (median survival PD-L1 >1% 8 months and PD-L1<1% 19 months). No statistical 
differences were observed with this analysis, however in multivariate analysis PD-L1 
expression on tumour cells was found to be significant as shown in Table 3.3. The no 
differences were seen when assessing cutoff scores of 5% and 50%, might reflect the small 
number of samples. Nevertheless, these data demonstrate immune evasion mechanisms at play 
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Figure 3.10 Patients with tumour cells expressing 1% and higher PD-L1 have reduced OS. 
Kaplan-Meier survival curve show OS stratified on tumour cells expressing <1% (blue line) or 
>1% PD-L1 (green line) on tumour cell surface. Survival based on PD-L1. Median survival for 
<1% 19 months compared to 8 months for 1% and higher (log rank p =0.253), n=98 patients in 
total. 
 
Across both microsatellite stable and unstable tumours, CD8+ infiltrate did not influence OS, 
despite some tumours having a high frequency of CD8+ T-cells present. Additionally, 
expression on PD-L1 >1% on tumour cells affected OS but only in multivariate analysis. This 
may suggest that tumours are suppressing immune responses via exploitation of immune 
evasion. It also indicated “aggressive” tumour progression is likely to be in operation, perhaps 
through other oncogenic mechanisms. 
3.3 Tumour Characteristics in Primary Tumours of Patients with de novo mCRC 
To assess other tumour cell intrinsic mechanisms that may influence the TME, protein 
expression of MYB and GRP78 was assessed by IHC. This has been associated with a poor 
outcome in patients with Stage I-III CRC. It has also been associated with immune-modulation, 
where high MYB expression on tumour cells had an inverse relationship with CD8+ immune 
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Figure 3.11 Expression of MYB is more prevalent in MSS tumours. Scatter-plot 
represents tumours expressing MYB, using the histoscore that evaluates intensity x extent 
(0-12). This was done at the (A) CT and (B) IM in both tumour and stromal cells. n=49, n=10 
(MSI-H) and n=39 (MSS), black line represents mean ± SEM. 
The areas at the CT and IM selected for MYB and GRP78 expression were matched with the 
areas originally selected by a pathologist for CD8+ T-cell analysis. The histoscore was utilised 
and assessed intensity of expression multiplied by extent of expression ranging from 0-12. As 
seen in Figure 3.11 no detection of MYB expression was observed in the tumour or stromal 
cells at the CT in tumours that were MSI-H. Most expression was detected in MSS tumours at 
both the CT and IM. 
 
To investigate the relationship between MYB and survival, the median histoscore value was 
used as a cut-off to define MYB high and low expression in the CT. As seen in Figure 3.12, no 
statistical difference was observed between MYB expression on tumour cells in the CT and OS. 
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Figure 3.12 Expression of MYB on tumour cells at the CT does not influence survival in 
Stage IV CRC patients. Kaplan-Meier survival curve showing OS stratified on tumour cells 
expressing MYB. Low MYB (blue line) median survival 19 months, compared to high MYB 
(green line) 32 months (log rank p =0.222): n=109. 
To investigate if GRP78 influenced the TME, samples were scored using the same histoscore as 
described for MYB expression. As seen in Figure 3.11, GRP78 expression is present across 
microsatellite unstable and stable tumours. In the microsatellite stable group, at both the CT and 
IM, GRP78 expression is higher on the tumour cells than stromal cells. Therefore assessment of 
GRP78 expression and survival was only done for tumour cell expression. 


















Figure 3.13 Expression of GRP78 is more prevalent in MSS tumours, with greater 
expression on tumour cells than stromal cells. Scatter-plot represents tumours expressing 
GRP78, using the histoscore that evaluates intensity x extent (0-12). This was done at the (A) 
CT and (B) IM in both tumour and stromal cells. n=111, n=13 (MSI-H) and n=85 (MSS), black 
line represents mean ± SEM. 
Association between OS and GRP78 expression on tumour cells at the CT (Figure 3.14) and IM 
(Figure 3.15) was assessed. In both tumour areas, there was a trend, where patients with 
tumours expressing GRP78 had a reduced OS. However when evaluated in univariate and 
multivariate analysis, no statistical differences were observed. 
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Figure 3.14 Expression of GRP78 on tumour cells at the CT does not influence survival in 
Stage IV CRC patients. Kaplan-Meier survival curve showing OS stratified on tumour cells 
expressing GRP78 at the CT, median survival 19 months for low, compared to 13 months for 
high (log rank p = 0.325) n=45. 


















Figure 3.15 Expression of GRP78 on tumour cells at the IM does not influence overall 
survival in Stage IV CRC patients. Kaplan-Meier survival curve showing OS stratified on 
tumour cells expressing GRP78 at the IM. Median survival 20 months for low, compared to 13 
months for high (log rank p = 0.596) n=36. 
Finally, OS was interrogated based on RAD21 expression on tumour cells, as seen in Figure 
3.16. There was a trend observed where tumours that had a high expression of RAD21, had an 
apparent improved OS, but this was not significant. 


















Figure 3.16 Expression of RAD21 on tumour cells does not influence overall survival in 
Stage IV CRC patients. Kaplan-Meier survival curve showing OS stratified on tumour cells 
expressing RAD21. (Log rank p = 0.08) n=36. 
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Univariate and multivariate analyses were carried out to determine additional factors that 
influenced OS as seen in Table 3.3. Patients who were 65 years and older had a significantly 
reduced OS in univariate analysis. Those patients who had tumour PD-L1 expression >1% had 
significantly reduced OS in multivariate analysis, indicating that PD-L1 expression 
independently affects OS in this cohort of de novo mCRC patients. 
  
In summary microsatellite status alone did not affect OS in this cohort of de novo Stage IV 
mCRC patients. High CD8+ T-cell infiltrate was present in tumours that were both 
microsatellite stable and unstable but did not affect OS in these patients. This indicated that 
although T-cells are present within the TME, there are likely immunosuppressive mechanisms 
at play affecting the ability of the cytotoxic T-cells to elicit an effector response. Tumour 
expression of PD-L1 independently affected OS in multivariate analysis. Finally to assess if 
other tumour cell intrinsic factors played a role; MYB, GRP78 and RAD21 protein expression 
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was assessed. No significant difference was found with MYB, GRP78 or RAD21 expression 
and OS. These data provided insight into the immune response and the TME of these patients 
with de novo Stage IV mCRC. 
3.4 Discussion  
Approximately 15-25% of patients with CRC will present with synchronous metastatic disease 
at time of diagnosis (Leporrier et al., 2006). The traditional strategy for management of 
synchronous disease is a staged surgical approach, resecting the primary tumour first 
(Silberhumer et al., 2015). Surgical resection for cure is the only possibility to obtain long-term 
survival. However, despite surgical intervention, 5-year survival rates for CRC patients 
presenting with synchronous disease is only 30-37% (Fong et al., 1997; Fong et al., 1999; 
Gayowski et al., 1994).  
 
CRC patients with microsatellite unstable tumours have an improved survival (Stage I-III) and 
are currently the only patients that are considered for CBI trials. However the circumstances are 
very different in the advanced stage of disease, and this needs to be understood in the context of 
the immune response. Metastatic stage IV CRC patients with MSI-H tumours represent a 
distinct subset of CRC patients that do not respond to conventional chemotherapy and have a 
reduced OS. In this study we employed a unique cohort of advanced stage IV de novo mCRC, 
including patients with microsatellite unstable tumours. OS was not significantly different when 
stratifying patients based on microsatellite status alone. However, there was a trend for patients 
with MSI-H tumours to have a reduced OS, reiterating the current view that this subset of 
mCRC patients has an overall poor prognosis. So why is this the case, and is it immune 
mediated?  
 
To understand if the immune response influenced survival in these patients, cytotoxic CD8+ T-
cells were quantified in the primary tumour. Although some tumours had a high number of 
CD8+ T-cell infiltrate, CD8+ T-cell presence alone did not influence survival. This is a very 
different scenario when compared to early-stage CRC. We reported that local early-stage CRC 
tumours infiltrating cytotoxic CD8+ T-cells correlated strongly with relapse-free survival 
(Millen et al., 2016). What this suggests is that in the early stages of disease; the immune 
response still plays a substantive role in tumour control. However, once the tumour progresses 
beyond immune control, into the advanced setting of disease, things are very different. 
 
The fact that these patients have distant metastasis alludes to the concept that these primary 
tumours are: 1) aggressive with oncogenic potential to survive, proliferate and migrate and 2) 
these tumours have already evaded the immune response and have undergone immunoediting. 
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When contemplating the ‘three E’s’ in the context of metastasis and within this cohort of 
patients, it is clear that tumour progression has reached the escape phase and beyond. Not only 
is the tumour able to escape locally through immunoediting, cell migration and invasion, but it 
has also escaped systemically to establish in a distant organ (Chambers, Groom, & MacDonald, 
2002; Friedl & Wolf, 2003). It is likely that the primary tumour has undergone both genetic and 
epigenetic changes that provide oncogenic cell-intrinsic potential of the tumour cells and can 
influence cell-extrinsic properties such as affecting the TME. An example of this, in the context 
of CRC, is the RAS gene that is frequently mutated in tumours. The common RAS gene mutation 
in CRC is KRAS and is present in 30-50% of CRC tumours (Cox, Fesik, Kimmelman, Luo, & 
Der, 2014; Porru, Pompili, Caruso, Biroccio, & Leonetti, 2018). This mutation has the ability to 
extrinsically enhance the induction of T-reg cells (Zdanov et al., 2016), leading to an 
immunosuppressive environment that can promote tumour growth. Understanding 
immunoediting in the context of metastasis may provide insight into mechanisms of escape. 
Additionally other mechanisms of escape may include immune checkpoint mechanisms such as 
PD-L1 and CTLA-4, but there are certainly more. 
 
Although no statistical difference was observed with OS and CD8+ T-cell infiltrate, high 
frequencies of CD8+ T-cells were present in most MSI-H tumours and interestingly, some 
patients that were MSS. Yet 50% of the entire cohort succumbed to the disease within 24 
months, and so the immune system appears inefficient in tumour control. One reason this may 
occur is due to an immunosuppressive TME, with inhibition of cytotoxic CD8+ T-cells by 
tumour cells. 
 
This immunosuppressive phenotype is reflected by the expression of PD-L1 on tumour cells. In 
multivariate analysis, PD-L1 expression on tumour cells did influence OS as an independent 
factor. The literature reports that selecting patients based on the expression of PD-L1 alone is 
not sufficient to predict response to CBI against PD1/PD-L1 (Dong et al., 2002; Gatalica et al., 
2014; Patel & Kurzrock, 2015). It is likely that the expression of PD-L1 is dynamic, and 
capturing it using IHC alone may not demonstrate the fluctuating interplay between the immune 
response and tumour cells. The tumours analysed in this data set had all progressed to 
metastasis, as all patients had de novo mCRC. There was an interesting observation that tumour 
cells positive for PD-L1 expression were detected in the lymphovascular compartment. This 
highlighted a probable mechanism of tumour cells escaping the primary site and proceeding to 
metastasis. This observation clearly demonstrates how tumour cells have the ability to be 
undetectable to immune cell recognition and migrate to distant metastatic sites, via lymphatic’s 
and the vasculature. When assessing PD-L1 expression on immune cells, there was a correlation 
between PD-L1 expression and CD8+ T-cell quantity. Cytotoxic CD8+ T-cells secrete IFNγ and 
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within the TME this can lead to up regulation of PD-L1 on tumour cells. The expression of PD-
L1 on infiltrating immune cells likely reflects the IFNγ-induced adaptive regulation of 
infiltrating effector T-cells (Kowanetz et al., 2018). To counteract this, immune cells including 
MDSCs are known to express PD-L1 which also reflects an attempt to suppress immune 
responses occurring in the TME (F. Tang & Zheng, 2018). Additional immune evasion 
pathways to investigate in this cohort would be loss of MHC-I expression, to determine if the 
tumour cells down regulate this pathway to bypass immune control. As these tumours have 
progressed, the immune response has failed and this may also be attributed to additional 
oncogenic factors at play. 
 
To assess if there were additional tumour-cell mechanisms influencing tumour growth and the 
immune response, MYB and its target GRP78 were quantified in this cohort. Expression of 
MYB in MSS tumours was more prominent than microsatellite unstable tumours. High MYB 
and GRP78 expression on tumour cells did not appear to affect the ability of CD8+ T-cells to 
infiltrate. Therefore these markers do not track with immune cells in the advanced setting of 
CRC. That is the opposite of what was observed in early-stage CRC, where high MYB 
expression had an inverse relationship to CD8+ T-cell infiltrate (Millen et al., 2016). This 
highlights the difference in progression of these tumours. In the early stage of tumour 
development including the equilibrium phase, where the T-cells may be in a more naïve/effector 
phase and can be influenced by tumour oncogenic factors such as MYB and GRP78. However, 
in the advanced stage of CRC, the tumour has evaded the immune response. If the CD8+ T-cells 
are terminally exhausted TILs within the TME, MYB and GRP78 may be important for tumour 
survival, but do no longer modulate the immune response. 
 
Expression of MYB was not associated with survival. When assessing GRP78 expression on 
tumour cells and survival, no statistical difference in OS was observed in multivariate analysis. 
However, there was a trend to suggest that high expression of GRP78 in both regions of the 
tumour reduced OS. This was observed in our previous study that reported in early stage CRC, 
tumours with high expression of GRP78 was associated with relapse (Millen et al., 2016). 
Conversely, one study documented that high GRP78 expression was associated with an 
improved 5-year survival in CRC patients and improved response to adjuvant chemotherapy. 
Additionally, they found that cells were more resistant to 5-FU treatment when knocking down 
GRP78 expression, through mechanisms altering cell cycle (Thornton et al., 2013). All of the 
patients in this cohort had adjuvant chemotherapy, either 5-FU, FOLFOX or FOLFIRI, and 




It is known that RAD21 expression on tumour cells can influence resistance to DNA damaging 
agents such as chemotherapy, including 5-FU (Deb et al., 2014). RAD21 is a protein that has 
been previously reported to prognosticate and predict patients with CRC, and was investigated 
in this cohort. It has been found that tumours overexpressing RAD21 have a reduced OS (Deb 
et al., 2014). When assessing RAD21 expression in de novo mCRC tumours, there was a trend 
for high RAD21 expression being associated with an improved OS. It is known that the 
prognostic significance of RAD21 reduces when assessed in microsatellite unstable tumours 
(Deb et al., 2014), yet in other advanced primary tumours, including breast and endometrial 
cancer, it is associated with a poor prognosis (Supernat et al., 2012; Xu et al., 2010). In the 
current analysis of RAD21 expression, patients were stratified on expression alone and not 
stratified on microsatellite status. The other factor not taken into account in multivariate 
analysis was the chemotherapy regimen these patients underwent. Therefore accounting for 
previous chemotherapy treatment to determine if RAD21 expression influences survival in this 
cohort warrants further investigation. 
 
In this unique cohort of patients, we identified that microsatellite status and cytotoxic T-cell 
infiltrate does not affect OS and this is likely due to the advanced stage of disease. Despite this, 
CD8+ T-cells are still present in high numbers in MSI-H tumours and some tumours that are 
MSS. As these tumours have progressed to metastasis, the anti-tumour immune response has 
been unable to control tumour progression and it is therefore probable that these TILs are 
dysfunctional or being inhibited in the TME. The current Checkmate142 open-label Phase II 
trial highlights the fact that TILs in mCRC MSI-H tumours are in a state of immune suppression 
because CBI can subsequently rescue TIL function. Understanding the quality of TILs in MSS 
tumours is also of interest, as it is known these patients do not respond to CBI and interrogating 
their biology may provide insight into why this is the case. Finally, additional focus should also 
be on interrogation of the TILs that are present at the distant metastatic site in CRLM, and this 
will be addressed in the Chapter 4. 
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4 DETERMINING THE FUNCTION OF IMMUNE CELLS AT THE METASTATIC 
SITE IN mCRC 
 
4.1 Introduction 
Chapter 3 provided insight into the immune response at the primary site in patients with 
advanced stage IV mCRC. It was evident in these primary tumours that the immune response 
had failed, as the tumour had by definition escaped and progressed to a distant site. This chapter 
will focus on the immune response at the metastatic site in CRLM tumours to understand the 
mechanisms at play during tumour progression. 
 
In humans, the presence of TILs generally indicates a favourable prognosis (Atreya & Neurath, 
2008; Galon et al., 2006; Galon, Fridman, & Pages, 2007; Naito et al., 1998). The Immunoscore 
proposed by Pagès & Galon et al has contributed greatly to the field of immuno-oncology and 
will likely influence clinical decision-making in the future, as both a prognostic and predictive 
marker. Subsequent studies have investigated functional aspects of the immune infiltrate by 
looking at cytotoxic markers including granzyme B and proliferative markers such as Ki67 
(Mlecnik et al., 2016).  
 
Although these surrogate functional markers are instructive, the immune response remains 
highly dynamic and is multifaceted. The data obtained from assessing these markers using IHC 
only provides a “snapshot-in-time” of the tumour immune response and expression of these 
markers likely fluctuates over time and spatially. Although TILs are present in tumours, it is 
difficult to gauge their function using IHC alone. Understanding their dynamic activity is thus 
important to determine if these TILs are functional or dysfunctional; particularly in the era of 
immunotherapies. For instance, if the TILs are intrinsically dysfunctional, they may never be 
rescued by use of CBI. Therefore developing dynamic assays to assess cytotoxicity of TIL 
function has been of great interest to researchers in the field. 
 
The current “gold standard” technique for measuring cytotoxic immune activity is the 
51chromium release assay (CRA) (Biron et al., 1999; Verneris, Karimi, Baker, Jayaswal, & 
Negrin, 2004). This assay has the ability to measure the cytotoxicity of cytotoxic immune cells 
including NK cells and cytotoxic T lymphocytes (CTLs), it was developed in 1968 and is still a 
commonly used (Karimi et al., 2014). Both primary and clonal cell lines can be used as target 
cells, and these are loaded with radioactive chromium [51Cr] prior to the co-culture. The 
cytotoxic cells of interest are then added at various ratios and the supernatant is collected at the 
endpoint of the co-culture, with a time-limitation of 4-16 hours. Cytotoxicity is measured 
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indirectly by measuring the amount of chromium that has been released (via cell lysate) into the 
supernatant, this is roughly relative to the amount of killing that has occurred (Brunner, Mauel, 
Cerottini, & Chapuis, 1968). However, there are some disadvantages of this assay; one of them 
is that only the endpoint of the assay can be measured for each test, and therefore understanding 
the kinetics of killing over time is not an easy option. This is also due to the time limitation of 
how long the target cells can spontaneously retain chromium (16-24 hours). Using 2D-cultures 
challenges the capacity of the assay and the use of 3D cultures including spheroids and 
organoids has not been routinely adopted either.  
 
More recently, a non-labelling cell death assay utilises electrical impedance measurements of 
target cells. Adherent target cells attach to a matrix of microelectrodes on the bottom of the 
multi-well plate, causing an increase of impedance to an electric current. Conversely, when cells 
die and detach from the plate, impedance is reduced, and this is measured using the 
Xcelligence™ system. This can be used for cytotoxic drug screening of cancer cells and co-
culture assays that include immune cells, as immune cells in the suspension do not substantially 
affect impedance (Peper et al., 2014). The main advantage of this system is that cells do not 
require labelling, which is often an issue of other assays including the CRA or the 
carboxyfluorescein succinimidyl ester (CSFE) assay that involves labelling of target cells to 
record cellular proliferation, using dye dilution. However, the limitation of this system is that it 
is currently confined to adherent 2D culture system. Nevertheless, there has been some progress 
in developing electrical cell–substrate impedance sensing (ECIS) for 3D cultures and matrices 
to investigate cell migration (Nguyen, Yin, Reyes, & Urban, 2013). Again, this system involves 
adherent cells covered by a 3D matrix and focuses on the ability of cancer cells to migrate. 
However, it lacks the ability to measure cell death within a 3D matrix, and investigating 
cytotoxic-mediated death of spheroids or organoids could not be employed in this assay. Thus 
there is a need to investigate other possibilities that allows researchers to test the capacity of 
cytotoxic immune cells particularly with 3D cultures. 
 
This is apparent with very recent studies being published investigating immune cells and their 
interaction with patient-derived tumouroids, including our own, as detailed in chapter 1. Using 
this platform and other techniques, I sought to address the question of TIL function in CRLM, 
by isolating lymphocytes from the tissue and phenotyping these using fluorescent activated cell 
sorting (FACS), multiplex immunohistochemistry (Opal) and assessing TIL function using the 












1. Establish a platform to assess patient-derived TIL effector function ex vivo 
2. Assess TILs isolated from CRLM tumours against matched patient-derived tumouroids  
3. Investigate the proportion and phenotype of TILs in CRLM 
 
4.2 Patient Characteristics  
As part of this project I wrote the human ethics application and recruited patients with CRLM. 
Patients with CRLM were provided with informed consent and recruited to the study. On the 
day of the surgical operation, blood was drawn from the patients pre-incision for collection of 
PBMCs. After the specimen had been surgically removed from the patient, tumour and normal 
liver pieces were dissected in the operating theatre or by a registered pathologist (to ensure that 
the surgical margins were not compromised). The tissue was then placed in ice-cold media and 
transferred to the laboratory for immediate processing. The patient characteristics are listed in 
Chapter 2. 
 
4.3 Establishment Of A Cytotoxic Assay 
The initial learning curve of establishing tumouroids was steep, and this was due to the 
demanding technical aspects of organoid tissue culture. Only mouse-derived organoids had been 
successfully cultured in the lab prior to this project, and therefore human-derived organoids and 
tumouroid culture had not been routinely established. With the help of Dr. Jordane Maleterre in 
the laboratory, who had experience culturing mouse organoids, and alongside two other PhD 
students in the laboratory, Joe Kong and Glen Guerra, I successfully established and maintained 
tumouroid lines from patients with CRLM.  
 
The idea to combine tumouroids and lymphocytes in a co-culture assay was extremely novel at 
the time, in 2015. This had not been reported in the literature, and with the success of 
establishing tumouroids in our lab; we had the ability to advance this concept. Initially I decided 
that microscopy would be the ideal method to visualise the interaction between the tumouroids 
and lymphocytes. The very first attempt to do this was in December 2015, using one of the 
CRLM tumouroid lines that I had established from the IM of the tumour. Central Tumour (CT), 
Invasive Margin (IM) and matched distant ‘normal’ liver (DL) lymphocytes were expanded 
	 103 
from the same tumour. Healthy donors PBMCs were used as a positive control for killing. Both 
the TILs and PBMCs were stained using a cell labelling dye; propidium iodide (PI) and 
organoids were stained with cell labelling dye CFSE that traces generations of cell division. 
This was imaged over time to visualise trafficking and immune cell homing towards the 
tumouroid as seen in Figure 4.1 A-C.  
 
The images in Figure 4.1 A-C are “still-shots” from a live movie that was imaged over the 
course of every 1-minute following 24 hours of co-culture. The pink lines highlight 4 
representative cells, of the many cells visualised that traffic towards the tumouroid. This was an 
informative observation because it depicts selective immune cells can actively migrate toward 
the tumouroid. In most cases, the immune cells stop and ‘hover’ in the area, and fail to progress 
or interact with the tumouroid. The distance travelled by each immune cell is quantified in 
Figure 4.1D. As can be seen, each cell migrates closer to the tumouroid, one cell more rapidly 
than the other three. This was the first documentation of lymphocytes having the ability to 
migrate through the 3D scaffolding matrix, matrigel, and also only selective lymphocytes 
migrating towards the tumouroid, perhaps indicative of chemotaxis. The rate of each immune 
cell was also calculated (Fig. 4.1E) which provided an indication of how far individual cells 
travelled. 
 
In addition to fluorescent microscopy, a second plate was set up for measurement at the 
endpoint of the co-culture assay (24 hours). Cell trace violet (CTV) dye was added to the wells 
to stain the tumouroids, in order to visualise and assess the diameter of the tumouroids 
following exposure to immune cells. The plate was imaged on a wide field microscope and the 
diameter of each organoid was measured using Spotfire software (TIBCO), to quantitate the 





Figure 4.1 Select lymphocytes home towards tumouroid through 3D-matrix. Autologous 
TILs cells were labelled with PI and visualised after 24 hours of co-culture. “Still-shot” 
images taken on wide field microscope over a 1 minute time lapse at (A) 0.15 min (B) 0.30 min 
and (C) 1.00 min, scale bar=10 μm to depict distances travelled by immune cells, pink lines 
highlight 4 immune cells homing towards tumouroid. (D) Dot-plot depicting the quantified 
distance travelled (μm ) by 4 immune cells over 1 minute (E) Rate of migration of individual 
cells calculated as distance travelled (μm) over time (min), n=1. 
The diameter of tumouroids was measured, as seen in Figure 4.2, highlighting if tumouroids 
have either: increased (grown), remained stagnant or decreased in size, the latter indicating cell 
death and disruption. Tumouroids alone had a mean diameter of 240 μm and this is comparable 
to tumouroids + CT TILs (mean: 242 ± 26.68 μm ) indicating that the CT TILs are not effective 
killers against IM tumouroids. IM TILs were more effective at reducing tumouroid diameter 
(mean: 142 ± 21.37 μm ). The distant liver lymphocytes, expanded from healthy normal liver, 
were able to reduce the diameter of the tumouroids by 50% (mean: 93 ± 13.53 μm ). Healthy 
T=0.15min T=0.30min T=1.00min10 μm 
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donor PBMCs, used as a positive control, were comparable to DL lymphocytes, confirming this 
effect. These were the first data to indicate that autologous TILs and tumouroids can be 
successfully co-cultured together and both qualitative and quantitative data can be extrapolated. 
However measuring diameter alone, as a read out of tumouroid death was not instructive 
enough in regards to specific killing. It was also too ambiguous, deciphering the difference 
between tumouroids being resistant to immune attack and growing (increase), being controlled 
by the lymphocytes and not growing (static) or killed by the lymphocytes and reducing in size. 
To address this further, an improved method to detect specific killing was developed. 
 
 
Figure 4.2 Tumouroid death is induced by functional distant liver lymphocytes but not 
TILs. Autologous tumouroids were co-cultured for 24 hours and stained with CTV to visualise 
the diameter of the tumouroid (A) Scatter-plot displaying diameter of tumouroids (μm) after 
exposure to lymphocytes expanded from different regions of the autologous tumour. Each 
individual dot represents one tumouroid, error bars represent SEM, n=20-50 tumouroids 
measured per condition, One-Way ANOVA, *p=0.041, ****p<0.0001 (B) Microscopy images 
taken for each condition after staining with CTV showing tumouroids after 24 hours of 




























































Following this pilot experiment, I next approached this assay using live-imaging microscopy. 
The concept of using live imaging microscopy is to gain an understanding of the kinetic 
interaction of the TILs with tumouroids, and to decipher if TILs specifically interact with 
tumouroids. To achieve this, the wide-field Olympus IX3 microscope was used. PI was included 
in the assay to highlight target cell death (M. R. Jenkins et al., 2015). Lymphocytes were pre-
labelled with a live cell-tracer dye Syto11 (Thermo Fisher Scientific, Massachusetts, US) that 
allowed tracking of the lymphocytes. PI was used, as a marker of cell death upon binding to the 
nuclear DNA and RNA. The assay ran for 24 hours and was imaged at 0, 4 and 24 hours, as 




Figure 4.3 Autologous TILs home to tumouroids and induce tumouroid death using wide 
field IX83 microscope. “Still-shots” of patient-derived rectal cancer (RC) tumouroids that were 
co-cultured with autologous TILs and imaged at 4 and 24 hours (A) Bright-field images 
displaying tumouroid alone as negative control (B) Tumouroid + autologous TILs overlay of 
stained TILs (green) and dead cells (red) (C) Tumouroid + allogeneic PBMCs overlay. Scale 
bars=100 μm, images acquired at 20X magnification, n=1. 
Live imaging microscopy provided more insight into the dynamic process of lymphocytes 
inducing cytotoxic death, particularly by acquiring time-lapse images, shown only as “still-
shots” in Figure 4.3. In the live-imaging videos, it is evident that by 4 hours of co-culture, 
lymphocytes have already homed towards the tumouroid as indicated by the green flux that is 
observed. The red flush stained by PI is also evident at 4 hours on the exterior of the tumouroid 
and increases towards the centre of the tumouroid (Figure 4.3B). This is very obvious in the 
allogeneic PBMC condition (Figure 4.3C), where by 24 hours the entire tumouroid has become 
red. This is likely to be due to NK cells being present in the PBMC, due to alloreactivity of the 
















































NK cells against the tumouroids in the absence of recipient MHC-I ligands (Ruggeri et al., 
2002). 
 
The wide field microscope used in the previous experiment provided a good platform to 
visualise the interaction between lymphocytes and the tumouroid. However, the resolution of 
the images was not ideal. Therefore, I developed a method to distinguish tumouroid cells dying 
or lymphocytes surrounding the tumouroid dying due to cytotoxic-induced cell death (CICD) 
(Chavez-Galan, Arenas-Del Angel, Zenteno, Chavez, & Lascurain, 2009). To gain better 
resolution, the same experiment was set up and acquired on the confocal SP5 microscope. 
Images were acquired at 0, 4, 8 and 20 hours as seen in Figure 4.4. This approach provided 
higher resolution images, where PI uptake can be associated to a more refined area than 
observed with the wide-field microscope (Figure 4.3). In this example, architectural disruption 
is more evident after tumouroids have been exposed to autologous TILs or allogeneic PBMCs 
as observed by tumouroid ‘blebbing’ seen on the exterior of the tumouroid (Figure 4.3B-C). 
Also observed in this experiment is the centre of the tumouroid appearing darker after 
lymphocyte exposure compared to tumouroid alone, indicating an increased optical density of 





Figure 4.4 Imaging of co-culture assay on confocal SP5 microscope provides better 
resolution than wide field microscope. “Still shots” from time-lapse video of tumouroids at 0, 
4, 8 and 24 hours hours taken on the confocal SP5 microscope. Green indicates Syto11 stained 
lymphocytes and red indicates cell death by PI uptake (A) Tumouroid alone (B) Tumouroid + 
autologous TILs and (C) Tumouroid + allogeneic PBMCs. Scale bars=100 μm, images acquired 
at 200X magnification, n=1. 
 
Following these initial pilot experiments, a series of optimisation experiments were undertaken 
to optimise the platforms that included both wide field fluorescence and confocal microscopy. 
Additionally, titrations of lymphocyte concentrations were also optimised. Generally with 
immune co-culture assays, effector to target cell ratios are titrated in order to obtain a killing 
curve to determine the percentage of cytotoxicity. When passaging organoids, tumouroids are 
broken up to obtain a single cell suspension, but there are sometimes still cell clusters, and 
therefore calculating the effector: target (E:T) ratio is challenging. The tumouroids are seeded 7-
10 days prior to conducting the co-culture and growth of tumouroids is not always uniform, 
despite attempting to seed the same number of cells. To overcome this, the numbers of 

































size of 50 μm consists of 300-500 single cells. There were a series of experiments carried out to 
achieve this titration as well as optimizing other aspects of the assay including cell tracer dyes 
and the microscopic platform, as seen in Table 4.1. 
 
When optimising the assay on the Leica SP5 confocal microscope, some technical challenges 
were posed. For instance, it is important that there are not confounding factors that could 
contribute to cell death during the imaging process, as the output of this assay was measurement 
of cell death. One factor that was of concern when using confocal microscopy was the laser 
phototoxicity of the cells. As cells are rarely exposed to light, phototoxicity has the ability to 
affect cell viability. It is known that fluorescence excitation can cause phototoxicity to tissues 
and cells over time (Frigault, Lacoste, Swift, & Brown, 2009; Pattison & Davies, 2006). When 
imaging using the confocal microscope, images were acquired every hour to gain an 
understanding of the lymphocyte dynamics. However, it was evident in the negative control 
(tumouroids alone) that this constant acquisition on the confocal microscope caused some 
phototoxicity. This was especially noticed when there were multiple dyes being used to stain 
each component of the assay. Therefore, we decided to move back to the original platform, on 
the wide-field fluorescent microscope, for simplicity and with fewer exposure time points.  
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Table 4.1. Series of experiments carried out to optimise various aspects of cytotoxic assay 
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Initial experiments to titrate E:T ratio included staining of the tumouroids with Hoechst 33342, 
which is a DNA-binding dye. In these experiments, a marker of apoptosis was used instead of 
PI, that is: Caspase-3/7 Green ReadyProbes® which binds to activated caspase 3, specifically 
detecting early apoptosis. To optimize the E:T ratios using this platform, 1:1, 5:1 and 10:1 were 
tested. This was acquired on the IX3 wide field microscope (Olympus) at 4, 8, 12 and 24 hours,  
as seen in Figure 4.5. 
 
 
Figure 4.5 Higher E:T ratio results in more rapid killing of tumouroids. Rectal cancer 
tumouroids were used to optimise the E:T over time, Hoechst dye (blue) was used to stain the 
tumouroids and caspase 3/7 dye (green) was included in the media detecting cells undergoing 
early apoptosis. Images captured at 0, 4, 8, 12, 20 and 48 hours, E:T ratios are (A) 1:1 (B) 5:1 
and (C) 10:1. Scale bars= 200 μm, images acquired at 20X magnification, n=1. 
This was the first robust example of an effective E:T ratio. As can be seen in Figure 4.5C, when 
the effector to target ratio is increased to 10:1, tumouroids are rapidly killed by 12 hours. A 
second observation was that tumouroids at the edge of the matrigel, which is in a dome shape, 
as depicted in cartoon form in Figure 4.6, are the first tumouroids to be targeted by the 
lymphocytes. The tumouroids that are within the centre of the matrigel appear to take longer to 
be killed, as the lymphocytes have to penetrate further into the matrigel. Therefore, only 




















E:T was found to be 10:1, and this was the ratio taken forward in the assay. Caspase 3/7 dye 
was used for titration only to detect specific apoptosis and therefore only PI was continued for 
use in subsequent acquisition of the assay. 
 
 
Figure 4.6 Schematic diagram of processing tissue: from surgical resection to cytotoxic 
assay. Following surgical resection or biopsy, tumouroids are established from viable tumour 
tissue and embedded in 3D matrigel. TILs are expanded from a separate piece of tumour tissue 
in recombinant human IL-2 (6,000 IU/mL). TILs are co-cultured with tumouroids, in the 
presence of PI and imaged on a wide-field fluorescence microscope for 48 hours. Uptake of PI 
by tumouroids indicates tumouroid death and TIL-mediated cytotoxicity. Lack of uptake of PI 
indicates minimal cytotoxicity and may be an indication of dysfunctional TILs or 
immunologically resistant tumouroids. 
As previously mentioned, it was sometimes difficult to distinguish TILs from tumouroids when 
visualising the co-culture with wide-fide fluorescence microscopy. This was particularly 
apparent when the cells within the tumouroid start dying and it is complex to decipher if they 
are TILs sitting on top of the tumouroid or cells within the tumouroid itself. To make this 
distinction clearer, scanning electron microscopy was utilised. The experiment was set up where 
tumouroids were exposed to autologous TILs for 8 hours or not exposed to TILs at all. As seen 
in Figure 4.7B, following co-culture with autologous TILs, the surface of the tumouroid is 
completely disrupted compared to the smooth surface as seen in the tumouroid alone panel in 
Figure 4.7A. Lymphocytes are rendered pink and highlighted by pink arrows, and are evidently 
much smaller (≤10μm diameter) than tumouroids. Thus confirming that the cell death observed 
in the fluorescence microscopy images is more likely to be coming from the cells within the 
tumouroid rather than lymphocytes on the surface of the tumouroids. These qualitative data also 
highlight the E:T ratio being ideal, as this is reflective of 10:1 ratio and is in keeping with E:T  











Figure 4.7 Autologous TILs cause architectural disruption to tumouroids after co-culture. 
Scanning electron micrographs showing tumouroid structure from three different patients (A) 
tumouroids cultured alone or (B) with autologous TILs at high concentration for 8 hours and 
then subjected to fixation and processing for SEM. As observed, there are morphological 
irregularities denoted by the ruffled surface in panel (B). Pink arrows highlight lymphocytes 
rendered in pink, providing a sense of size of the lymphocytes (<10 μm) compared to 
tumouroid, scale bar = 20, 50 and 100 μm, respectively. 
4.4 Quantitation of the Cytotoxic Assay 
Up to this point, most of the data collected to establish the protocol was qualitative, however 
there was a strong desire to configure a way to gain quantitative data from these experiments. 
As mentioned before, we established the protocol on the Olympus IX3 wide-field fluorescent 
microscope, imaging at least 10 tumouroids per well at the periphery of the matrigel. Selection 
of tumouroids was within 100 μm of the edge of the matrigel at time zero. Acquisition of these 
images was captured with the differential interference contrast (DIC) to visualise the tumouroid 
structure and then subsequently captured with the dsRed filter to detect PI uptake, as a measure 
of cell death. Sequential acquisition was every 2 hours for 48 hours. Once the assay had been 
completed, images were exported and converted to a tagged image filed format (TIFF) file. The 
subsequent data analysis pipeline was then completed using the National institutes of health 
(NIH) software ImageJ (Chapter 2). 
 
First individual TIFF files were “stitched” together to create a time-lapse movie over 48 hours. 
To quantitate tumouroid death, each tumouroid within 100 μm of the matrigel edge, was 





















area was then copied to the dsRed channel to quantitate the mean fluorescent intensity (MFI) of 
PI uptake in that tumouroid. 
 
Figure 4.8. Selection of tumouroids for quantitation of tumouroid death. Tumouroids 
around the edge of the matrigel are selected for acquisition and quantitation using the DIC 
channel. These areas are then applied to DsRed channel and the MFI of PI uptake is then 
quantitated over time to obtain kinetic killing data as a measure of TIL-induced cytotoxicity. 
Scale bar = 50 μm. 
The data obtained from this analysis provides kinetic information- where the same tumouroid is 
imaged for 48 hours. This then details the MFI of PI uptake over time and therefore tumouroid 

























Figure 4.9. Quantifying tumouroid death by kinetic and maximum analysis. (A) XY-plot of 
rectal tumouroid death as measured by MFI of PI over time (hours). Heterogeneous killing of 
tumouroids by TILs. All experiments used 10:1 E:T ratio, lines represent the mean, n=6. (B) 
Scatter-plot of maximum MFI representing tumouroid killing. Background tumouroid death 
(purple circles) and tumouroid + TILs (orange triangles) at any time point during the co-culture, 
data representative of one experiment, individual dot represents one tumouroid, n=11 
tumouroids per condition. 
Additionally the maximum MFI value of each tumouroid was determined at any time point to 
obtain differences between test conditions as seen in Figure 4.9B. This is another representation 
of the data and allows statistical differences to be inferred between different test conditions. 
 
To expand TILs from the tumour, viable tumour pieces were placed in complete media enriched 
with recombinant human IL-2, at 6,000 IU/mL. Expansion was continued for 7-10 days, whilst 
tumouroids were established. On the same day as the co-culture assay, TILs were 
phenotypically assessed using flow cytometry to understand the sub population frequencies post 
expansion including: CD4+, CD8+, T-regulatory cells, NK (CD56+) and NKT cells (CD56+ 
CD3+). Expression of activation markers was also confirmed including CD69, PD-1 and 
CD45RO. Through this analysis, a sense of immune frequencies present in the TIL culture were 
understood; however the whole TIL culture would mostly be used in the co-culture assay. To 
gain a deeper understanding of which sub population of TILs were most responsible for killing, 
TILs were separated by FACS into: CD8+/CD56-, CD8+/CD56+, CD4+ and CD56+/CD8- 
populations. This was done for three different RC patients, in three separate experiments, as 
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Figure 4.10. CTL killing is mostly driven by cytotoxic CD8+ T-cell population. Sub-
populations of IL-2 expanded TILs were separated by FACS into CD8+/CD56- (yellow line), 
CD8+CD56+ (green line), CD4+ (grey line) and CD56+CD8- (blue line) populations and this 
was compared to all TILs (orange line) and tumouroids alone (dotted navy line). XY-plot 
showing MFI of PI uptake in tumouroids detailing kinetics of different TIL populations killing 
patient derived tumouroids over time (hours) in three different patients with RC (A) patient 1 
(B) patient 2 and (C) patient 3. (D) Representative still shot images taken on Olympus IX3 
wide-field fluorescent microscope at 0, 24 and 46 hours for tumouroid alone, all TILs and each 
sub-population separated by FACS. Caspase 3/7 dye (green) was used to document apoptosis 
and PI (red) was used to quantitate tumouroid death. Scale bars=50 μm, n=3. 
 
From this experiment, the most prominent killing population found was CD8+ T-cells. In each 
patient, CD8+ T-cells had the most rapid onset of killing. The CD8+CD56+ frequency, which is 







































































































































































did not induce cell death in the tumouroids, and the CD56+CD8-, likely to be NK cells did not 
have much effect. Alongside the CD8+ population, the condition that included all TILs was just 
as effective at inducing tumouroid death. It is likely that the combination of T-cells orchestrate 
tumouroid killing in unison, where the CD4+ helper T-cells likely produce cytokines to assist 
the CTL killing. This experiment also confirms that TIL killing is mostly CD8+ mediated, and 
that these CD8+ T cells are likely to be recognising tumour antigen. 
 
 
Figure 4.11. Process of steps involved developing the cytotoxic assay. In order to achieve an 
assay that can be used to address clinical questions regarding patient response, the initial set-up 
and optimisation steps must be achieved and this can then be applied to answer key biological 
and therapeutic questions. 
The process of developing an assay involved many learning experiences including initial set up 
of tissue culture techniques, TIL expansion and tumouroid establishment from patient-derived 
material. Many optimising steps were required to determine if autologous tumouroids and TILs 
would specifically react in an ex vivo setting, and define an ideal setting to measure this. The 
mechanism of apoptosis was important to confirm this killing was inducing direct apoptosis and 
not just unspecific necrosis. Quantitating this to achieve kinetic and comparative analysis to 
determine differences between treatment conditions was essential. Determining this is mostly 
CD8+ mediated also validated the specificity of the assay. Finally optimising this assay to the 
point where key biological and therapeutic questions could be posed was the main objective. 
This assay could now be applied to start answering these questions. 
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4.5 Application Of The Cytotoxic Assay 
The application that was envisioned for this assay, was the potential use of assessing CBI with 
patient derived TILs and tumouroids in the co-culture. We decided to target PD-1 and used the 
anti-PD-1 (αPD-1) checkpoint antibody Pembrolizumab (Keytruda®) and performed the 
experiment on three patient samples. We first assessed the basal levels of PD-1 expression on 
the expanded TILs by flow cytometry. The basal levels were 17.2%, 12.5% and 17.8% and 
following CD3/28 stimulation were 45.5%, 73.2% and 40.3% PD-1 positive on CD8+ cytotoxic 
T-cells, respectively (Figure 4.12A-C). Induction of PD-1 expression was achieved by 
stimulating the expanded TILs via the TCR using magnetic Dynabeads® human T-cell activator 
reagent targeting anti-CD3/28. These stimulated TILs were then taken into the cytotoxic assay. 
TILs were co-cultured with autologous tumouroids for 48 hours, and supernatants were taken at 
the endpoint of the assay (48 hours) and assessed by cytometric bead array (CBA). IFNγ and 
TNFα were assessed in each co-culture assay of each patient (Figure 4.12D-F), addition of 
αPD-1 (purple bars) showed a strong induction of both IFNγ and TNFα in all three patients, 
compared to no αPD-1 (blue bars). 
 
In many functional immune cell assays, IFNγ is a typically a readout of effector function. 
However, what this experiment demonstrated was that assessment of cytokines does not always 
reflect the cytotoxic function. When analysing the cytotoxic assay co-culture (Figure 4.12G-I) 
without (blue bars) or with (purple bars) αPD-1, it can be seen that the response to CBI is 
heterogeneous between patients. When observing the responses individually, with patient 1 
(Figure 4.12G), addition of aPD-1 rapidly enhances cytotoxic TIL function. However with 
patient 2 (Figure 4.12H) this does not occur until 8 hours, but eventually the TILs without aPD-
1 reach the same cytotoxic effect. Finally, patient 3 (Figure 4.12I) there is no effect of αPD-1, 
highlighting the heterogeneity of response to CBI between patients. This experiment also 
emphasises the observation that measuring cytokine secretion alone does not always equate to 
the cytotoxic function, and therefore both measurements should ideally be assessed when 




Figure 4.12. PD-1 blockade results in heterogeneous responses between patients in 
cytotoxic assay co-culture. (A-C) Bar graphs showing expanded TILs assessed for basal 
expression of PD-1 on CD8+ T-cells (yellow bars) and PD-1 expression following CD3/28 
stimulation (blue bars) in three different RC patients (A, B, C, respectively). CD3/28 stimulated 
TILs were co-cultured with matched tumouroids and supernatant was assessed by CBA. IFNγ 
(right panel) and TNFα (left panel) secretion (pg/mL) was analysed without αPD-1 (blue bar) 
and with αPD-1 (purple bar) in three different patients. XY-plots show tumouroid killing by 
matched stimulated TILs without (blue) and with (purple) aPD-1 blockade, measuring MFI of 
PI uptake over time (hours). n=3 patients, conducted over three separate experiments.  
The establishment of this assay was the first step in moving towards asking key immunological 
questions about patient-derived TILs and their function ex vivo. I therefore used this assay and 






















































































































































































































4.6 Assessment of TIL Function In CRLM 
When this project was first designed, one of the main objectives was to compare the immune 
response at the primary site in the colon/rectum and the distal metastatic site in the liver. To 
address this question, we aimed not only to recruit patients with metachronous isolated liver 
metastasis, but also recruit patients with synchronous disease, where the primary and metastatic 
liver tumour are in situ and surgically resected simultaneously. 
 
We recruited six patients that had synchronous surgical resections. Of the six patients, only one 
was successful in the generation of both tumouroids and TILs from each site, and we were able 
to utilise the cytotoxic assay to assess functional immune differences between these sites. In this 
proof of principle experiment, following expansion of TILs from both sites, on the day of the 
cytotoxic assay, the immune cells were assessed post expansion to determine different 
lymphocyte and T-cell subset frequencies as seen in Figure 4.13. T-cells are enriched in the 
expansion protocol and these frequencies are similar in the primary (blue bar) and liver met 
(yellow bar) tumours (Fig. 4.13A). T-helper cells (CD4+) are enriched from the primary tumour 
and cytotoxic T-cells (CD8+) are enriched from the met tumour (Fig. 4.13B). The CD8+ T-cells 
expanded from the met tumour have a more activated memory phenotype than those expanded 
from the primary tumour (Fig. 4.13C) 
 
 
Figure 4.13. TIL populations from different tumour sites have different phenotypes. TILs 
were expanded from the primary tumour in the rectum (blue bars) and liver met (yellow bars) 
and assessed by flow cytometry (A) Bar plots showing TILs from one patient with synchronous 
primary rectal tumour and liver metastases analysed for sub-populations of lymphocytes, 
including T-cells (CD3+), NKT cells (CD3+CD56+) and NK cells (CD3-CD56+) (B) T cell 
subsets (T helper cells: CD4+, Cytotoxic T-cells (CD8+) and T-reg cells (CD25+Foxp3+) and 
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Figure 4.14. TIL populations from different tumour sites have distinct killing capacity. 
Pooled cytotoxicity data from tumouroids from two patients with synchronous primary rectal 
tumour and liver metastases challenged with (A) matched TILs expanded from the same (site) 
tumour are shown (B) The same samples with the addition of anti-PD-1 antibody (mean +/- 
SEM). P < 0.05 (*), P < 0.01 (**), P < 0.001 (***), P < 0.0001 (****); 2way ANOVA. 
The function of these TILs was then investigated using the cytotoxic assay as seen in Figure 
4.14. The first experiment was comparing the TILs ability to kill the tumouroids of the same 
origin (tumour). As can be seen in Figure 4.14A, primary TILs have the ability to kill matched 
primary tumouroids. However, the metastatic TILs have a reduced ability to do this. A cross 
over experiment was then done with (whole lines) or without (dotted lines) the addition of αPD-
1. Primary tumour TILs were co-cultured with met tumouroids and met TILs were co-cultured 
with met tumouroids. As can be seen in Figure 4.14B, primary TILs have better killing efficacy 
than met TILs to the met tumouroids. This may imply that those TILs are the primary site are 
inherently more functional than those at the metastatic site. Interestingly, addition of αPD-1 
rescues only the metastatic TIL function, and not the primary TILs. This may also be associated 
with the higher PD-1 expression on the met CD8+ TILs as seen in Figure 4.14C. So although 
the TILs at the metastatic site may not kill efficiently on their own, addition of αPD-1 rescues 
this function, also suggesting that they are not intrinsically dysfunctional. 
 
To investigate this further in more patient samples, 4 CRLM patients were assessed using the 
cytotoxic co-culture assay. As seen in Figure 4.15A-B, autologous TILs (red line) have the 
ability to induce tumouroid death 1-2 fold greater than background tumouroid death (purple 
line). However, unlike the anecdotal example in Figure 4.12 where the TIL function was 
rescued with αPD-1, addition of αPD-1 in all patients assessed in Figure 4.15A-B did not 
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Figure 4.15. Autologous T-cells induce killing in matched tumouroids, addition of 
checkpoint blockade does not enhance killing. Patient-derived tumouroids were co-cultured 
with autologous IL-2 expanded TILs for 48 hours. (A) Bar-plot displaying mean maximum 
killing of tumouroids, each point represents the average of one tumouroid, error bars represent 
SEM (mean; one-way ANOVA ****p<0.001) (B) XY-plot describing kinetic data of tumouroid 




Figure 4.16. PD-1 expression is lower on TILs expanded in culture compared to TILs 
freshly isolated from tumour of CRLM patients. Bar-plots showing PD-1 expression on 
immune cell subsets of (A) TILs expanded from tumours of CRLM patients, error bars 
represent SEM, n=4 and (B) Freshly isolated TILs from tumours of CRLM patients, error bars 
represent SEM, n=11. 
It may be possible that no effects were observed with addition of anti-PD-1 antibody due to low 
expression of PD-1 on immune cells. As seen in Figure 4.16A, lymphocyte PD-1 expression 
was below 25% on all subsets of immune cells. When this is compared to PD-1 expression on 
immune cells freshly isolated from tumours of CRLM patients as seen in Figure 4.16B, PD-1 
expression is between 25-50% across all immune subsets. Therefore PD-1 expression on 
****p<0.0001
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immune cells is downregulated during culture. Although not included in this thesis, subsequent 
experiments to artificially induce PD-1 expression on expanded TILs used anti-CD3/28 
stimulation, which did induce PD-1 expression. Another confounding factor of use of anti-PD-1 
antibody in this assay was determination of PD-L1 expression on tumouroids. This was realised 
after completing these experiments, however it was found by a Ramsay laboratory member, that 
stimulation of tumouroids using IFNγ induced upregulation of PD-L1 on tumouroids in culture. 
Hence, the PD-1/PD-L1 axis should be present to see effects of blockade of this interaction, 
which may have been the reason no enhanced cytotoxic effects were observed. To assess 
phenotype of expanded TILs, a flow cytometry panel was used to determine the phenotype type 
of expanded TILs in culture. 
 
The gating strategy to define populations of T-cells and gating for positive expression of surface 
markers is outlined in Figure 4.17 in a representative sample. It can be observed that there is 
~80% enrichment of T-cells in the expansion process. The proportions of CD8+/CD4+ T-cell 
ratio is similar to what is observed when assessing T-cell proportions from fresh tissue in 
CRLM, with a predominance of CD4+ T-helper cells. Expression levels of PD-1 on CD4+, 
CD8+ and T-reg cells was assessed by the positive percentage of each population, that was 










Figure 4.17. Representative flow cytometry gating strategy of expanded TILs from patient 
tumour tissue. Expanded TIL phenotype on the day of the cytotoxic assay. Lymphocytes are 
gated on morphology (SSC-A vs. FSC-H), viable cells using BV605 viability dye, BV510 
CD45+. T-cells are gated on CD3+ T-cells and subpopulations defined by CD8+(purple) and 
CD4+ (blue) T-cells. T-regulatory cells (red) are defined by CD25+Foxp3+ staining. PD-1 
expression levels were assessed on all sub-populations, using an isotype control (green) to 
define PD-1+ cells.  
From the combined data analysis of the cytotoxic assay, it can be concluded that cytotoxic TIL 
function cannot generally be enhanced with addition of αPD-1. To investigate this on an 
individual basis, each patient assay was assessed, along with PD-1 expression levels, as seen in 
Figure 4.18. Patient 1 had the lowest expression levels of PD-1 on the entire T-cell population, 
and this was the only patient where the αPD-1 reduced the effect of TIL-mediated killing (Fig 
4.18A). Patient 2 and 3 both had PD-1 expression levels of ~15%, αPD-1 did not enhance 
killing, but remained at a similar killing efficiency as TILs alone (Fig. 4.18B-C). Patient 4 had 
PD-1 expression levels of ~9%, and addition of αPD-1 only enhanced this effect slightly (Fig. 
4.18D).  
 





Figure 4.18. TIL-mediated cytotoxicity in individual patients demonstrates killing, PD-1 
expression on T-cells does not affect response to αPD-1. XY-plot showing the mean kinetic 
data of tumouroid death by measuring MFI of PI uptake over time (hours). Bar-plots displaying 
the percentage of PD-1 expression on T-cells, CD8+, CD4+ and Treg by flow cytometry as 
gated in Figure 4.15. Individual data plotted for (A) Patient 1, (B) Patient 2, (C) Patient 3 and 
(D) Patient 4.  



















Patient #1 Kinetic tumouroid death 
Tumouroid
Tumouroid + PD-1
Tumouroid + TIL 
Tumouroid + TIL + 
PD-1

























































Patient #1 PD-1 








































































































































































In addition to assessing immune function using the cytotoxic assay, supernatants were also 
taken over the time course of the assay to assess both cytokine and cytolytic molecule secretion. 
IFNγ production was increased when αPD-1 was added to the tumouroid + TILs and also TILs 
alone (Fig. 4.19A). Cytolytic molecules including granzyme B and FasL were also induced with 
the addition of αPD-1. However, the exclusive use of cytokine data as readout of cytotoxicity 




Figure 4.19. Addition of anti-PD-1 induces cytokine secretion over time. Autologous 
tumouroids and TILs were co-cultured and supernatants taken at 24 and 48 hours. CBA was 
performed to analyse the amount (pg/mL) of (A) IFNγ (B) IL-2 and (C) TNFα secreted over 
time. Mean +/- SEM, n=3 
This ex vivo functional data provides insight into the biology of the TILs and their ability to 
respond to CBI. It is important to keep in mind that expanding the TILs in the presence of IL-2 
and tumour may not be biologically optimal or reflect exactly what occurs in vivo.  However, by 
expanding specific TILs and assessing their maximum function, we gain insights into the 
biology of these cells. Most importantly, it provides a platform to assess patient-derived 
samples, particularly assessing CBI, in a functional approach. To understand the in situ status of 
the immune response in patients with CRLM, I next assessed the frequency and phenotype of 
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Figure 4.20. Addition of anti-PD-1 induces cytolytic molecule secretion over time. 
Autologous tumouroids and TILs were co-cultured and supernatants taken at 24 and 48 hours. 
CBA was performed to analyse the amount (pg/mL) of (A) FasL and (B) Granzyme B secreted 
over time. Mean +/- SEM, n=3. 
4.7 Assessment of in situ TILs In CRLM 
Flow cytometry was used to assess the frequency and phenotype of immune cells from within 
the TME in CRLM. Lymphocytes were freshly isolated from the resected specimen and stained 
on the same day. As seen in Figure 4.21A the predominant leukocyte population in both tumour 
and normal liver are T-cells. It can be observed that both NK and NK T-cells are significantly 
reduced in the tumour compared to normal liver tissue. Also reduced in the tumour are the 
MDSC population. When assessing the T-cell distribution in CRLM tumours as seen in Figure 
4.21B, cytotoxic CD8+ T-cells are significantly reduced in the tumour compared to surrounding 
liver. Conversely, T-helper CD4+ cells are significantly increased in the tumour compared to 
surrounding liver. Of these CD4+ T-cells, ~16% are T-reg cells, that are more predominant in 
the tumour than in the surrounding liver. However, as can be seen in Figure 4.21, there is a 

























































Figure 4.21. Leukocyte distribution in CRLM involves T-cells that are mostly CD4+. 
Lymphocytes were freshly isolated from tissue and assessed using flow cytometry. Bar-
plots represent lymphocytes isolated from tumour (red) or normal distant liver (blue) detecting 
(A) the percentages CD45+ cells that are: NK cells (CD3-CD56+), NKT cells (CD3+CD56+), 
T-cells (CD3+) and MDSCs (CD45+HLA-DR-CD33+CD11b+). (B) T-cells are detected as a 
percentage of CD3+ cells including: Cytotoxic CD8+, T-helper CD4+ and T-reg cells 
(CD4+CD25+Foxp3+). Mean +/- SEM, n=11, Wilcoxon two-tailed t-test, *p=0.0021, 
***p<0.0001.  
Next I assessed the phenotype of these immune cells investigating markers of activation (PD-1), 
cytotoxicity (CD107a) and memory (CD45RO). As can be seen in Figure 4.22, PD-1 
expression is prominent in all T-cells subsets within the tumour, and this is distinct from T-cells 
in the peripheral blood, demonstrating a local immune phenotype at the tumour site. Expression 
of PD-1 can indicate activation as well as exhaustion; the latter requires other transcription 
factor expression to confirm this, which was not included in this flow cytometry panel. 
Importantly expression of PD-1 indicates that these immune cells have the potential ability to 
bind anti-PD-1 antibody and perhaps respond to it.  
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Figure 4.22. PD-1 expression on lymphocytes is distinct in tissue compared to peripheral 
blood. PD-1 expression was quantified as percentage positive on (A) Cytotoxic CD8+ (B) T-
helper CD4+ T-cells and (C) T-regulatory cells, gating on the positive population as defined by 
an isotype control. This was assessed in lymphocytes from the tumour, liver and PBMCs. Mean 
+/- SEM, n=11, One-Way ANOVA (non-parametric) Friedman test, **p=0.0021, ***p=0.0002. 
	
 
Figure 4.23. CD107a expression on cytotoxic lymphocytes is reduced on CD8+ T-cells from 
the tumour. CD107a expression was quantified as percentage positive on (A) Cytotoxic CD8+ 
(B) NK cells and (C) NKT cells, gating on the positive population as defined by an isotype 
control. This was assessed in lymphocytes from the tumour, liver and PBMCs. Mean +/- SEM, 
n=11, One-Way ANOVA (non-parametric) Friedman test, *p=0.03. 
 
Next to assess the cytotoxicity of the cytotoxic lymphocytes in situ, CD107a expression was 
measured CD8+ cytotoxic T-cells, NK and NKT cells as seen in Figure 4.23. It can be seen that 
CD8+ T-cells in the tumour have reduced expression of CD107a compared to those in the liver, 
indicating a reduced “cytotoxic” phenotype in the tumour. Conversely NK cells in the tumour 
express more CD107a (Fig. 4.23B) and there is no difference in expression of CD107a between 
the tumour and liver in the NKT subset (Fig. 4.23C).  
Finally to evaluate immune memory, CD45RO expression was interrogated as seen in Figure 
4.24. Certainly expression of this marker is distinct in the tissue compared to the peripheral 
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CD45RO on CD4+, CD8+ T-cells and T-regulatory cells was higher in the tumour compared to 
the liver. These data indicate that these immune cells are antigen experienced in the tumour.  
 
 
Figure 4.24. Memory phenotype is distinct in the tissue compared to peripheral blood. 
CD45RO expression was quantified as percentage positive on (A) Cytotoxic CD8+ (B) T-helper 
CD4+ T-cells and (C) T-regulatory cells, gating on the positive population as defined by an 
isotype control. This was assessed in lymphocytes from the tumour, liver and PBMCs. Mean +/- 
SEM, n=11, One-Way ANOVA (non-parametric) Friedman test, *p=0.03, **p=0.002, 
***p=0.0002, ****<0.0001. 
The phenotyping analysis provides a “snap-shot” insight into the in situ immune response at the 
tumour site, following surgical resection of the metastasis. What is evident from these data is 
that the cytotoxic immune infiltrate is reduced numerically and has a reduced cytotoxic function 
as assessed by CD107a expression. The CD8+ T-cells in the tumour also have an increased PD-
1 expression, which could be targeted to restore cytotoxic function. The presence of T-
regulatory cells that are both active and antigen experienced suggests these cells could play a 
role in suppressing effector function of the cytotoxic T-cells. The CD4+ T-cells also have this 
phenotype, however determining if the helper T-cells are Th1 or Th2 is beyond the scope of this 
flow cytometry panel. Using this flow cytometry panel, we can however conclude that within 
the tumours of CRLM, there is a reduced cytotoxic function and presence of T-regulatory cells 
that may contribute to a more immunosuppressive tumour microenvironment.  
 
The disadvantage of using flow cytometry to assess freshly isolated lymphocytes is that the 
tissue is macroscopically segmented into tumour and normal liver. This method does not assess 
immune cells residing at particular areas within the tumour such as CT, IM and DL. To gain a 
sense of spatial location of infiltrating immune cells, multiplex immunohistochemistry (mIHC) 
was utilised to assess the location and frequency of the aforementioned immune subsets. This 
technique allows for detection of up to 7 cell surface markers on the same tissue section. This is 
unlike traditional chromogenic IHC where only one cell surface marker can be interrogated per 
section, requiring multiple sections to be used, or immunofluorescence (IF) that can be limited 



























































The advantage of opal is evaluation of multiple markers on the one cell, especially defining 
immune cells that require multiple surface markers. In this opal panel DAPI was used to stain 
and define all nucleated cells. Cytotoxic T-cells were defined using an antibody for CD8+ and 
T-helper cells were identified using an antibody for CD4+. T-regulatory cells were noted as 
CD4+ Foxp3+ nuclear stain. Antibodies targeting PD-1 on immune cells and PD-L1 on 
tumour/other cells were also included. Tumour cells were defined as DAPI+ and AE1/AE3+, a 
cytokeratin marker used in the pathological diagnosis of CRC. Tumour and stromal areas were 
defined using a classifier system in HALO (PerkinElmer) software; detailing the 
DAPI+AE1AE3+ tumour cells are tumour and normal surrounding liver.  
 
When assessing the immune infiltrate in CRLM tumours using opal, there were no statistical 
differences observed between tumour and stromal infiltrate, as seen in Figure 4.25. This is 
different to the data generated using flow cytometry at the single cell level, where distinctions 
were observed. However, the advantage of using the opal technique details spatial location of 
immune cells to the tumour cells. Overall, the CD8+ T-cell cell infiltrate is low (<150 
cells/mm2) compared to published data by Galon et al where recurrent CRC patients had 150-




Figure 4.25. Immune cell infiltrate in CRLM quantified using mIHC analysis does not 
show differences between tumour and stromal infiltrate. Immune cells were identified using 
mIHC detailing CD8+, CD4+ and T-regulatory cells in the tumour and stromal regions of the 
tissue, quantified as cell count/mm2. (A) Bar plots of all sub populations showing CD8+, CD4+ 
and T-reg populations in the tumour (red symbols) and surrounding liver (blue symbols). 
Individual bar plots of (B) CD8+ (C) CD4+ and (D) T-regulatory cell distribution in the tumour 
and surrounding liver per mm2. Mean +/- SEM, n=12, paired Wilcoxon t-test. 
 
To compare the differences observed between FACS and opal CD4:8 ratios were calculated 
from the T-cell frequencies of each method. As seen in Figure 4.26 there is not a significant 
difference when using either method with the exception of one outlier. Both methods provide 
complementary information; FACS provides single-cell protein expression of phenotypic 
markers and opal documents the spatial location of the immune cells in the context of tumour 
cells. 












































































Figure 4.26. CD4:8 ratio is similar when comparing TILs using FACS vs. Opal. CD4:CD8 
ratios were compared from FACS and opal analysis by dividing CD4+/CD8+ frequencies. n=8, 
paired two-tailed Wilcoxon test. 
Expression of PD-1 on CD8+, CD4+ and T-reg cells was assessed, and no differences were 
observed between those immune cells in the tumour vs. liver (Fig. 4.27). However there were 
more CD4+ T-cells expressing PD-1 than CD8+ and T-reg cells. There were some outlier 




Figure 4.27. No differential expression of PD-1 on immune cells from the tumour vs. 
stroma observed using multispectral analysis. Immune cells were identified using 
multispectral IHC detailing CD8+, CD4+ and T-regulatory cells in the tumour and surrounding 
liver regions of the tissue, quantified as cell count/mm2. Bar plots of PD-1 expression on (A) 
CD8+ (B) CD4+ and (C) T-regulatory cells in the tumour (red symbols) and stroma (blue 
symbols) of CRLM tumours per mm2. Mean +/- SEM, n=12, paired Wilcoxon t-test. 
One other advantage of using mIHC is the spatial location of immune cells relative to tumour 
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117 μm to the tumour. It was observed that smaller micrometastases were surrounded by 
immune cells as seen in Figure 4.28B. 
 
 
Figure 4.28. CD8+ cell proximity to tumour cells is on average within 100 μm. (A) Bar plot 
showing distance between tumour cells and CD8+ cytotoxic cells (μm), error bar represent 
SEM, n=14. (B) Representative image of tumour cells (magenta) surrounded by immune cells 
of different subtypes. 
 
Unlike the micrometastases that were engulfed by immune cells, immune cell exclusion was 
observed in large areas of tumour. It can be seen in these large areas of tumour that the immune 
cells reside in the surrounding liver tissue, with a reduced frequency within the tumour cells. 
This implies that the TME is suppressing immune cell infiltration, and is therefore able to evade 
the immune response. It is particularly important to highlight the volume of tumour, which 
suggests that when a tumour increases in size, the immune response is unable to maintain 
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Figure 4.29. Immune cell exclusion in the tumour of CRLM. mIHC staining documenting 
immune cell exclusion including CD8+ T-cells within the tumour of CRLM at (A) 200 μm and 


















From the findings in Chapter 3, it is clear that the immune response at the primary site in 
mCRC patients has failed. Through failure of an effective immune response, the tumour has the 
ability to progress to metastatic sites. This is ultimately what causes death from the disease. To 
understand the immune response at the distant metastatic site, in this chapter, I sought out to 
assess the tumours from patients with CRLM. The initial design of this study was to compare 
the immune response in the primary tumour to the metastatic site in patients with synchronous 
disease. Unfortunately, due to limited patient numbers of synchronous presentation of disease, I 
was unable to undertake this. Instead, I assessed the immune response in CRLM tumours that 
presented following treatment of the primary tumour. 
 
Compared to earlier stages of CRC (I-III), in metastatic stage IV CRC, TIL presence does not 
appear to improve survival. The disease progression at this stage is advanced and the impact of 
the immune response is limited. Evaluation of immune cell presence alone is not enough, and 
more in-depth assessment of TIL function should be considered.  
 
In this chapter, I employed flow cytometry to assess immune cell frequency and phenotype in 
CRLM tumours. It was found that CRLM tumours had a reduced cytotoxic environment, with 
reduced NK, NKT cells and CD8+ T-cell infiltrate. Conversely, these tumours had an increased 
CD4+ frequency and determining if these CD4+ T-cells are Th1, Th2 or Th17 warrants further 
investigation. This would indicate whether the CD4+ immune cells promote or inhibit tumour 
progression in the TME. Fifteen per cent of this CD4+ T-cell population were T-regulatory 
cells, which is increased in the tumour compared to the liver. Thus it can be concluded the TME 
in CRLM tumours is more suppressed, with a reduced cytotoxic ability. 
 
But does this reduction in cytotoxic T-cell frequency, described above, also equate to a reduced 
cytotoxic function? The in situ phenotype data suggest that CD8+ T-cells in the tumour have 
reduced cytotoxic function as measured by expression of degranulation marker CD107a. 
Additionally the CD8+ T-cells in the tumour have higher expression of PD-1 compared to distal 
normal liver and peripheral blood and this is the first indication that these cells may be 
exhausted. In order to determine their effector function, the cytotoxic assay developed in this 
chapter was used to assess TIL function in CRLM tumours, ex vivo. 
 
TILs were expanded ex vivo from CRLM tumours and this was done in the presence of IL-2 and 
tumour pieces. Throughout this project there were a number of patient samples where the TILs 
failed to expand. Although not experimentally controlled, this observation provided some 
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insight, as it implies TILs from those samples have an inability to proliferate, even when 
provided with exogenous potent stimulation of IL-2. Proliferative non-responsiveness is a 
hallmark associated with exhaustion (Mueller et al., 1989). Other hallmarks of exhaustion 
include transcriptional reprogramming, expression of markers including PD-1, CTLA-4, 
Lymphocyte activation gene-3 (LAG-3) and T-cell immunoglobulin and mucin-domain 
containing-3 (TIM-3), altered metabolism and failure to produce Th1 secreted cytokines 
(Pauken & Wherry, 2015). It may be possible that due to heterogeneity of tumours, some 
tumour pieces may not have had any TIL and subsequent expansion did not occur. There were 
some patient samples where no TILs expanded, despite plating multiple tumour pieces. This 
observation highlights an inability of the TILs to proliferate and could be indicate dysfunction. 
 
On the other hand, this expansion protocol also highlights the potential of immune function ex 
vivo. When one considers tumour growth in vivo, the ability of immune cells to function and 
control it is based on tumour volume and tumour-mediated immune inhibition. The ability of 
tumour cells to suppress TIL function can be through checkpoint mechanisms and soluble 
factors in the TME. Those TILs that did expand, in the absence of tumour growth and 
inhibition, in vitro, demonstrated that the immune cells are no longer suppressed. This is what is 
observed in those tumours where TIL expansion did occur, and highlights that some aspects of 
immune cell function is contextual. 
 
Direct cytotoxic TIL function was then tested utilising the cytotoxic assay developed in this 
chapter. In all 4 CRLM patients assessed, the TILs were able to kill autologous tumouroids. 
However, it seems apparent that in the patient, these TILs were not able to control tumour 
growth in situ. This suggests that immune cells are likely to be inhibited in the 
immunosuppressive TME in vivo. Unlike the co-culture system in vitro, where tumour: immune 
cell ratio is accounted for, the tumour burden in the patient may be large. Therefore the shear 
volume of tumour is unable to be controlled by the TILs, and this contest is reversed in vitro. 
Additionally, the co-culture system does not have arterial or venous blood flow, thus trafficking 
immune cells that may play a role in vivo were not assessed here. 
 
When assessing CBI using the co-culture assay none of the four patients tested demonstrated 
response to anti-PD-1. This was not altered by expression of PD-1 on the expanded TILs, with 
low-expressing PD-1 cells having a similar killing capacity as moderate PD-1 expressing cells. 
Clinically, only CRC patients who respond to CBI are those with microsatellite unstable 
tumours. The patients included in this cohort all had microsatellite stable tumours, and this may 
be explain why these TILs are unable to be therapeutically reinvigorated. Importantly, the 
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majority of CRC patients are MSS and thus do not respond to CBI and identifying why this is 
the case is really crucial to improving therapies. Only 4 patients with CRLM were assessed 
using the co-culture assay in this study, and increasing the sample size will be essential if we are 
to observe variations in response to CBI in rare patients.  
 
In addition to live-cell imaging, TIL function was evaluated by measuring cytokine secretion in 
the supernatant of the co-culture. When tumouroid and TIL were cultured together there was 
minimal production of IFNγ and TNFα, however this was enhanced with addition of anti-PD-1. 
These data indicate that despite anti-PD-1 not affecting direct cytotoxic killing, it was able to 
induce TILs to secrete cytokine. Induction of Th1 cytokines can affect the TME by recruiting 
and activating more cytotoxic T-cells, improving tumour control but also increase PD-L1 
expression on tumour cells (Barber et al., 2006).  
 
The importance of these observations is that despite being MSS, the TILs from these patients 
have the capacity to function ex vivo. This probably reflects the ability of the tumour to suppress 
immune responses in vivo. Assessment of TIL function utilising the assay may provide another 
dimension to understand the dynamic biology of T-cells from solid tumours and how we can 
therapeutically enhance their function. Our assay has a clinical potential to study dynamic 
interactions between TIL and patient-derived tumouroids. This assay also has the capacity to 
test CBI in patient-derived material. In a different use, our assay has recently been used to test 
the efficacy of drugs in combination with chimeric antigen receptor (CAR) T-cells against 
patient derived tumours (Michie et al., 2019). Therefore, the application of the assay both 
clinically and scientifically can provide insight and be utilised as a platform to test therapeutics 
targeting immune responses. The tumours from MSS CRLM patients appear to have a reduced 
cytotoxic and enhanced suppressive phenotype. It is evident that patients with MSS tumours do 
not respond to current CBI. Thus, therapeutically, there should be a continued focus on altering 
the balance in the immune infiltrate to a more cytotoxic and reduced suppressive state.
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In Chapter 3 my results showed that TIL abundance is no longer predictive in primary CRC in 
patients with synchronous metastases. However, the presence of an immune infiltrate in 
colorectal tumours has been strongly associated with prognosis in earlier stages of disease 
(Pages et al., 2005). Our group and others have found that conventional CD8+ T-cells are the 
most significant population to correlate with prognosis in primary CRC tumours (Galon et al., 
2006; Millen et al., 2016; Pages et al., 2009). The question then arises about the status of TILs 
in mCRC.  
 
The most common site of metastatic spread in CRC is the liver (CRLM) (Nordlinger et al., 
2013). The liver is an important organ for processing nutrients and clearing toxins and acts as an 
immunological organ, harbouring a high frequency and variety of immune cells (Racanelli & 
Rehermann, 2006). This is due to the continuous arterial and venous blood supply, 80% of 
which is delivered via the portal vein (Sheth & Bankey, 2001). This vein drains from the gut, 
bringing nutrients and pathogen-derived molecules directly to the liver. Due to the constant 
supply of antigen trafficking through the liver, the immune response balances immunity with 
tolerance (Racanelli & Rehermann, 2006). Both high blood flow and intrahepatic immune 
tolerance may underpin why CRC disseminates within the liver. Investigating the immune 
response in the setting of CRLM is therefore important to understand the steps involved in the 
progression of metastasis to this organ. Hence, the liver being a unique immunological site and 
the preference of CRC to disseminate indicates we need to explore this context in further detail.  
 
The immune response in tumours is comprised of both innate and adaptive immune cells, the 
latter being extensively studied in the context of primary CRC (Galon et al., 2013; Naito et al., 
1998; Ropponen et al., 1997). A novel cell type that bridges the innate and adaptive immune 
system are mucosal-associated invariant T-cells (MAIT cells), which have been recently defined 
as a subset of unconventional T-cells. The physiological and pathological roles of MAIT cells 
are still being elucidated. However, it is known that bacteria and some yeast activate MAIT 
cells via the MAIT cell TCR-MR1 axis (Gold et al., 2010; Le Bourhis et al., 2010). This TCR is 
restricted by the highly conserved molecule MR1 that captures a novel class of antigens that are 
released into the extracellular environment or can be found in the lumen of phagosomal 
compartments following microbe engulfment (McWilliam et al., 2016). This unique class of 
ligands belong to vitamin B antigens, and MAIT cell activation depends on recognition of the 
ligands bound to MR1. In this context, it is thought that MAIT cells play a protective role in 
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controlling bacterial infections, as the known ligand to activate MAIT cells is 5-OP-RU, a by-
product of microbial riboflavin synthesis (Le Bourhis et al., 2013). Viruses including dengue, 
hepatitis C and influenza are also known to activate MAIT cells in a TCR-independent 
mechanism via cytokines including IL-12 and IL-18 (Loh et al., 2016; van Wilgenburg et al., 
2016). During viral infections it has been found that peripheral MAIT cell frequencies are 
depleted, and this may increase host susceptibility to opportunistic bacterial infections, 
providing more evidence that MAIT cells play a protective role in this context (Ussher, 
Willberg, & Klenerman, 2018). 
 
As MAIT cells reside within the mucosal tissue, it is thought that they may play an important 
role in patrolling the epithelial barrier interface. When the epithelial barrier is damaged, immune 
homeostasis is disrupted, with a high chance of microbial and resident lymphocyte interactions, 
possibly including MAIT cells. This has been highlighted in inflammatory bowel diseases 
(IBD), such as Crohn’s disease (ChD) where high MAIT cell accumulation was detected in 
damaged ileum tissue compared to normal healthy tissue (Serriari et al., 2014). 
 
Because MAIT cells reside in mucosal tissues, and play a role in IBD, there has been a 
particular interest to determine their role in CRC. When colorectal tumours develop, disruption 
to the epithelial barrier occurs, creating inflammation (Grivennikov et al., 2012; Peterson & 
Artis, 2014). As highlighted in Chapter 1, MAIT cells have been detected in colorectal tumours 
with reduced production of IFNγ (Sundstrom et al., 2015). The same observation was found in 
CRLM, with reduced MAIT cells in the tumour that were functionally impaired and unable to 
produce IFNγ. The conclusion from these studies was that MAIT cell effector function was 
suppressed in the TME. Additionally across all studies of patients with CRC MAIT cell 
frequency was not affected by chemotherapy, implying that MAIT cells are chemotherapy 
resistant (Shaler, Tun-Abraham, et al., 2017). 
 
As well as being chemotherapy resistant (Dusseaux et al., 2011; Novak, Dobrovolny, Brozova, 
Novakova, & Kozak, 2016), the majority of MAIT cells have been reported as CD8+ 
(Gherardin, Souter, et al., 2018). We know from other studies that conventional CD8+ TILs in 
the primary and metastatic tumours of CRC patients correlate with a better OS (Kwak et al., 
2016; Shibutani et al., 2018). As MAIT cells commonly express the CD8α receptor, it is very 
likely that MAIT cells are erroneously included in the quantification of CD8+ TILs. Therefore 
there is a sub population of CD8+ cells that has not been accounted for previously and this 
population warrants further investigation. As previously mentioned, MAIT cells in the primary 
tumour have been associated with a less favourable clinical outcome. Since MAIT cells are 
abundant in normal liver tissue I decided to investigate their role in CRLM, and when I 
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embarked on this study there were no publications addressing this matter. 
 
In the current study, I investigated the presence and phenotype of MAIT cells within human 
CRLM, surrounding normal liver and peripheral blood. Using the patient-derived tumouroid 
model previously described, I investigated the function of MAIT cells in the setting of tumour 
immunity. I also explored the response of MAIT cells to CBI, to evaluate the therapeutic 
attributes and utility of these therapies in the context of mCRC. 
 
Hypothesis:  
MAIT cells are present within CRLM tumours due to their abundance in the liver. 
 
Aims: 
1. Investigate the functional capacity of MAIT cells in the context of colorectal cancer.  
2. Determine the presence and abundance of MAIT cells in CRLM. 
5.2 Patient Characteristics  
To enrol patients to this study, I wrote the human ethics application and recruited patients with 
CRLM. Patients with CRLM were provided with informed consent and recruited to the study. 
On the day of the surgical operation, blood was drawn from the patients pre-incision for 
collection of PBMCs). After the specimen had been surgically removed from the patient, 
tumour and healthy liver pieces were dissected in theatre, or by a registered pathologist (to 
ensure that the surgical margins were not compromised). The tissue was then placed in ice-cold 
media and transferred to the laboratory for immediate processing. The patient characteristics are 
listed in Chapter 2. 
5.3 MAIT Cells in the Context of Colorectal Cancer 
To first determine if primary and metastatic tumours of CRC origin have the ability to express 
MR1, RNAseq was performed on tumour samples from CRLM patients. As seen in Figure 5.1 
MR1 expression was detectable in all samples tested, however expression was found to be 
heterogeneous across both primary and metastatic tumours. What these data demonstrate is the 
potential ability of tumours to express MR1, which may indicate a role of MAIT cell presence 










Figure 5.1. MR1 expression in tumour tissue is heterogeneous in both primary and 
metastatic CRC. RNA was isolated from primary (CRC) (CT) and metastatic (CRLM) (LT) 
tumours and sequenced using RNAseq. Samples are clustered based on location of tumour with 
shades of purple indicating the LogTPM expression change. 
Due to MAIT cell abundance in the liver, MAIT cell presence in CRLM tumours was 
interrogated. The majority of MAIT cells are CD8+, suggesting that when conventional CD8+ 
T-cells are scored (e.g. for the Immunoscore™) it is highly likely that MAIT cells are included 
in this count. To address this question, using flow cytometry, I quantified MAIT cells as a 
proportion of the CD8+ population in the tumour and liver. As can be seen in Figure 5.2 MAIT 
cells in the tumour comprise of ~20% of total CD8+ T-cells in the tumour and ~45% in the 
liver. This demonstrates that it is very likely that by scoring CD8+ T-cells, a substantial 










































































































































Figure 5.2. MAIT cells account for a high proportion of CD8+ T-cells and show similar 
expression of PD-1. T-cells form the tumour and liver were quantitated using flow 
cytometry. (A) Bar-graphs represent total CD8+ T-cells (blue) as proportion of CD3+ T-cells, 
MAIT cells (purple) shown as a proportion of CD8+ T-cells (B) Bar-graphs showing 
quantitation of PD-1 and (C) CD69 expression on only CD8+ T-cells and MAIT cells in the 
tumour, represented as GMF. Each data point represent individual patients samples, error bars 
represent SEM, n=11 CRLM patients, non-parametric One-Way ANOVA Friedman test, 
**p<0.0021. 
To determine if MAIT cells are phenotypically different to conventional CD8+ T-cells, I 
compared expression of PD-1 and CD69. As seen in Figure 5.2, no significant difference is 
observed between PD-1 expression on MAIT cells and total CD8+ T-cells in the tumour. 
However, when assessing CD69 expression on conventional CD8+ T-cells and MAIT cells in 
the tumour, it can be seen that MAIT cells express significantly more CD69 compared to 
conventional CD8+ T-cells. 
5.4 Detection of MAIT Cell Frequency Using Flow Cytometry 
To determine the frequency of MAIT cells within CRLM patient samples, a flow-cytometry 
panel for MAIT cell detection was developed. This was initially optimised on healthy control 
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primary CRC tumours (Sundstrom et al., 2015). Using this gating strategy MAIT cells were 
defined by excluding doublet cells, including viable, CD45+CD3+ T-cells with Vα7-2+ TCR 
expression and high expression of CD161. Included in this panel were CD8α+ and CD4+ 
markers, to define different subsets of MAIT cell populations. This panel was initially 
optimised and acquired on the BD FACSCanto™ and then subsequently acquired on the BD 
Fortessa™ as depicted in Figure 5.3. 
 
 
Figure 5.3. Gating strategy used to define MAIT cells in different tissue regions. Single cell 
lymphocyte preparations from CT, IM and DL were acquired on a BD Fortessa™. All 
events are gated on singlets to exclude doublet populations, viable cells using the cell fixable 
viability stain (FVS) 620, and lymphocyte morphology based on SSC-A v FSC-H, 
CD45+CD3+ double positive T-cells and co-expression of CD161 and Vα7-2 to define MAIT 
cells. 
Following establishment of the MAIT cell flow cytometry panel, the first 13 patients were 
screened for MAIT cells within tumour tissue, liver tissue and PBMCs. After collection, tumour 
specimens were initially divided macroscopically into CT and IM sections and compared to 
distant liver (DL). This approach was designed based on the work of Galon et al documenting 
differential infiltration of TILs, in FFPE sections, at the CT and the IM (Galon et al., 2006). At 
the time, it was unknown if MAIT cells had the ability to infiltrate CRLM tumours, a question I 
considered required addressing. 
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However, due to the steep learning process of tissue processing, lack of tissue and low cell 
numbers, only 5/13 patients had paired datasets with both CT and IM analysed. Flow cytometric 




Figure 5.4. No difference in degree of T-cell infiltration between the CT and IM regions in 
patients with CRLM. Percentage of infiltrating T-cells was assessed in the CT and IM of 
patients with colorectal liver metastasis by flow cytometry. (A) CD3+ T-cells were assessed as 
a percentage of viable lymphocytes (B) CD4+ (C) CD8+ T-cells and (D) MAIT 
(CD161highVα7.2+) cells were assessed as a percentage of CD45+CD3+ T-cells. Each point 
represents an individual patient, n=5, paired Wilcoxon t-test, p<0.05. 
When comparing T-cell infiltration in the tumour, there were no statistical differences between 
CT and IM, as seen in Figure 5.4 A-D. Therefore, all subsequent samples were only assessed 

































































































Figure 5.5. Colorectal-liver tumours have increased T-helper (Th) and reduced cytotoxic 
lymphocytes including MAIT cells. Lymphocytes from patients with CRLM were isolated 
from the tumour and liver as paired samples and analysed by flow cytometry. (A) CD3+ T-cells 
were assessed as a percentage of viable lymphocytes (B) CD4+ (C) CD8+ T-cells and (D) 
MAIT (CD161highVα7.2+) cells. Each point represents an individual patient as a paired samples, 
n=12 CRLM patients, error bars represent SEM, Wilcoxon paired t-test, (*p<0.01, **p<0.001, 
***p<0.0001. 
 
When using this approach to assess T-cell infiltrate, there was an increase of Th-CD4+ T-cells 
in the tumour compared to liver (mean 42.3% vs. 21.3%) (Fig. 5.5 B). The opposite is observed 
when quantifying cytotoxic CD8+ T-cells in the tumour compared to liver (mean 42.6% vs. 
58.5%) (Fig. 5.5 C). When quantifying MAIT cells, a decrease is observed in the tumour 
compared to the liver tissue (mean 9.6% vs. 19.8%) (Fig. 5.5 D). These data highlight a 






























































































MAIT cell presence was then assessed in all patient samples, as seen in Figure 5.6. There was a 
significant reduction of MAIT cells in the tumour compared to the liver. It can be seen that the 
majority of samples have fewer MAIT cell infiltrate in the tumour (mean: 9.4%, lower 95% CI: 
4.6, upper 95% CI: 14.3) than the liver tissue (mean: 20.3, lower 95% CI: 11.9, upper 95% CI: 
28.7), with a wider spread. Interestingly, there are still some cases with a high percentage of 
MAIT cells infiltrating the tumour. Representative flow cytometry plots show the differences 
between a patient with low (Fig. 5.6B) and high (Fig. 5.6C) MAIT cell infiltration across both 
tumour and liver. 
 
 
Figure 5.6. MAIT cell infiltration in the tumour is generally reduced, but is individually 
heterogeneous. All CRLM samples were combined (A) MAIT cell infiltration was significantly 
reduced in the tumour compared to the liver (*p<0.05). Representative flow cytometry plots of 
(B) a patient with low MAIT cell infiltrate (C) and high MAIT cell infiltrate in the tumour and 
liver. Each data point represents individual patient, n=24 CRLM patients, error bars are SEM, 
unpaired Mann-Whitney t-test, and p <0.05. 
When this project started in October 2015, the widely accepted detection method for MAIT 
cells was the use of the surrogate markers: Vα7-2+, CD161high or IL-18Rα+. An MHC tetramer 
acts as a ligand to detect specific TCR and this is conjugated to a fluorophore to detect specific 
T-cell populations in lymphocyte samples. Therefore, the 5-OP-RU tetramer specific for the 
MAIT cell TCR was developed at the Peter Doherty Institute in Parkville, Melbourne 
(Reantragoon et al., 2013). However, this was an in-house tetramer and was not publically 
available. Towards the end of 2016, the tetramer became publically available through the NIH 
tetramer facility in the United States of America. I obtained this reagent and incorporated it into 
the flow cytometry panel. There were some issues with staining using the tetramer, where flow 
MAIT cells MAIT cells








































cytometry plots displayed a “smeared” appearance (Fig. 5.7) and had a less defined population 
compared to the surrogate marker detection Vα7-2+CD161high. When comparing the detection 
methods in five samples, there were no differences observed. To ensure consistency across the 
cohort, I decided to continue detecting MAIT cells using the Vα7-2+CD161high method. 
 
 
Figure 5.7. Comparison of MAIT cell frequencies using surrogate markers and the 5-OP-
RU tetramer. Representative flow cytometry plots and quantitation of MAIT cell detection 
from (A) tumour, (B) liver and (C) PBMC. Two detection methods were directly compared: 
specific 5-OP-RU tetramer staining or surrogate marker detection Vα7-2+CD161high. Each data 
point represent individual patients samples, n=5 CRLM patients, paired Wilcoxon t-test, p<0.05. 
It is known that MAIT cells in the peripheral blood range from 1-10% of all T-cells in healthy 
donors, and a reduced frequency has been reported in patients with CRC (Gherardin, Loh, et al., 
2018; Ling et al., 2016). In my quantitation of MAIT cells in the periphery of CRLM patients, I 
found no significant difference when compared to healthy donors (Fig. 5.8C). The range of 










































































































15.4% of healthy donor PBMCs. No statistical difference was observed when quantifying 
conventional CD8+ T-cells (Fig. 5.8B). However, there was a significant difference when 
assessing CD4+ T-cell frequencies (Fig 5.8A). This is a similar observation with a higher 
frequency of CD4+ T-cells infiltrating the tumour compared to the surrounding normal liver, 




Figure 5.8. Peripheral MAIT cell frequency in patient PBMCs is similar to healthy donor 
PBMC. Peripheral T-cells were quantified by flow cytometry from CRLM patients (n=25) and 
healthy donors (n=13). (A) Peripheral CD4+ T-cells were significantly increased in CRLM 
patient blood compared to healthy donors (*p<0.05). No significant differences seen in (B) 
CD8+ or (C) MAIT cell frequencies. Each data point represent individual patients samples, 
error bars represent SEM, n=25 CRLM patients and n=13 healthy donors, unpaired Mann-
Whitney t-test. 
5.5 MAIT Cell Phenotype In Situ in Tumours from Patients with CRLM 
In order to characterise MAIT cell phenotype in more detail, the activation profile of MAIT 
cells from the tumour; liver and peripheral blood was assessed by expression of PD-1, CD69, 
HLA-DR and CD45RO. As seen in Figure 5.9, MAIT cells express PD-1 and CD69, and this 
expression is distinct in the tissue compared to peripheral blood. 
 
Similar to PD-1, another conventional T-cell activation marker is CD69. This indicates that the 






















































Figure 5.9. MAIT cell PD-1 and CD69 expression is distinct in tissue compared to PBMCs. 
Expression of PD-1 was assessed by flow cytometry on MAIT cells in the tumour, liver and 
PBMCs. Bar-plots represent expression of (A) PD-1 as the Geometric Mean Fluorescence 
(GMF) of MAIT cells and % PD-1+ MAIT cells and (B) CD69 as the GMF of MAIT cells and 
% CD69+ MAIT cells. Each data point represent individual patient samples, n=11 CRLM 
patients, error bars are SEM, One-Way ANOVA (nonparametric) Friedman’s test, *p<0.03, 
**p<0.002, ***p<0.0002. 
MAIT cells are known to express HLA-DR, which has been used to assess activation of the 
cells in the liver (X. Z. Tang et al., 2013). The tumour and liver MAIT cells had a higher 
expression of HLA-DR than MAIT cells in the peripheral blood (Fig. 5.10A). Again, this 
suggests that MAIT cells in the tissue are activated. Finally to assess if MAIT cells have the 
capacity of memory, expression of the memory T-cell marker CD45RO was assessed. Across 
all sample types, MAIT cells expressed CD45RO (Fig. 5.10B), indicating that these MAIT cells 


































































































Figure 5.10. HLA-DR and CD45RO expression on MAIT cells. Expression of HLA-DR 
and CD45RO was assessed by flow cytometry on MAIT cells in the tumour, liver and 
PBMCs. Bar-plots represent expression (A) of HLA-DR as the Geometric Mean Fluorescence 
(GMF) of MAIT cells and % HLA-DR+ MAIT cells and (B) CD45RO as the GMF of MAIT 
cells and % CD45RO+ MAIT cells. Each data point represent individual patients samples, n=11 
CRLM patients, error bars are SEM, One-Way ANOVA (nonparametric) Friedman’s test, 
*p<0.03, **p<0.002, ***p<0.0002. 
Collectively these phenotyping data demonstrate that the MAIT cells within the tissue are 
phenotypically distinct from MAIT cells in the peripheral blood. Some of the current published 
work only assesses peripheral MAIT cells, as access to tissue can be difficult. However, my 
results highlight the importance of assessing MAIT cells isolated from the tissue of interest to 
determine differential phenotypes. 
5.6 Cytotoxic Capability of MAIT Cells Against Patient-Derived Tumouroids 
Understanding the effector functions of MAIT cells against tumour cells was the main aim of 
this study. It is known that MAIT cells are specifically activated through the MAIT cell 
TCR/MR1 axis, when the ligand 5-OP-RU binds MR1; MAIT cells have the ability to induce 
cytotoxicity and produce cytokines (Corbett et al., 2014; Kjer-Nielsen et al., 2012). Previous 

















































































































been pulsed with 5-OP-RU, in an MR-1 dependant manner (Gherardin, Loh, et al., 2018). 
However, there have been no in vivo reports of tumours having the ability to present 
endogenous ligand and activate MAIT cells. It is plausible that mucosal tumours provide an 
environment, which attract and activate MAIT cells (Godfrey, Le Nours, Andrews, Uldrich, & 
Rossjohn, 2018). Hence, activated MAIT cells could have direct anti-tumour effector function 
or act within the TME as bystander immune cells secreting cytokines. As viruses can also 
activate MAIT cells in a TCR-independent manner, MAIT cell anti-tumour activity might also 
operate in a TCR-independent manner noting that they express a highly restricted TCR 
repertoire. 
 
In order to understand MAIT cell interaction with tumour cells, the assay developed in Chapter 
4 was used to assess MAIT cell-mediated cytotoxicity. Patient-derived tumouroids were 
established ex vivo and co-cultured with allogeneic healthy donor MAIT cells. The first pilot 
experiment assessed MAIT cell ability to kill patient-derived tumouroids, and addressed two 
key questions: (1) Do MAIT cells kill tumouroids and (2) do tumouroids have the ability to 
present 5-OP-RU? 
 
Purified expanded MAIT cells were obtained from Professor Dale Godfrey’s laboratory at the 
Peter Doherty Institute. These healthy donor MAIT cells had been purified using the 5-OP-RU 
tetramer by FACS and expanded in the presence of 5-OP-RU, plate bound anti-CD3/28 
antibodies and cytokines as described in Chapter 2 and had been cryopreserved. A tumouroid 
line and expanded autologous TILs were established from a CRLM patient and used in the 
assay. To address the question of TCR/MR1-mediated activation of MAIT cells, 5-OP-RU 
soluble ligand was added to the culture to assess the ability of tumouroids to present ligand to 
MAIT cells. 
 
Tumouroid death was assessed by uptake of PI, as a measure of cell death. As seen in Figure 
5.11A autologous TILs co-cultured with tumouroids induced tumouroid death, with clear 
evidence of PI uptake. This also occured in the allogeneic purified MAIT cells however to a 
lesser degree. When kinetic killing was assessed in Figure 5.11B, MAIT cells (red line) were 
able to induce tumouroid death, which was enhanced with the addition of the ligand 5-OP-RU 
(orange line). However, MAIT cell killing was inferior to autologous TIL killing (green line), 
which had a greater killing capacity and enhanced kinetic killing. 
 
When cytokine function was assessed, it was evident that, MAIT cells did not produce IFNγ 
when co-cultured with tumouroids alone, but did secrete IFNγ in the presence of 5-OP-RU 
(Figure 5.11C). In contrast, although the TILs were able to effectively kill the tumouroids as 
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seen in Figure 5.11B, TILs failed to produce IFNγ in the co-culture (<1 pg/mL at all time 
points) compared to MAIT cells and tumouroids + 5-OP-RU (>500 pg/mL at 4 hours) (Figure 
5.11D). These data demonstrated that MAIT cells have the ability to kill patient-derived 
tumouroids, but to a lesser extent than patient-matched TILs. 
 
 
Figure 5.11. Purified MAIT cells are able to kill tumouroids, but are inferior to autologous 
TILs. Allogeneic purified expanded MAIT cells and autologous patient TILs were co-cultured 
with patient-derived tumouroids, respectively. (A) Representative images from differential 
interference contrast (DIC) live-imaging microscopy co-culture over 21 hours, showing PI 
uptake (red) in tumouroids. (B) XY-plot showing kinetic killing of tumouroids by quantitation 
of the MFI of PI uptake in tumouroids over time (hours) with immune cell co-culture, n=21 
tumouroids measured per condition. Bar graphs show the amount of IFNγ secretion by (C) 
MAIT cells and (D) autologous TILs during co-culture, over 24 hours in pg/mL, representative 
































































MAIT IFN  secrection 
+ MAIT  cells
















TIL IFN  secrection 
TILs





To build on the pilot experiment, the next questions addressed were: (1) Do MAIT cells have a 
bystander role by enhancing autologous TIL-mediated killing through cytokine secretion and 
(2) does addition of anti-PD-1 antibody enhance the effector function of MAIT cells? Therefore, 
to develop this assay in more depth, fresh healthy donor MAIT cells were used against patient-
derived tumouroids. Ideally, patient-derived MAIT cells would be used with autologous 
tumouroids; however, the biggest challenge of these experiments was isolating sufficient 
quantities of MAIT cells from patients for functional experiments. Importantly, MAIT cells are 
not MHC-restricted and therefore, using allogeneic MAIT cells against patient-derived 
tumouroids did not induce human leukocyte antigen (HLA)-mismatch. Conversely, access to 
healthy donors and large amounts of blood was not a limitation in these assays. 
 
Instead of using FACS to purify MAIT cells, healthy donor MAIT cells were enriched using 
Vα7-2+ magnetic separation kits from Stemcell technologies (Vancouver, Canada). In 
comparison to the pilot study (Fig. 5.11), this experiment used freshly isolated MAIT cells, 
which had not been expanded, activated, or cryopreserved. As with the pilot experiment, 
autologous IL-2 expanded TILs were used to directly compare the killing efficiency of TILs vs. 
MAIT cells. Addition of anti-PD-1 antibody was used as an experimental condition, to assess if 
MAIT cell or TIL killing was enhanced with CBI. A final condition was included, where MAIT 
cells and TILs were combined, to understand if MAIT cells played a bystander role to either 
enhance or hinder TIL function, through secretion of cytokines. 
 
In this experiment (Fig. 5.12A), TILs alone (red line) proved to be the most efficient at killing 
tumouroids, and addition of anti-PD-1 (dotted red line) slightly decreased this efficiency. MAIT 
cells (green line) were able to induce tumouroid death, compared to tumouroid alone, but this 
effect was much less than with TILs. Addition of anti-PD-1 antibody (dotted green line) did not 
enhance the cytotoxicity. Addition of 5-OP-RU to the culture (blue line) improved MAIT cell 
killing, and this was the second experiment to show that tumouroids have the ability to present 
ligand and activate MAIT cells. Finally, when MAIT cells and TILs were combined at a 1:1 
ratio with anti-PD-1 antibody (dotted purple line), this decreased the cytotoxic ability of the 
TILs. It cannot be determined from this experiment if this was due to MAIT cells alone or the 
addition of anti-PD-1 antibody as I did not include a MAIT cell + TIL only condition, due to 
limited cell numbers. 
 
The maximum killing capacity was assessed at any given time point (Fig. 5.12B), and it showed 
that TILs alone had the most substantive cytotoxic effect when compared to background (mean 
MFI 2257 vs. 765.7). There was not a large difference observed with the addition of anti-PD-1 
antibody (mean MFI MAIT cells 2257 vs. MAIT cells + anti-PD-1 antibody). Addition of 5-OP-
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RU did not significantly enhance MAIT cell killing (Fig. 12B) In summary, MAIT cells alone 
were able to induce tumouroid death. 
 
Finally, cytokine secretion in each condition was assessed including IFNγ (Fig. 5.12C) and 
TNFα (Fig. 5.12D). Interestingly, although MAIT cells + TILs + anti-PD-1 antibody did not 
have a significant effect in terms of cytotoxicity, there is an increased cytokine production of 
both IFNγ and TNFα (>1000 pg/mL). These quantities are comparable to MAIT cells + 
tumouroids + 5-OP-RU, indicating again that MAIT cells are robust producers of cytokines. 
This is again demonstrates that MAIT cells have the ability to act as bystanders and perhaps 
influence the TME. 
 
 
Figure 5.12. Autologous TILs are more efficient inducers of tumouroid cytotoxicity than 
allogeneic MAIT cells. (A) XY-plot showing kinetic killing of tumouroids by quantitation of 
cytotoxicity by MFI of PI uptake in tumouroids over time (hours). (B) Box and whisker plots of 
the maximum MFI of PI uptake over 48 hours in tumouroids following co-culture with immune 
cells including all conditions. (C) Bar graphs showing the amount of IFNγ and (D) TNFα 
secretion over 48 hours when immune cells and tumouroids were co-cultured, representative of 
one experiment. 
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The previous pilot experiments assessed peripheral MAIT cells in a ‘resting’ state. To assess the 
full cytotoxic potential of MAIT cells, I decided to compare stimulated and resting peripheral 
MAIT cells and their cytotoxic capabilities against patient-derived tumouroids. To do this, I 
adapted the MAIT cell stimulation protocol from Professor Godfrey’s laboratory that is 
regularly used to expand pure populations of MAIT cells (Gherardin, Loh, et al., 2018). This 
stimulation protocol is described in Chapter 2, but briefly, plate-bound anti-CD3 and soluble 
anti-CD3/28 antibodies were used to stimulate MAIT cells that have been purified by FACS 
from healthy donor PBMCs. This expansion protocol included a combination of cytokines: IL-
2, IL-7, IL-12, IL-15 and IL-18, and the stimulus 5-OP-RU. I decided to omit 5-OP-RU from 
this stimulation protocol, because I found in the pilot experiments that addition of 5-OP-RU did 
not improve cytotoxicity. Importantly, there is literature reporting that IL-7 is produced by 
hepatocytes in an inflammatory state, and that IL-7 can license MAIT cells through regulated 
TCR-mediated activation (X. Z. Tang et al., 2013). MAIT cells can also be activated by IL-15 
and IL-18 and profoundly boosts their activation in concert with TCR ligation (Sattler, Dang-
Heine, Reinke, & Babel, 2015). Therefore, I attempted to maximally stimulate these MAIT cells 
and assessed their full cytotoxic potential. 
 
To investigate the phenotype of MAIT cells stimulated using this method, cells were assessed 
using flow cytometry and CBA. As seen in Figure 5.13A-B, both TCR stimulation alone and 
TCR + cytokine stimulation; resulted in a strong effector phenotype where nearly 100% of cells 
expressed CD69 and granzyme B. In comparison, IL-15/18 stimulation in the absence of TCR 
stimulation resulted in nearly all cells expressing the activation marker CD69, but only 31.4% 
of cells expressed granzyme B (Fig. 5.13B). When assessing the secreted cytokine as seen in 
Figure 5.13C, TCR + cytokine stimulation produced the most substantial amount of granzyme 
B. For subsequent experiments, anti-CD3/28 antibodies & cytokine stimulation were used to 
artificially activate MAIT cells, in order to study their interaction with patient-derived 




Figure 5.13. Stimulation of peripheral MAIT cells via TCR and cytokines results in a 
cytotoxic phenotype. MAIT cells were freshly isolated from healthy donors via FACS and 
stimulated with anti-CD3/28 antibody alone, anti-CD3/28 antibody + cytokines or IL15/18 only 
for 48 hours. (A) Representative flow cytometry plots from three donors following stimulation 
(B) Scatter-plots showing expression of CD69 (orange) and granzyme B (blue) following 
stimulation detected via flow cytometry. (C) Scatter-plots showing cytokine secretion in 
supernatant following stimulation measuring IFNγ (purple), granzyme B (blue) and TNFα 
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Figure 5.14. MAIT cell stimulation induces activation phenotype. Peripheral MAIT cells 
from healthy donors were freshly isolated by FACS and stimulated with anti-CD3/28 antibody 
and cytokine cocktail. Representative flow cytometry plots showing gating strategy of freshly 
isolated unstimulated MAIT cells (top) and stimulated MAIT cells (bottom). 
To further investigate the functional phenotype of MAIT cells using this stimulation protocol, 
MAIT cells were isolated from three healthy donors and phenotypically assessed. Figure 5.14 
shows the phenotype of unstimulated vs. stimulated MAIT cells. As seen in Figure 5.14, 
following stimulation, MAIT cells were only detected by Vα7-2+ CD161high expression. MAIT 
cells could not be detected using 5-OP-RU tetramer (bottom panel Fig. 5.14), which was 
observed across all three donors. This was most likely due to occupation of the receptor by the 
soluble anti-CD3/28 antibody or alternatively downregulation of the receptor. I was confident it 
was not an artefact of staining, as the unstimulated MAIT cells were detected using the 5-OP-
RU tetramer and stained simultaneously. In the example of Figure 5.14, it was also observed 
that the FACS isolation was not optimal, as only 63.8% were pure MAIT cells. This implied 
that the initial sort was not pure and likely had other T-cell populations that expanded during the 
stimulation. In both unstimulated and stimulated MAIT cells, CD8+ and DN populations were 
observed, with little to no CD4+ MAIT cell subpopulations. Upon stimulation it can be seen 
that MAIT cells upregulated PD-1 and CD69 expression (Fig. 5.15). Interestingly, in all 
experiments CD45RO downregulation was observed, why this occurs during activation is 
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Figure 5.15. MAIT cell stimulation induces an activation phenotype. Peripheral MAIT cells 
from healthy donors were freshly isolated by FACS and stimulated with anti-CD3/28 antibody 
and cytokines. (A) Representative flow cytometry plots showed expression of CD69, (B) PD-1 
and (C) CD45RO in unstimulated (red) and stimulated (blue) MAIT cells (C) Scatter plots 
showed quantitation of percentage of MAIT cells expressing CD69, PD-1 and CD45RO 
following stimulation. Each data point represents one healthy individual, n=2 (unstimulated) 



















































































































To compare the killing capacity of unstimulated and stimulated MAIT cells against patient-
derived tumouroids, a series of cytotoxic assays were performed. To determine if MAIT cells 
are activated via MR1 in this assay, anti-MR1 blocking antibody was used to determine the 
mechanism of activation. Figure 16A depicts the kinetic killing of tumouroids by unstimulated 
MAIT cells, which takes at least 20 hours to see any effects. As shown in Figure 16B, in the 
stimulated state, MAIT cell killing occurs rapidly within 10 hours and induces greater levels of 
cytotoxicity. Assessment of the maximum tumouroid death induced by MAIT cells is shown in 
Figure 5.17. Unstimulated MAIT cells were able to significantly kill tumouroids (mean MFI 
1680, tumouroid alone vs. 5302, + MAIT cells), which demonstrated that MAIT cells have the 
capacity to kill tumouroids. Blocking MR1 did not alter this, suggesting that unstimulated 
MAIT cells have cytotoxic effect that is MR1-independent. Blocking PD-1 did not enhance 
MAIT cell killing. Compared to unstimulated MAIT cells, stimulating MAIT cells did not 
significantly enhance tumouroid killing. This effect was also MR-1 independent, and not 
affected by anti-PD-1 antibody. These data indicate that MAIT cells are able to kill tumouroids, 
in an MR-1 independent manner, and addition of anti-PD-1 antibody does not enhance killing. 
 
To assess specificity of MAIT cell killing directed against tumouroids, normal liver organoids 
were established from normal liver tissue of a hepatocellular carcinoma (HCC) patient, by the 
Visvanathan laboratory. Figure 5.17 highlighted that unstimulated and stimulated MAIT cells 
are able to kill normal liver organoids. Through which mechanism this occurs was unknown, as 




Figure 5.16. Kinetic killing of tumouroids by MAIT cells is enhanced when pre-stimulated. 
Unstimulated and stimulated MAIT cells were co-cultured with tumouroids for 40 hours. Cell 
death of tumouroids was assessed using MFI of PI uptake over time. XY-plot showing kinetic 
killing of tumouroids and normal liver organoids by unstimulated MAIT cells quantitating MFI 
of PI uptake in tumouroids over 40 hours in (A) unstimulated and (B) stimulated MAIT cells. 
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Figure 5.17. MAIT cells kill in an MR-1 independent mechanism. Unstimulated and 
stimulated MAIT cells were co-cultured with tumouroids (solid grey bars) or organoids (pattern 
bars) for 40 hours. Cell death of tumouroids was assessed by the maximum cytotoxicity (MFI of 
PI) at one time point over 40 hours. Bar graphs displaying the maximum fluorescence of 
tumouroid/organoid uptake at any given time point. Bar graphs displaying the maximum MFI 
(tumouroid death), over 30 hours, error bars represent SEM, one-way ANOVA, ****p<0.0001 
n=4 MAIT cell donors, 2 repeat experiments. 
All of these co-cultures used healthy-donor peripheral blood-derived MAIT cells and may not 
have been reflective of tissue-derived MAIT cells. Stimulation of peripheral MAIT cells was 
used as a surrogate to recapitulate the phenotype of tissue-derived MAIT cells. There were 
multiple attempts to culture tissue-derived MAIT cells from the tumour and liver, however 
following FACS sorting for purification, the cells were very sensitive and did not survive in 
culture. Although anecdotal, there was one patient where MAIT cells from the normal liver 
were successfully purified and expanded (using the aforementioned stimulation protocol). This 
expansion was for two weeks prior to being co-cultured with autologous tumouroids. This was 
the ideal co-culture experiment to assess autologous MAIT cell function, ex vivo. Addition of 
anti-PD-1 antibody was used to assess the response of tissue-derived MAIT cells with CBI. As 
shown in Figure 5.18A-B, the normal liver-derived MAIT cells were able to induce 



























































































































Figure 5.18. Autologous liver-derived MAIT cells are able to effectively kill tumouroids ex 
vivo. MAIT cells were isolated and expanded from normal-liver and co-cultured with matched 
autologous patient-derived tumouroids. (A) XY-plot showing kinetic killing of tumouroids by 
expanded normal liver-MAIT cells quantitating MFI of PI uptake in tumouroids over 30 hours 
(B) Bar graphs displaying the maximum MFI (tumouroid death), over 30 hours, error bars 
represent SEM. 
From these cytotoxic data it can be concluded that tissue derived and expanded MAIT cells 
were able to kill patient-derived tumouroids ex vivo. Thus demonstrating the potential killing 
capability of MAIT cells, providing insight into their function. Understanding their phenotype 
in situ provided additional clues into their role in a pathological state. 
 
In conclusion, I have found that both unstimulated and stimulated MAIT cells have the ability to 
kill patient-derived tumouroids, and are potent producers of IFNγ. This indicated that MAIT 
cells possess the capability to influence the TME under inflammatory conditions. MAIT cells 
isolated from tissue of CRLM patients are phenotypically distinct compared to peripheral MAIT 
cells, assessed by activation and memory markers. However, despite MAIT cells being activated 
in the tumour, they are reduced in frequency. Understanding why this is the case is yet to be 
clarified. These data contribute to the field of MAIT cells in the context of tumour immunity, to 
better understand their role in this pathological state. 
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In a review of the literature documenting TILs in various tumour types, Pagès et al reported that 
in 98% of these studies, cytotoxic CD8+ T-cells were associated with a good prognosis. In 
contrast, other immune cells subsets were associated with either a good or poor prognosis 
depending on the method used or the cancer type (Pages et al., 2018). Therefore, it is clear that 
CD8+ T-cells play a role in controlling tumour progression, due to their cytotoxic ability. What 
the field has failed to recognise is that not all of the CD8+ T-cells accounted for are 
conventional CD8+ T-cells. Included in the assessment of CD8+ T-cells is the MAIT cell 
subset, where function in tumour immunity is less defined. 
 
Approximately 80-90% of blood MAIT cells express either CD8αα homodimer or CD8αβ 
heterodimer. Therefore, MAIT cells are likely to be included in the quantitation of conventional 
CD8+ T-cells when assessing TILs especially in colorectal tumours and CRLM. Based on this 
information, it would also imply that CD8+ MAIT cells are associated with good prognosis in 
CRC in the primary tumour, stages I-III. However, in the more advanced stage of disease and at 
the metastatic site, it may not be the case. Assessment of MAIT cells as a proportion of CD8+ 
T-cells revealed that CD8+ T-cells comprise up to 50% of MAIT cells. Ongoing work in the 
lab, that is not part of this thesis, will confirm this using mIHC. This approach will provide 
more information about the spatial location of MAIT cells within and around the tumour and 
provide a more definitive proportion of MAIT cells of CD8+ T-cells compared to FACS 
assessment. 
 
To understand the different phenotypes between conventional CD8+ T-cells and MAIT cells, 
expression levels of PD-1 and CD69 were compared. The expression of PD-1 on conventional 
CD8+ T-cells and MAIT cells was not significantly different and suggested that both cell 
populations may be exhausted. More importantly it indicates that expression of PD-1 by these 
cells could be therapeutically targeted with anti-PD-1 antibody. Hence, MAIT cells may 
represent an additional T-cell population that may respond the CBI, which has not been 
described previously. Conversely, CD69 expression is significantly higher on MAIT cells than 
conventional CD8+ T-cells and indicates activation. In recent years, CD69 is becoming more 
widely accepted as a tissue-residency marker, however assessment of the additional CD103+ 
marker would be required (Kumar et al., 2017). If it was the case, then it demonstrates that these 
MAIT cells in the TME are likely to be local tissue-resident cells from the liver. Whether MAIT 
cells are tissue resident T-cells or not is still contentious in the field (Booth et al., 2015; Voillet 
et al., 2018).  
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It is clear that MAIT cells make up a significant proportion of T-cell populations at mucosal 
sites in humans. The most abundant population of MAIT cells is found in the liver, and accounts 
for 20-40% of T-cells (Dusseaux et al., 2011). When assessing the frequency of these cells in 
CRLM, MAIT cell frequency was numerically reduced in the tumour compared to surrounding 
liver. There are two likely reasons for this: (1) MAIT cells are not tumour specific or (2) the 
TME is generally immunosuppressive, and results in a reduction of MAIT cell infiltration. 
 
MAIT cells are known to be protective in bacterial infections, where they are able to kill 
bacterially infected cells in an MR1-dependant fashion (Kurioka et al., 2015; Le Bourhis et al., 
2013). However MAIT cells also have the ability to produce pro-inflammatory cytokines 
independent of MR1, through IL-12 and IL-18 (Banki et al., 2019). In some tumours analysed, 
an increased (>20%) frequency of MAIT cells was observed. Understanding why these tumours 
had a high MAIT cell infiltrate warrants further investigation. The results from the functional 
cytotoxic assay show that peripheral MAIT cells were able to kill independent of MR1. Because 
killing is independent of MR-1, it suggests that MR-1 expression on tumour cells from patients 
may not be informative of MAIT cell presence, as may have been predicted. However, it is still 
unclear of the exact activation of killing in the ex vivo assay. Future work will be required to 
understand if both tumour tissue and tumouroids have protein expression of MR1 and activating 
NKG2D cell receptor ligands such as MICA/B, ULBP16 or Rae1 (Spear, Wu, Sentman, & 
Sentman, 2013). This is because MAIT cells are known to have NK cell receptors including 
inhibitory NKG2A and activating NKG2D receptors and cytotoxic effector function could be 
occurring through these pathways (Dusseaux et al., 2011). It is therefore unlikely that MAIT 
cells are tumour specific, but perhaps play a role as bystander cells within the TME. 
 
Further studies to understand if MAIT cells kill tumour cells are required, to achieve more 
clarity on this question. This is of course a key question in the context of cancer therapy because 
if MAIT cells have the ability to kill tumour cells they may be good targets for immunotherapy. 
What sets my investigations apart from the aforementioned functional in vitro studies is the use 
of patient-derived tumouroids, which better recapitulate tumour cell heterogeneity compared to 
traditional cell lines (M. Fujii et al., 2016). The data generated from my collective cytotoxic 
experiments show that MAIT cells do have the capability to kill patient-derived tumouroids and 
this is without the inclusion of 5-OP-RU in the co-culture. This indicates that there is another 
mechanism of action that MAIT cells function through, independent of MR1.	
	
The results of this thesis show that MAIT cells explored from the tissue displayed an activated 
state. Hence, artificial activation of peripheral MAIT cells would determine their maximal 
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functional capability. However, I was concerned that these polarised MAIT cells may have the 
ability to kill normal cells non-specifically. To address this concern, I included patient-derived 
normal liver organoids to assess specific tumour killing. Both unstimulated and stimulated 
MAIT cells did kill normal liver organoids. This is of some concern as use of MAIT cells 
therapeutically could cause damage to normal tissues. As the normal liver organoids were only 
derived from one patient, it is important to repeat this experiment, particularly using normal 
liver organoids from the same patient as the tumouroids used in the assay. The presented 
cytotoxic data are the first report that donor MAIT cells have the ability to kill patient-derived 
tumouroids. MAIT cells may be potentially considered for therapeutic use to kill tumour cells. 
One caveat of CAR T-cell therapy is the eligibility of patients to meet established 
criteria/measures for such therapy. This includes the requirement to provide sufficient amounts 
of blood for effective transduction of autologous CAR T-cells, which are then re-infused back 
into the patient. Patients are often unwell, may be lymphopenic and therefore not be able to be 
eligible for this therapy. The advantage of using MAIT CAR T-cells is that MAIT cells function 
independent of MHC-I and MAIT cells could be used allogeneically in this context (Godfrey et 
al., 2018). 
 
To understand MAIT cell biology in the context of tumour, future studies will attempt to assess 
the in situ MAIT cell phenotype from tissue-derived cells using single-cell RNAseq. It will 
compare differential expression of immune markers on conventional CD8+ T-cells and MAIT 
cells derived from the tumour and liver. The initial RNAseq data from CRLM indicate that 
tumours from primary and metastatic CRC have the ability to express MR1. This requires 
further validation at the protein level. To further address MAIT cell presence in the tumour and 
surrounding liver, I plan to perform mIHC, to visualise where the MAIT cells are located within 
the TME. It is clear from the flow cytometry data that MAIT cells are present in tumours and 
some are at higher frequencies than others. Due to complete disruption of tissue using flow 
cytometry to assess MAIT cell phenotype at the single-cell level, we don’t have the ability to 
visualise whether there is an accumulation in CT or IM. Therefore, using mIHC to address this 
will be highly informative.  
 
In this chapter I was able to identify the ability of MAIT cells to kill tumouroids ex vivo. I also 
found that MAIT cells make up a significant proportion of conventional CD8+ T-cells, which 
have not been previously accounted for. MAIT cell frequency was reduced in the tumour, a 
finding that is consistent with the current literature. An activation phenotype of MAIT cells 
from the tumour and liver was observed. Due to the detected expression of PD-1 on MAIT cells, 
cytotoxic assays were designed to test if anti-PD-1 antibody enhanced MAIT cell effector 
function. From these experiments anti-PD-1 antibody did not enhance killing. The ability of 
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MAIT cells to rapidly secrete cytokines and cytotoxic molecules highlight that these cells could 
be used therapeutically (e.g. CAR-MAIT cells). Understanding their role in pathologies of the 
liver will contribute to the field of MAIT cell biology. Thus, understanding the biology of 
MAIT cells provides important insight into the potential of these cells therapeutically and to 
more precisely define the nature of TILs in mCRC. 
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6.  DISCUSSION  
Twenty years ago, diagnosis of Stage IV CRC was associated with <1% five-year survival (Jones 
et al., 2012; Rougier et al., 1995). Metastatic spread to the liver is common, and now, with 
advances in surgical technique and both neo-adjuvant and adjuvant chemotherapy, five-year 
survival of patients with colorectal liver metastasis is between 30-40% (Choti et al., 2002; Luca 
Vigano, 2012; Manfredi et al., 2006; Tomlinson JS1, 2007). However a significant proportion of 
these patients develop recurrence at some stage (D'Angelica et al., 1997; Tomlinson JS1, 2007) 
and most patients succumb to death as a result of their metastatic disease. This thesis seeks to 
identify why this might occur in the context of the innate and adaptive immune responses.  
 
We know that TILs have prognostic significance in CRC, where a high TIL frequency is 
associated with improved survival (Galon et al., 2006; Pages et al., 2005; Pages et al., 2009; 
Pages et al., 2018; Smyrk, Watson, Kaul, & Lynch, 2001). The seminal work by Galon et al, 
confirmed that patients with CRC stratified by TNM staging alone had a stage-dependant reduced 
survival (I-IV). Stage IV had the worst DFS, which is unsurprising (Manfredi et al., 2006). 
However when those patients, who were TNM stage I-III were then stratified by infiltration of 
CD3+ T-cells, they had a different prognosis, regardless of TNM stage. Importantly, stage IV 
CRC patients stratified based on CD3+ T-cell alone did not show a statistically significant 
improved OS (Galon et al., 2006). Thus this work demonstrates that the immune response 
influences time to recurrence and overall survival in stage I-III CRC, but is less pronounced in 
metastatic stage IV CRC. Based upon these observations, I question what immunological factors 
might be involved in the progression of primary CRC to metastatic disease. 
 
In Chapter 3, immunological factors were investigated in the context of the primary tumour, 
which had been surgically resected in patients who also had de novo mCRC. Included in this 
unique cohort of patients were patients with microsatellite unstable tumours. This MSI-H 
subgroup of patients is known to be unresponsive to conventional chemotherapy and have a 
worse outcome compared to stage I-III CRC patients (Goldstein et al., 2014; Koopman et al., 
2009; Overman et al., 2017). There was no statistical difference in OS observed when comparing 
patients with MSI-H to MSS. To evaluate whether the immune response plays a role in OS of 
stage IV disease, cytotoxic CD8+ T-cell infiltration was assessed at the primary site. No 
difference was found in OS between high and low frequencies of CD8+ T-cells. These data 
suggest that the immune response in both primary and metastatic sites has failed. Verifying this 
view would involve assessment of the CD8+ T-cell infiltrate in matched distant metastatic 
tumours, however the clinical realities are completely consistent. It suggests that for the disease to 
progress to metastasis, the TILs in the primary tumour must be unable to control tumour growth. 
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Similarly at the metastatic site, upon dissemination, the tumour cells likely undergo immune 
evasion and maintain this through immunosuppression. This entire process supposedly occurs due 
to “aggressiveness” of the tumour through accumulation of genetic and epigenetic events as well 
as immune evasion and suppression (Dienstmann et al., 2017). 
 
The tumour-intrinsic progression to metastasis, by definition, encompasses an immune evasive 
microenvironment. This can be through mechanisms including downregulation of immunogenic 
properties such as antigenic machinery including MHC-I (Becht, Giraldo, Dieu-Nosjean, Sautes-
Fridman, & Fridman, 2016). Tumour cells can impede the immune response through checkpoint 
inhibitory mechanisms including the PD-1/PD-L1 axis. In Chapter 3, I found that immune 
evasion by these proposed mechanisms in the primary tumour did not correlate with survival. 
Tumour PD-L1 expression of >1% did not influence OS, and highlights that other immune 
evasion mechanisms must be at play. Investigating the distant metastatic tumours would be of 
interest, to assess if PD-L1 expression is present. Not only is it the tumour-mediated 
immunosuppression in the TME but activated APCs also have the ability to express PD-L1. 
Evaluation of infiltrating immune cells showed PD-L1 expression on immune cells was present. 
Despite high expression of PD-L1 on these cells, this property did not correlate with OS. 
 
 Evaluation of MHC-I expression would also provide valuable insight into other immune escape 
mechanisms by the tumour cells and should be explored in future studies. Finally to investigate 
the oncogenic properties of the tumour, whole exome sequencing (WES) should be done for both 
primary and metastatic tumours. Of particular interest would be the TGF-β pathway. Increased 
levels of TGF-β can lead to immune evasion and promotion of T-cell exclusion from tumours 
(Tauriello et al., 2018). Of course there could be another mechanism the tumour cells operate to 
evade the immune response and progress to metastasis. 
 
The other component of metastatic progression is the possibility of T-cell dysfunction in the 
tumour of either primary or metastatic lesions in patients with mCRC. This is because the tumour 
has progressed to a clinically detectable stage indicating that is has bypassed elimination and 
equilibrium phases, directed by immune cells. As observed in Chapter 3, despite some tumours 
having a high quantity of CD8+ T-cells, this did not affect OS, yet these immune cells are still 
present in the tumours. If these T-cells are present, what then is their purpose and indeed are they 
functional? 
 
To address the state of TIL function, now in the metastatic lesion, Chapter 4 investigates the 
immune milieu in CRLM tumours. The axis of T-cell activation and exhaustion is intertwined. 
Immune checkpoints exist to reduce autoimmunity and maintain T-cell homeostasis. But this 
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mechanism can be hijacked by tumours to evade immune surveillance (Keir, Butte, Freeman, & 
Sharpe, 2008). When T-cells are in a chronic state of activation, also known as anergy this can 
produce a phenotype of “functionally exhausted” T-cells. Exhausted T-cells fail to function 
normally with reduced production of effector cytokines, reduced ability to proliferate, metabolic 
changes and reprogramming of transcription factors (Ahmadzadeh et al., 2009). Expression of 
PD-1 can indicate activation in the early stages of T-cell activity and later exhaustion in the 
chronically stimulated stage of T-cell activity. When evaluating PD-1 expression on CD4+, 
CD8+ and T-regulatory T-cells from CRLM, PD-1 expression was higher in the tumour 
compared to normal liver and peripheral T-cells. This is a similar finding to initial reports of TILs 
in melanoma having high PD-1 expression in the tumour compared to surrounding tissue and 
peripheral blood (Ahmadzadeh et al., 2009). This is the first indication these TILs are potentially 
dysfunctional, however additional evaluation of transcription factors such as NFAT, BLIMP-1, 
T-BET and EOMES would provide insight into the transcriptional reprogramming of these cells 
to confidently render them dysfunctional. Functional studies assessing the ability of the freshly 
isolated TILs to produce IFNγ and IL-2 as well as their proliferative capacity from the tumour 
would also be informative of this phenotype. 
 
To more directly address this function dynamically, we developed the cytotoxic assay. This was 
designed to address quality over quantity of the TILs and interrogate the function of these 
immune cells. In Chapter 4, assessment of TILs from CRLM demonstrated the ability of these 
TILs to kill autologous tumouroids suggesting that these TILs are not terminally exhausted. 
However, although the TILs used were directly isolated ex vivo, they were subsequently 
expanded in presence of IL-2 and tumour debris as a source of tumour antigen. A common 
feature of dysfunctional TILs is their inability to proliferate. When given the opportunity of 
expansion in vitro, all of the TILs assessed with the cytotoxic assay had the ability to proliferate. 
As recorded in the results, there were many patient-TIL samples that failed to expand in culture. 
This could be attributed to the area of the tumour section, which may have been necrotic or may 
simply not have had enough immune cells to expand. However this was accounted for in our 
protocol, with multiple cultures established with a tumour fragment provided. Sometimes 
heterogeneity of the tumour fragment would be observed where only a few wells would 
proliferate. But in those tumours where no TIL proliferation occurred, the autologous tumouroids 
established would grow rapidly. Although these observations are at present anecdotal findings 
and not experimentally controlled, it does suggest that the TILs are likely under tumour control in 
vivo and unable to function normally. When removed from this TME and then provided with the 
opportunity to proliferate in culture, TILs are functional without the constant competition of 
tumour cells with potential inhibitory mechanisms at play. Nevertheless, they may not have been 
tumour specific as others have found many TILs are bystanders (Simoni et al., 2018). 
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To assess if these expanded TILs could be enhanced with the addition of CBI, anti-PD-1 blockade 
was evaluated in the context of the immune co-culture, ex vivo. It is important to note that in these 
studies, all patients assessed had microsatellite stable tumours, which are known to not respond to 
CBI. PD-1 expression was confirmed by flow cytometry, however compared to in situ expression 
levels on T-cells from CRLM of 15-75%, expanded TILs ranged from 0-15%. PD-L1 expression 
was also evaluated on the culture tumouroids, with no endogenous expression. Following 
stimulation with IFNγ, upregulation of MHC-I and PD-L1 can be observed. Unfortunately this 
methodology was only realised after completing the CRLM cytotoxic assay co-culture 
experiments. Therefore, it may be possible that without PD-L1 expression, addition of anti-PD-1 
antibody will not affect killing, because the axis is not present to manipulate. Future experiments 
will therefore aim to include these conditions to account for PD-L1. 
 
There is growing evidence to suggest that those TILs that are unable to exert effector functions, 
and are not rescued by CBI, are therefore intrinsically dysfunctional. Comprehensive rescue of 
function by CBI was observed only in one MSS rectal cancer sample, which demonstrates that 
some MSS tumours have the ability to respond (Kong, 2018). Those tumours with immune cells 
that do not kill and cannot be rescued by CBI therefore exhibit dysfunction. Whether or not this is 
reversible is a pressing area that should be focused on in the field. 
 
One final measurement of TIL function utilised in the assay was production of cytokines secreted 
into the supernatant. Of particular interest is production of IFNγ and TNFα as effector cytokines. 
Tumouroids and TILs alone produced minimal IFNγ levels (<20 pg/mL) however the addition of 
anti-PD-1 antibody increased this a modest two to three-fold over time. These data indicate that 
although the TILs are able to kill the tumouroid as seen in the cytotoxic assay, there is an inability 
to produce robust levels of IFNγ. However, despite not observing an improved killing capacity, 
an induction of IFNγ production is observed with the addition of anti-PD-1. This phenomenon 
has been documented previously, where cytotoxic lymphocytes that lacked perforin-dependent 
machinery were unable to kill target cells. Instead these cytotoxic lymphocytes entered a state of 
hypersecretion of inflammatory cytokines including IFNγ production (M. R. Jenkins et al., 2015). 
Therefore this state is what was observed with the addition of anti-PD-1 antibody, where no 
enhanced killing was observed but enhanced secretion of IFNγ occurred. In the context of the 
TME this is not ideal as IFNγ can induce PD-L1 expression on tumour cells. This phenomenon 
has been demonstrated in recent experiments in the Ramsay lab where tumouroids and TILs were 
co-cultured together and secreted IFNγ by the TILs resulted in PD-L1 expression on the 
tumouroids. Perhaps these are some of the mechanisms at play by which CBI is not effective in 
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MSS tumours, as it creates a more immune-evasive phenotype rather than a direct enhancement 
of a cytotoxic environment. 
 
Collectively these data presented in Chapter 4 suggest that the metastatic site has an infiltration 
of CD3+ T-cells. The majority of these cells are CD4+ and the T-reg population (CD4+Foxp3+) 
is also increased in the tumour compared to ‘normal’ liver. Cytotoxic NK, NKT and CD8+ T-
cells are reduced in the tumour compared to liver, but are nonetheless still present and remain 
unable to exert effector functions in situ. A recent study by Scheper et al documented a limited 
number of tumour-reactive TCR clones of CD8+ T-cell infiltrating the tumour. Therefore, despite 
high numbers of TILs there may only be a select few TCR clones that react to the tumour 
specifically. Such observations firstly highlight the concept of quantity versus quality, that 
despite high numbers of TILs it does not indicate they are tumour specific and functional. 
Secondly, it suggests T-cells present that are not tumour specific are likely to play a bystander 
role. Simoni et al recently investigated this concept, where they identified CD39+ as a marker of 
tumour-specific T-cells. It was discovered that CD8+ T-cells infiltrated lung and CRC tumours 
and only those that were not tumour specific and were CD39- lacked hallmarks of chronic antigen 
stimulation, classifying them as bystanders (Simoni et al., 2018). Bystander cells are therefore not 
tumour specific, but they nonetheless have the ability to infiltrate the tumour and contribute to the 
TME. It would seem that discerning the exact role bystander cells play is just as important as 
interrogating the tumour specific cells. 
 
One type of non-classical CD8+ T-cell is a MAIT cell (Gherardin, Souter, et al., 2018). This is a 
cell population that is beginning to be accounted for in CRC. It is possible that MAIT cells also 
play a bystander role in the TME. MAIT cells are abundant in the liver, comprising between 30-
50% of T-cells. The role of MAIT cells in the context of tumour is gradually being uncovered. A 
recent publication by Shaler et al found that MAIT cells in CRLM were reduced in the tumour 
and functionally impaired with reduced IFNγ production (Shaler, Tun-Abraham, et al., 2017). I 
confirmed this with my findings of MAIT cells being reduced in the tumour of CRLM compared 
to surrounding normal liver, outlined in Chapter 5. Some patient tumours harboured more MAIT 
cells than others. Interrogating why some tumours had high MAIT infiltrate would be of benefit 
to understand whether they are functional or not. It is plausible that bacterial ligands may be 
present in context with the tumour, due to the tissue (e.g. vessels) disruption by tumour growth. 
To address this; tumours could be probed for 16S rRNA genes, which can detect bacterial gene 
sequences and could provide insight into reasons MAIT cells may be present. In this context, 
MAIT cells would be considered bystanders within the TME. Once again, it is unlikely that 
MAIT cells are specific for tumour cells, but these data suggest that MAIT cells still have the 
ability to infiltrate and may influence the TME. 
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What was determined from the evaluation of MAIT cells in the tumour was the majority of MAIT 
cells were CD8+ and this is a sub-population of CD8+ cells that have not been previously 
accounted for. MAIT cell PD-1 expression was comparable between the tumour and liver and, 
therefore, in this context they are likely to be activated rather than exhausted as those MAIT cells 
in the liver are presumed to be normal. Expression of CD69 on MAIT cells was also comparable 
between the tumour and liver, but most importantly, MAIT cells in the tissue are distinct from 
those in the peripheral blood.  
 
When assessing the ability of donor peripheral MAIT cells to kill tumouroids in vitro, utilising 
the cytotoxic assay, unstimulated MAIT cells were able to kill tumouroids. This was independent 
of MR1, and the mechanism of recognition and inducing cytotoxicity is still unknown. MAIT 
cells are also known to have NK cell receptors (Gherardin, Souter, et al., 2018), which have not 
been investigated in this study, but should be in the future. Determining the role of this previously 
undefined population of CD8+ T-cells is still yet to be determined. This is a population that is 
abundant in the liver and needs to be functionally understood in the context of tumours arising in 
the liver. 
6.1 SUMMARY 
CRC that has metastasised is the most advanced stage of the disease. Only 20% of patients are 
deemed resectable at time of diagnosis (Manfredi et al., 2006). Even though surgical resection 
offers improved five-year survival, recurrence frequently occurs. Understanding the progression 
of disease from the primary tumour to the metastatic lesion is critical to improve clinical 
management of these patients.  
 
From this body of work, it is apparent that advanced CRC disease in the metastatic setting has 
progressed beyond immune control. Determining the mechanism of progression from primary to 
metastatic lesions highlights targetable stages in this sequence. In the primary tumour of de novo 
mCRC patients, CD8+ T-cells do not offer a survival benefit indicating an inability to control 
tumour growth.  
 
In the metastatic tumours that have progressed to the liver, the immune context is tipped towards 
a suppressive phenotype, with a reduced infiltration of cytotoxic T-cells. In a milieu such as this, 
immune-mediated tumour control is impeded with these suppressive factors at play. Assessing the 
cytotoxic capability of TILs provides functional assessment and demonstrates that some of these 
TILs are able to mount a cytotoxic response, when removed from the immunosuppressive 
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environment ex vivo. This further highlights the influence of tumour control over the immune 
response. 
 
Finally this work has identified a novel subset of CD8+ T-cells that were not previously 
accounted for in the context of the Immunoscore, quantifying conventional CD8+ T-cells. This 
subset of cells known as MAIT cells are abundant in the liver and have the capacity to kill 
patient-derived tumouroids ex vivo, highlighting them as a cell type that may potentially be 
targeted immunotherapeutically. 
 
Improving patient outcome in the setting of metastasis is challenging, yet this work highlights 
some avenues to pursue in the context of immunotherapies in patients with CRLM. 
6.2 FUTURE DIRECTIONS 
6.2.1 Interrogating the Specificity of Infiltrating CD8+ T-cells 
Since its fruition, the concept of this study has been to interrogate the difference between quantity 
and quality of TILs. The Immunoscore does not inform the quality of the TILs. It informs 
clinicians of prognosis but does not actually guide therapeutic options. As I found in Chapter 3, 
despite the number of TILs being present it does not equate to tumour control or survival 
advantage in the metastatic setting of CRC. Currently the field defines a solid tumour as either 
‘hot’ or ‘cold’ in regards to immune infiltrate. However the quality of the TILs in terms of their 
effector function really needs to be taken into account. Additionally their tumour specificity also 
needs to be considered, as with recent studies it is apparent that only a small proportion of TILs 
are actually tumour reactive. This approach from a clinical perspective would involve 
phenotyping the TIL from patients using high-throughput analysis including mass cytometry 
(CyTOF), where >30 parameters can be assessed in one sample, such a technique is feasible to 
achieve rapid results following surgerySequencing TCR’s from patient tumours would also 
provide insight into tumour-reactive T-cells, however this may take analytical time and would be 
expensive. Tumouroid and immune cell co-cultures such as the one we’ve developed is a novel 
platform to investigate the dynamic interactions between immune cells and tumouroids. 
Transcriptomic sequencing of the immune cells and tumouroids after co-culture would further 
highlight transcriptional reprogramming the immune and tumour cells undergo, after exposure to 
one another. This would perhaps highlight pathways of immune-resistance and immune evasion 
by tumour cells and thus pathways that could be targeted therapeutically.  
 
6.2.2 Therapeutic Strategies to Improve Immunogenicity of Tumours  
Currently in the immuno-oncology field, the focus is targeting the immune cells to exert effector 
functions. This is still important but imperative that the field focuses on increasing the 
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immunogenicity of the tumour. We must not forget the importance of chemotherapy and 
radiotherapy to achieve this. Destruction of the tumour cells via these therapies exposes the 
immune cells to neoantigens and improves immunogeneic responses. However these therapies 
should also not be considered to be mutually exclusive. Combination therapies of immune 
checkpoints in line with chemotherapy and/or radiotherapy may see improved efficacy of both of 
these treatments. Another avenue to increase immunogenicity of the tumour is the use of vaccines 
against tumour cells to prime the immune response. Vaccines such as DNA-based vaccines are 
currently in trials including MYPHISMO as Peter MacCallum Cancer Centre. Again these 
approaches may not have been effective as single agents, but now in the era of CBI these 
approaches are potentially more efficacious. First boosting the immune response with a vaccine, 
and then having checkpoint blockade antibodies to ensure immune evasion by the tumour cells 
does not occur, theoretically should enhance efficacy.  
 
Finally, we are now in an era where CAR T-cells have been approved by the federal drug 
association (FDA) and are being used in the clinic for haematological malignancies. Strong 
efforts are now being pursued to improve efficacy of these therapies in the solid tumour setting. 
Therefore utilising other endogenous immune cells that may not be tumour specific, but classify, 
as bystander cells should be exploited. This has been addressed in the efficacy of CAR T-cell 
therapy in combination with inhibitors of apoptosis protein (IAP) antagonists. This combination 
enhanced tumour death by sensitising tumour cells to TNFα, resulting in indirect bystander 
killing (Michie et al., 2019). 
 
6.2.3 Utilising Bystander Immune Cells Therapeutically 
Bystander cells are those cells that are present within the tumour but are not exclusively tumour 
reactive. That isn’t to say they do not influence to TME, and they likely have the ability to do this 
by secreting cytokines. One kind of potential bystander cell within the TME of CRLM tumours 
are MAIT cells. The abundance of MAIT cells in both the liver and peripheral blood and the 
ability of these cells to rapidly secrete cytokine and have cytotoxic function make them attractive 
cells to therapeutically target. MAIT cells may indeed be ideal CAR T-cells for these reasons. 
The other advantage of these cells is they do not function through MHC-I, but are restricted to 
MR1 and this means that if used as a CAR T-cell, healthy donors of MAIT cells that can function 
in an allogeneic setting (Godfrey et al., 2018). Embarking on their use therapeutically requires 
further investigation and this stems from understanding their role in the TME, which this body of 
work has contributed to. 
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6.3 CONCLUDING SUMMARY 
Patients with advanced stage CRC have a significantly poorer prognosis compared to those 
patients with earlier stage CRC. Therefore, investigating the biology of these tumours both at the 
primary and metastatic site is integral to improve therapeutic options. In the era of 
immunotherapies, understanding the immune response is key to gain insight into these dynamic 
immune interactions occurring during tumour progression. What this body of work has found is 
that tumours in the advanced setting of CRC have evaded the immune response. This is evidenced 
by the findings that cytotoxic CD8+ T-cell infiltrate in primary tumours of de novo mCRC 
patients no longer affects OS, as what is observed in earlier stages of CRC. The immune context 
at the metastatic site in CRLM tumours is angled towards an immunosuppressive phenotype and 
reduced cytotoxic immune environment. Thus indicating these tumours have the ability to 
suppress the effector function of immune cells, and the TME is immunosuppressive. Efforts in 
altering this balance should therefore be made, with focus on counteracting the suppressive 
immune cells and improving the immunogenicity of tumours so they are more recognisable by 
the cytotoxic immune cells. Targeting other immune cells that can rapidly respond within the 
TME is another strategy that should be focused on, particularly in the era of CAR T-cell therapy. 
Improving knowledge of these immune responses in mCRC patients is crucial to improving 
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